Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K/A

Amendment No. 1

10-K

(Mark One)

þ    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 20172020

or

¨   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ___________

 

Commission File Number 1-5620

 Safeguard Scientifics, Inc.

(Exact name of registrant as specified in its charter)

Pennsylvania

 

Pennsylvania

23-1609753

(State or other jurisdiction of

incorporation or organization)

23-1609753

(I.R.S. Employer Identification No.)

   

170 North Radnor-Chester150 N. Radnor Chester Road

Suite 200F-200

Radnor, PA

19087

(Address of principal executive offices)

(Zip Code)

(610) 293-0600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock ($.10 par value)

SFE

New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ¨    No  x

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  x

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  x

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company”company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  ¨

Accelerated filer  þ

Smaller reporting company ¨

Non-accelerated filer   ¨

(Do not check if a smaller reporting company)

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

 

As of June 30, 2017,2020, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was $237,111,560$136,021,431 based on the closing sale price as reported on the New York Stock Exchange.

 

The number of shares outstanding of the registrant’s common stock as of April 25, 2018February 26, 2021 was 20,560,746.20,944,305.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.Portions of the definitive proxy statement (the “Definitive Proxy Statement”) to be filed with the Securities and Exchange Commission for the Company’s 2021 Annual Meeting of Shareholders are incorporated by reference into Part III of this report.

 


 

SAFEGUARD SCIENTIFICS, INC.

FORM 10-K/A10-K

December 31, 2017

TABLE OF CONTENTS2020

 

Explanatory Note

3

Page

PART I

PART IItem 1. Business

43

Item 1A. Risk Factors

48

Item 1B. Unresolved Staff Comments

13

PART IIIItem 2. Properties

1413

Item 3. Legal Proceedings

13

Item 4. Mine Safety Disclosures

13

PART II

Item 5. Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

14

Item 6. Selected Consolidated Financial Data

15

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

20

Item 8. Financial Statements and Supplementary Data

21

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

45

Item 9A. Controls and Procedures

45

Item 9B. Other Information

45

PART III

Item 10. Directors, Executive Officers and Corporate Governance

1446

Item 11. Executive Compensation

2146

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

5046

Item 13. Certain Relationships and Related Transactions, and Director Independence

5247

Item 14. Principal Accountant Fees and Services

5347

PART IV

PART IV54

Item 15. Exhibits and Financial Statement Schedules

5448

Signatures58

 

2

 

 

ExplanatoryPART I

Cautionary Note Concerning Forward-Looking Statements

This Annual Report on Form 10-K contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about Safeguard Scientifics, Inc. (“Safeguard” or “we”), the industries in which we operate and other matters, as well as management's beliefs and assumptions and other statements regarding matters that are not historical facts.  These statements include, in particular, statements about our plans, strategies and prospects.  For example, when we use words such as “projects,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “should,” “would,” “could,” “will,” “opportunity,” “potential” or “may,” variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Our forward-looking statements are subject to risks and uncertainties.  Factors that could cause actual results to differ materially include, among others, our ability to make good decisions about the deployment of capital, the fact that our ownership interests may vary from period to period, our substantial capital requirements and absence of liquidity from our ownership interests, fluctuations in the market prices of our publicly traded ownership interests, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, our ability to execute our strategy, market valuations in sectors in which our companies operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our ownership interests and their performance, including the fact that most of our ownership interests have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which our ownership interests operate, compliance with government regulation and legal liabilities, all of which are discussed in Item 1A. “Risk Factors.” Many of these factors are beyond our ability to predict or control. In addition, as a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. All forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by this cautionary statement. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report might not occur.

Item 1. Business

Business Overview

Over the recent past, Safeguard has provided capital and relevant expertise to fuel the growth of technology-driven businesses. In many, but not all cases, we are actively involved, influencing development through board representation and management support, in addition to the influence we exert through our equity ownership. We also continue to hold relatively small equity interests in other enterprises where we do not exert significant influence and do not participate in management activities. In some cases, those ownership interests relate to residual interests from prior larger interests or from companies that acquired companies in which we had ownership interests.

In January 2018, Safeguard announced that we would not deploy any capital into new opportunities and will focus on supporting our existing companies and maximizing monetization opportunities to enable returning value to shareholders. In that context, we have, are and will consider initiatives including, among others: the sale of our ownership interests, the sale of certain or all of our ownership interests in secondary market transactions, or a combination thereof, as well as other opportunities to maximize shareholder value. We initiated the return of value to shareholders in 2019 with a $1.00 per share special dividend. We anticipate additional actions could occur in the future, once significant dispositions occur, in the form of stock repurchases and/or special dividends based on available cash resources, prevailing market conditions and other factors.

During 2020, Safeguard was impacted by the circumstances of COVID-19 and the related economic impacts.  In addition to a slowed mergers and acquisitions environment, our companies have been impacted in a variety of operational ways including general declines in the markets in which they operate, reduced access to customers or prospective customers, reduced or delayed collections of amounts due from customers and different ways to work with their employee base.  Our companies have also been negatively impacted in their ability to access debt or equity capital.  The management teams of the entities in which the Company holds such ownership interests are continuing to take actions to respond to the rapidly changing environment, including implementing cost reduction efforts, securing additional capital or other actions, which could mitigate some of the expected impacts.  There are uncertainties as to if these actions will be successful or adequate in this uncertain economic environment.  

We incorporated in the Commonwealth of Pennsylvania in 1953. Our corporate headquarters are located at 150 N. Radnor Chester Road, Suite F-200, Radnor, Pennsylvania 19087.

Our Strategy

Founded in 1953, Safeguard has a distinguished track record of building market leaders by providing capital and operational support to entrepreneurs across an evolving and innovative spectrum of industries. Over the recent past, Safeguard has provided capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. Safeguard's existing group of companies consists of companies that are capitalizing on the next wave of enabling technologies. Since January 2018, Safeguard is no longer deploying capital into new companies. Safeguard remains focused on managing and financially supporting its existing ownership interests, with the goal of pursuing monetization opportunities and maximizing the value returned to shareholders.

Helping Our Companies Build Value

We offer strategic, operational and management support to certain of our ownership interests.

Strategic Support. We play an active role in developing the strategic direction to certain of our ownership interests, which include:

defining short and long-term strategic goals;

identifying and planning for the critical success factors to reach these goals;

identifying and addressing the challenges and operational improvements required to achieve the critical success factors and, ultimately, the strategic goals;

identifying and implementing the business measurements that we and others will apply to measure a company’s success; and

identifying sources of and providing capital to drive growth.

Management and Operational Support. Our executives serve on the boards of directors of certain of our companies, working with them to develop and implement strategic and operating plans. We measure and monitor achievement of these plans through regular review of operational and financial performance measurements.

Realizing Value

Since January 2018, Safeguard ceased deploying capital into new companies. Safeguard remains focused on managing and financially supporting its existing companies, with the goal of pursuing monetization opportunities and maximizing the value returned to shareholders. We have, are and will consider initiatives including, among others: the sale of our ownership interests, the sale of certain or all of our ownership interests in secondary market transactions, or a combination thereof, as well as other opportunities to maximize shareholder value.

From time to time, we engage in discussions with other companies interested in our ownership interests, either in response to inquiries or as part of a process we initiate. To the extent we believe that a company’s further growth and development can best be supported by a different ownership structure or if we otherwise believe it is in our shareholders’ best interests, we will seek to sell some or all of our position in the company. These sales may take the form of privately negotiated sales of stock or assets, mergers and acquisitions, public offerings of the company’s securities and, in the case of publicly traded companies, sales of their securities in the open market. In the past, we have taken companies public through rights offerings and directed share subscription programs. We will continue to consider these (or similar) programs and the sale of certain company interests in secondary market transactions to maximize value for our shareholders.

Given our strategy, the value of Safeguard is now dependent upon the value of our existing ownership interests and our ability to translate that value into cash as efficiently as possible and to return that capital to our shareholders in the form of stock repurchases and/or special dividends to shareholders.

Our Ownership Interests

An understanding of our ownership interests is important to understanding Safeguard. We categorize our ownership interests that we account for under the equity method and certain companies where we do not have significant influence but whose value is a substantial portion of our portfolio into stages based upon revenue generation. The Initial Revenue Stage is made up of businesses that have revenues of $1 million or less. The Expansion Stage is made up of companies that have revenue in the range of $1 million to $5 million. The Traction Stage is made up of companies that have revenue in the range of $5 million to $10 million. The High Traction Stage is made up of companies that have revenue in the range of $10 million to $15 million. Additionally, as some of our companies have grown we have added additional categories for our companies with revenues of $20 million to $50 million and greater than $50 million.  The Company reflects revenue categories based on a one quarter lag.

The ownership percentages indicated below are presented as of December 31, 2020 for certain companies in which we held ownership interests at February 26, 2021 and reflect the percentage of the vote we were entitled to cast at that date based on issued and outstanding voting securities (on a common stock equivalent basis), excluding the effect of options, warrants and convertible debt (primary ownership).

Initial Revenue Stage: Up to $1 million

There are no companies in which we have an ownership interest and account for under the equity method that are within this stage of growth. However, see section below regarding Other Ownership Interests.

Expansion Stage: $1 million to $5 million

Moxe Health Corporation

Expansion

(Safeguard Ownership: 27.6%)

Headquartered in Madison, Wisconsin, Moxe Health provides a clinical data clearinghouse that connects health systems with their network of health plans.  Moxe’s key products, Substrate and Convergence, allow for bi-directional data flow between payors and providers to complete various risk adjustment, quality, and prior authorization use cases. www.moxehealth.com

Traction Stage: $5 million to $10 million

Clutch Holdings, Inc.

Traction

(Safeguard Ownership: 42.3%)

Headquartered in Ambler, Pennsylvania, Clutch has revolutionized how marketing teams for premier brands develop and foster relationships with their customers. Clutch’s advanced marketing platform serves as a customer hub, delivering deep intelligence derived from real-time behaviors and transactions across in-store, online, mobile and social channels. www.clutch.com

meQuilibrium

Traction

(Safeguard Ownership: 32.0%)

Headquartered in Boston, Massachusetts, meQuilibrium is an engagement and performance platform that leverages behavioral psychology and data science to improve workforce resilience, agility, and adaptive capacity.  The Company offers solutions for managers, teams, and individual employees. www.mequilibrium.com

Trice Medical, Inc.

Traction

(Safeguard Ownership: 16.6%)

Headquartered in Malvern, Pennsylvania, Trice Medical was founded to fundamentally improve orthopedic diagnostics for the patient, physician and payor by providing instant, eyes-on, answers. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physician's office. Trice's mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system. www.tricemedical.com

Zipnosis, Inc.

Traction

(Safeguard Ownership: 37.2%)

Headquartered in Minneapolis, Minnesota, Zipnosis provides health systems with a white-labeled, fully integrated virtual care platform. Through Zipnosis’ tech-enabled treatment and triage tools, clients can offer convenient access to care while improving clinician efficiency. Currently, patients may be treated for more than 90 conditions via such treatment and triage tools. www.zipnosis.com

Lumesis, Inc.

Traction

(Safeguard Ownership: 43.4%)

Headquartered in Stamford, Connecticut, Lumesis is a financial technology company focused on providing business efficiency, data and regulatory solutions to the municipal bond marketplace. Lumesis’ DIVER platform helps more than 500 firms with more than 43,000 users efficiently meet credit, regulatory and risk needs. www.lumesis.com

High Traction Stage: $10 million to $15 million

InfoBionic, Inc.

High Traction

(Safeguard Ownership: 25.2%)

Headquartered in Waltham, Massachusetts, InfoBionic is an emerging digital health company focused on creating patient monitoring solutions for cardiac arrhythmias. InfoBionic’s MoMe® Kardia cloud-based, remote patient monitoring platform delivers on-demand, actionable monitoring data and analytics directly to the physicians themselves. www.infobionic.com

Revenue of $20 million to $50 million

Aktana, Inc.

 $20 million to $50 million

(Safeguard Ownership: 15.1%)

Headquartered in San Francisco, California, Aktana is a pioneer in decision support for global life science sales teams. Aktana helps its customers improve their commercial effectiveness by delivering data-driven insights and suggestions directly to sales reps, coordinating multi-channel actions and providing insight regarding which strategies work best for which customers under which conditions. www.aktana.com

Prognos Health Inc.

$20 million to $50 million

(Safeguard Ownership: 28.5%)

Headquartered in New York, New York, Prognos is a healthcare platform company transforming the ability to access, manage and analyze healthcare data in partnership with Life Sciences brands, payers, and clinical diagnostics organizations. Prognos’ innovations enhance the value of laboratory results and clinical diagnostic data through advanced analytics and artificial intelligence techniques. www.prognos.ai

Syapse, Inc.

$20 million to $50 million

(Safeguard Ownership: 18.9%)

Headquartered in Palo Alto, California, Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Syapse’s platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. www.syapse.com

Greater than $50 million

Flashtalking, Inc.

Greater than $50 million

(Safeguard Ownership: 13.4%)

Headquartered in New York, New York, Flashtalking is a data-driven ad management and analytics technology company that uses data to personalize advertising in real-time, analyze its effectiveness and enable optimization that drives better engagement and ROI for sophisticated global brands. Spongecell, Inc. merged into Flashtalking in January 2018. www.flashtalking.com

MediaMath, Inc.

Greater than $50 million

(Safeguard Ownership: 13.3%)

Headquartered in New York, New York, MediaMath is a global technology company that is leading the movement to revolutionize traditional marketing and drive transformative results for marketers through its TerminalOne Marketing Operating System®. MediaMath empowers marketers with an extensible, open platform that activates data, automates execution and optimizes interactions across all addressable media, delivering superior performance, transparency and control to all marketers and better, more individualized experiences for consumers. www.mediamath.com

Other ownership interests

In addition to the above companies, we also have smaller ownership interests in a variety of other companies where we do not exert significant influence and do not participate in any management activities. In some cases, these ownership interests generally are the result of previous positions that have been diluted or residual interests resulting from the acquisition of companies where we had an ownership interest.

Britepool: Provider of digital marketing and advertising services created to serve a free website, online newspapers and magazines. The company specializes in identity verification, advertising and privacy, digital marketing and data for its clients, enabling its clients to inherently collect and match identities with large quantities of personal information for targeted advertising. www.britepool.com

b8ta: Operator of a software-powered retail showroom designed to make physical retail accessible for all. The company's showrooms are software-driven brick-and-mortar stores that help consumers to buy hardware, internet of things and other technology products, enabling customers to discover, try and buy the latest tech products. The company is headquartered in San Francisco, California. www.b8ta.com

Hoopla Software, Inc.: Headquartered in San Jose, California, Hoopla provides cloud-based software that helps sales organizations inspire and motivate sales team performance. Hoopla's Sales Motivation Platform combines modern game mechanics, data analytics and broadcast-quality video in a cloud application that makes it easy for managers to motivate team performance and score more wins. www.hoopla.net

MedCrypt: Developer of a data security platform designed to protect medical devices. The company's platform enables functions such as authenticating users, encrypting data and cryptographically sign settings and patient prescriptions, as well as has the ability to monitor transactions between clinicians and devices for malicious behavior, enabling hospitals and health systems to prevent unauthorized access and misuse of their medical devices. www.medcrypt.co

T-REX Group, Inc.: Headquartered in New York, New York, T-REX is an enterprise solutions provider for the complex financing of esoteric asset backed securities (“ABS”) and energy project finance. T-REX’s SaaS platform supplants manually-generated financial models, driving transparency, standardization, collaboration, efficiency and access in energy project finance and asset backed securitization. www.trexgroup.com

WellTrackONE: Provider of wellness program services intended to offer a comprehensive baseline report for detailing modifiable risk factors, preventative goals and measurable data. The company's services include scheduling, screening and documentation that provide valuable data for outcomes and clinical measurements while at the same time help to generate significant revenue, enabling healthcare professionals to offer wellness visits to their patients and help them to get services for all their medical needs. www.welltrackone.co

Velano Vascular: Developer of a needle-free blood collection medical device intended to reduce the risk and inefficiencies of vascular access practices. The company's flagship products single-use, sterile device, temporarily attaches to a peripheral IV catheter to collect a fresh venous sample to combat the urgent challenge of vascular access, enabling hospitals to deliver painless and secure healthcare solutions for inpatients. www.velanovascular.com

We also have residual interests in a variety of private funds that are in the process of winding down and other companies.  

FINANCIAL INFORMATION ABOUT OPERATING SEGMENTS

We operate as one operating segment based upon the similar nature of our technology-driven companies, the functional alignment of the organizational structure and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

OTHER INFORMATION

The operations of Safeguard and the companies in which it has ownership interests are subject to environmental laws and regulations. Safeguard does not believe that expenditures relating to those laws and regulations will have a material adverse effect on the business, financial condition or results of operations of Safeguard.

AVAILABLE INFORMATION

 

Safeguard Scientifics, Inc. (“Safeguard,”is subject to the “Company,” “we,” “us,” and “our”) is filing this Amendment No. 1informational requirements of the Securities Exchange Act of 1934, as amended. Therefore, we file our annual report on Form 10-K/A for the year ended December 31, 2017 (“Amendment”)10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy statements and other information with, and furnish other reports to, amend our Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (the “SEC”(“SEC”). You can read and copy such documents at the SEC’s public reference facilities in Washington, D.C., New York, New York and Chicago, Illinois. You may obtain information on March 7, 2018 (the “Original Form 10-K”). We are filing this Amendment to (i) revise one risk factor as described in Item 503(c) of Regulation S-K that is applicable to the Company; and (ii) present the information required by Part III of Form 10-K that was previously omitted from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K. The Company is hereby amending the Original Form 10-K as follows:

·On the cover page, to (i) delete the reference in the Original Form 10-K to the incorporation by reference of the Company’s proxy statement for its 2018 annual shareholders’ meeting and (ii) update the date as of which the number of outstanding shares of the Company’s common stock is being provided;

·To present in Part I, Item 1A, the risk factor captioned “Our success is dependent on our senior management,” which has been revised;

·To present the information required by Part III of Form 10-K, which information was originally expected to be incorporated by reference to our definitive proxy statement to be delivered to our shareholders in connection with our 2018 annual meeting of shareholders; and

·To amend and restate Exhibits 31.3 and 31.4, in Part IV, Item 15(b), in their entirety to contain the currently dated certifications from the Company’s principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. The certifications of the Company’s principal executive officer and principal financial officer are attached to this Amendment as Exhibits 31.3 and 31.4. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. The Exhibit Index has also been amended and restated in its entirety to include the certifications as exhibits.

Except as described above, no other changes have been made to the Original Form 10-K. This Amendment does not otherwise update information in the Original Form 10-K to reflect facts or events occurring subsequent to the filing dateoperation of the Original Form 10-K. This Amendment should be read in conjunction with the Original Form 10-K and with any of our filings made withSEC’s public reference facilities by calling the SEC subsequent toat 1-800-SEC-0330. Such material may also be accessed electronically by means of the SEC’s home page on the Internet at www.sec.gov or through Safeguard’s website at www.safeguard.com. Such documents are available as soon as reasonably practicable after electronic filing of the Originalmaterial with the SEC. Copies of these reports (excluding exhibits) also may be obtained free of charge, upon written request to: Investor Relations, Safeguard Scientifics, Inc., 150 N. Radnor Chester Road, Suite F-200, Radnor, Pennsylvania 19087.

The Internet website addresses for Safeguard and its ownership interests are included in this report for identification purposes. The information contained therein or connected thereto is not intended to be incorporated into this Annual Report on Form 10-K.

 

3

The following corporate governance documents are available free of charge on Safeguard’s website: the charters of our Audit, Compensation and Nominating & Corporate Governance Committees, our Corporate Governance Guidelines and our Code of Business Conduct and Ethics. We also will post on our website any amendments to or waivers of our Code of Business Conduct and Ethics that relate to our directors and executive officers.

 

 

Item 1A. PART IRisk Factors

Item 1A.RISK FACTORS

 

You should carefully consider the information set forth below. The following risk factors describe situations in which our business, financial condition and/or results of operations could be materially harmed, and the value of our securities may be adversely affected. You should also refer to other information included or incorporated by reference in this report.

The COVID-19 pandemic is adversely affecting the Original Form 10-Kbusinesses, financial conditions and this Form 10-K/A.operating results of the companies in which we have an ownership interest, as well as our ability to monetize such interests, and it may also cause us to increase the amount of additional capital we will need to provide to such companies.

The current economic and market conditions caused by the COVID-19 pandemic are negatively impacting the companies in which we have ownership interests, including, without limitation, their operations, supply chains, sales infrastructures and the demand for their products and services.  This is negatively affecting their businesses, financial conditions and operating results.  As a result, we may be required to provide additional capital to such companies, which may cause us to face liquidity issues that will constrain our ability to execute our business strategy and limit our ability to provide financial support to all of our existing companies in the amounts that we desire.  We are also experiencing a more challenging mergers and acquisitions market in general for such companies, which has resulted in lower valuation expectations and extended exit timelines for such companies, which, in turn, could negatively affect the amount and timing of the monetization opportunities for such companies and our ability to return value to shareholders.  

The intended monetization of our partner company interests and distributionthe return of net proceedsvalue to shareholders are subject to factors beyond our control.

 

In January 2018, we announced that we will not deploy any capital into new partner companies.  We will instead focus on supporting, and maximizing monetization opportunities for, our existing partner company interests to enable distributions of net proceedsreturn value to shareholders.  However, this strategic plan may require providing significant additional capital and operational support to such existing partner companies and we may not be able to sell our partner company interests during any specific time frame or otherwise on desirable terms, if at all, and there can be no assurance as to how long this process will take or the results that this process will yield.  There can be no assurance as to whether we will realize the value of escrowed proceeds, holdbacks or other contingent consideration, if any, associated with the sale of partnerour company interests.  Additionally, there can be no assurance that we will be able to satisfy our liabilities during this process.  Further, the method, timing and amount of any distributionsreturn of value resulting from the monetization of existing partner companiescompany interests will be at the discretion of our Board of Directors and will depend on market and business conditions and our overall liabilities, capital structure and liquidity position.

The continuing costs and burdens associated with being a public company will constitute a much larger percentageA disposition of one or more of our expensescompany interests may occur at a time that will yield less value than if we held such interests for a longer period of time.

Our companies are at various stages in their lifecycles. The value of our interests in our companies at any point in time is highly dependent on the progress and success such companies have made at such time with respect to the development and marketing of their products and services and that value may fluctuate significantly. In order to effect our strategy of monetizing our interests in our companies, we may dispose of such interests at a time prior to the applicable company reaching its maximum value. Doing so will result in the future delista return of value to shareholders that is less than that which may have been returned if we retained our Common Stock with the New York Stock Exchange and seek to deregister our Common Stock with the SEC.interests in such company for a longer period of time

 

We will remain a public company and will continue to be subject to the listing standards of the New York Stock Exchange and SEC rules and regulations, including the Dodd-Frank Wall Street Reform and Consumer Protection Act and the Sarbanes-Oxley Act of 2002.  The costs and burdens of being a public company will be a significant and continually increasing portion of our expenses under our new strategy.  As part of such monetization efforts, we will likely in the future, once the majority of our partner company interests have been monetized and proceeds therefrom distributed, delist our Common Stock from the New York Stock Exchange and seek to deregister our Common Stock with the SEC.  However, there can be no assurance as to the timing of such transactions, or whether such transactions will be completed at all, and we will continue to face the costs and burdens of being a public company until such time as our Common Stock is delisted with the New York Stock Exchange and deregistered with the SEC.

Our principal business strategy depends upon our ability to make good decisions regarding the deployment of capital into, and subsequent disposition of, our existing partner company interests and, ultimately, the performance of our partnersuch companies, which is uncertain.

 

If we make poor decisions regarding the deployment of capital into, and subsequent disposition of, our existing partner companies, our business strategy will not succeed. If our partnersuch companies do not succeed, the value of our assets could be significantly reduced and require substantial impairments or write-offs and our results of operations and the price of our common stock would be adversely affected. The risks relating to our partner companies include:

 

·

most of our partner companies have a history of operating losses and/or limited operating history;

·

the intense competition affecting the products and services our partner companies offer could adversely affect their businesses, financial condition, results of operations and prospects for growth;

 4

·the inability to adapt to changing marketplaces;

·

the inability to manage growth;

·

the need for additional capital to fund their operations, which we may not be able to fund or which may not be available from third parties on acceptable terms, if at all;

·

the inability to protect their proprietary rights and/or infringing on the proprietary rights of others;

·

that our partner companies could face legal liabilities from claims made against them based upon their operations, products or work;

·

the impact of economic downturns on their operations, results and growth prospects;

·

the inability to attract and retain qualified personnel;

·

the existence of government regulations and legal uncertainties may place financial burdens on the businesses of our partner companies; and

·

the inability to plan for and manage catastrophic events.

 

These and other risks are discussed in detail under the caption “Risks Related to Our Partner Companies” below.

Our Credit Facility subjects us to interest rate risk.

In May 2017,As we entered intoexecute against our strategy, a $75.0 million secured, revolving credit facility (“Credit Facility”) with HPS Investment Partners, LLC (“Lender”). Debt service costs under the Credit Facility are subject to interest rate changes. Interest rates could rise from time to time and significantly increase our cost of borrowing. If that were to occur, replacing the Credit Facility with alternative credit arrangements having a lower cost of borrowing would likely not be possible and no assurance can be given that we would be able to refinance the Credit Facility on attractive terms or at all.

Servicing the indebtedness under the Credit Facility will require a significant amount of cash and our ability to generate cash depends on many factors beyond our control.

Our ability to make payments on the indebtedness under the Credit Facility will depend on our ability to generate cash in the future. We generate cash from proceeds we receive in connection with the sales of our interests in our partner companies. Due to the nature of the mergers and acquisitions market, and the developmental cycle of companies like our partner companies, our ability to generate specific amounts of liquidity from sales of our partner company interests in any given period of time cannot be assured. Our ability to generate cash is also, to a certain extent, subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control. The risk exists that our business will be unable to generate sufficient cash flow to service our indebtedness under the Credit Facility.

Covenants in the agreements governing the Credit Facility could adversely affect our business and/or result in the operation of our business in a way other than as desired by management; our ability to comply with such covenants may be affected by events beyond our control; and a breach of any of these covenants could result in a default under the agreements governing the Credit Facility, which, if not cured or waived, could result in the acceleration of the indebtedness under the Credit Facility.

The Credit Facility contains various covenants that prohibit or limit, subject to certain exceptions, our ability to, among other things:

5

·Sell, transfer, lease, convey or otherwise dispose of all or any part of our business or property;

·Exceed concentration limits with respect to the amount of capital deployed to any single partner company;

·Exceed concentration limits with respect to the amount of capital deployed to one or more partner companies operating in the same or similar industries;

·Deploy capital to partner companies operating outside of certain specified industries;

·Incur or assume liens or additional debt or provide guarantees in respect of obligations of other persons;

·Pay any dividends or make any distribution (in cash or in kind) or payment in respect of, or redeem, retire or purchase any capital stock;

·Enter into, or permit any of our subsidiaries to enter into, any sale and leaseback transaction;

·Wind-up, liquidate or dissolve, or merge, consolidate or amalgamate with any person, or permit any of our subsidiaries to do (or agree to do) so;

·Enter into certain transactions with affiliates; and

·Amend, modify or otherwise change any of our governing documents.

In addition, the Credit Facility requires us to among other things, maintain (i) a liquidity threshold of at least $20 million of unrestricted cash; (ii) a tangible net worth, plus unrestricted cash, of at least 1.75x the amount then outstanding under the Credit Facility; and (iii) a minimum aggregate appraised value of the Company’s ownership interests in its partner companies, plus unrestricted cash in excess of the liquidity threshold, of at least $350 million.

The foregoing covenants could adversely affect our ability to finance our operations, engage in business activities that may be in our interest and plan for or react to market conditions or otherwise execute our business strategies.

Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions.

Our failure to comply with any of these covenants could result in a default under the Credit Facility. If that were to occur, the Lender could choose to accelerate the maturity of the indebtedness. If the Lender were to accelerate the maturity of the indebtedness, we may not have sufficient liquidity to repay the entire balance of the outstanding borrowings and other obligations under the Credit Facility.

A significant amount of our deployed capital may be concentrated in partner companies operating in the same or similar industries, limiting the diversification of our capital deployments.diversification.

 

Except as may be agreed to with our debt providers, we do not have fixed guidelines for diversification of capital deployments, and ourOur capital deployments could be concentrated in several partner companies that operate in the same or similar industries. This may cause us to be more susceptible to any single economic, regulatory or other occurrence affecting those particular industries than we would otherwise be if our partner companies operated in more diversified industries.

Our business model does not rely upon, or plan for, the receipt of operating cash flows from our partner companies. Our partner companies generallydo not provide us with no cash flow from their operations. We rely on cash on hand, liquidity events and our ability to generate cash from capital raising activities to finance our operations.

6

 

We need capital to fund the capital needs of our existing partner companies. We also need cash to service and repay our outstanding debt, finance our corporate overhead and meet our existing funding commitments. As a result, we have substantial cash requirements. Our partner companies generallydo not provide us with no cash flow from their operations. To the extent our partner companies generate any cash from operations, they generally retain the funds to develop their own businesses. As a result, we must rely on cash on hand, partner company liquidity events and new capital raising activities to meet our cash needs. If we are unable to find ways of monetizing our holdings of company interests or raising additional capital on attractive terms, we may face liquidity issues that will require us to constrain our ability to execute our business strategy and limit our ability to provide financial support to our existing partner companies.

Fluctuations in the price of the common stock of our publicly traded holdings may affect the price of our common stock.

 

From time to time, we may hold equity interests in companies that are publicly traded. Fluctuations in the market prices of the common stock of publicly traded holdings may affect the price of our common stock. Historically, the market prices of our publicly traded holdings have been highly volatile and subject to fluctuations unrelated or disproportionate to operating performance.

We may be unable to obtain maximum value for our holdings or to sell our holdings on a timely basis.

 

We hold significant positions in our partner companies. Consequently, ifIf we were to divest all or part of our holdings in a partner company, we may have to sell our interests at a relative discount to a price which may be received by a seller of a smaller portion.intrinsic value. For partner companies with publicly traded stock, we may be unable to sell our holdings at then-quoted market prices. The trading volume and public float in the common stock of a publicly traded partner company in which we have an interest may be small relative to our holdings. As a result, any significant open-market divestiture by us of our holdings in such a partner company, if possible at all, would likely have a material adverse effect on the market price of its common stock and on our proceeds from such a divestiture. Additionally, we may not be able to take our partner companies public as a means of monetizing our position or creating shareholder value.

Registration and other requirements under applicable securities laws and contractual restrictions also may adversely affect our ability to dispose of our partner company holdings on a timely basis.

Our success is dependent on our senior management.

 

Our success is dependent on our senior management team’s ability to execute our strategy. On April 6,In connection with our new strategy announced in 2018, we publicly announcedmade a series of management changes intended to streamline our organizational structure and reduce our operating costs. These aggressive cost-reduction initiatives are intended to better align our cost structure with the strategycosts and since then we announced in January 2018. Thesehave made, and may make, further management changes included the departure of three members of our management team, including our current President and Chief Executive Officer, our current Senior Vice President and Chief Financial Officer, and our current Senior Vice President of Investor Relations and Corporate Communications.from time to time.  A loss of one or more of the remaining members of our senior management team without adequate replacement could have a material adverse effect on us.

Our business strategy may not be successful if valuations in the market sectors in which our partner companies participate decline.

 

Our strategy involves creating value for our shareholders by helping our partner companies build value and, if appropriate, accessing the public and private capital markets. Therefore, our success is dependent on the value of our partner companies as determined by the public and private capital markets. Many factors, including reduced market interest, may cause the market value of our partner companies to decline. If valuations in the market sectors in which our partner companies participate decline, their access to the public and private capital markets on terms acceptable to them may be limited.

7

Our partner companies could make business decisions that are not in our best interests or with which we do not agree, which could impair the value of our holdings.

 

Although we currently own a significant, influential interest in some of our partner companies, we do not maintain a controlling interest in any of our partner companies. Acquisitions of interests in partner companies in which we share or have no control, and the dilution of our interests in or lossa further reduction of our control of partner companies, will involve additional risks that could cause the performance of our interests and our operating results to suffer, including:

 

·

the management teams or other equity or debt holders of a partner companyour companies having economic or business interests or objectives that are different from ours; and

 

·

the partner companies not taking our advice with respect to the financial or operating issues they may encounter.

 

Our inability to control our partner companies also could prevent us from assisting them, financially or otherwise, or could prevent us from liquidating our interests in them at a time or at a price that is favorable to us. Additionally, our partner companies may not act in ways that are consistent with our business strategy. These factors could hamper our ability to maximize returns on our interests and cause us to incur losses on our interests in these partner companies.

We may have to buy, sell or retain assets when we would otherwise not wish to do so in order to avoid registration under the Investment Company Act.

 

The Investment Company Act of 1940 regulates companies which are engaged primarily in the business of investing, reinvesting, owning, holding or trading in securities. Under the Investment Company Act, a company may be deemed to be an investment company if it owns investment securities with a value exceeding 40% of the value of its total assets (excluding government securities and cash items) on an unconsolidated basis, unless an exemption or safe harbor applies. We refer to this test as the “40% Test.” Securities issued by companies other than consolidated partner companies are generally considered “investment securities” for purposes of the Investment Company Act, unless other circumstances exist which actively involve the company holding such interests in the management of the underlying company. We are a company that partners with growth-stage companies to build value; we are not engaged primarily in the business of investing, reinvesting or trading in securities. We are in compliance with the 40% Test. Consequently, we do not believe that we are an investment company under the Investment Company Act.

 

We monitor our compliance with the 40% Test and seek to conduct our business activities to comply with this test. It is not feasible for us to be regulated as an investment company because the Investment Company Act rules are inconsistent with our strategy of actively helping our partner companies in their efforts to build value. In order to continue to comply with the 40% Test, we may need to take various actions which we would otherwise not pursue. For example, we may need to retain a controlling interest in a partner company that we no longer consider strategic, we may not be able to acquire an interest in a company unless we are able to obtain a controlling ownership interest in the company, or we may be limited in the manner or timing in which we sell our interests in a partner company. Our ownership levels also may be affected if our partner companies are acquired by third parties or if our partner companies issue stock which dilutes our ownership interest. The actions we may need to take to address these issues while maintaining compliance with the 40% Test could adversely affect our ability to create and realize value at our partner companies.

Economic disruptions and downturns may have negative repercussions for us.

 

EventsThe COVID-19 pandemic may adversely affect parties with obligations to us, including the subtenant of our previous office space.

In March 2019, we entered into a sublease of our prior corporate headquarters office space beginning in June 2019. The term of the sublease is through April 2026, the same as our underlying lease. Fixed sublease payments to us are escalating over the term of the sublease.  We remain obligated under the original lease for such office space and, in the United States and international capital markets, debt markets and economies may negatively impactevent the subtenant of such office space fails to satisfy its obligations under the sublease, we would be required to satisfy our stock price and our abilityobligations directly to pursue certain tactical and strategic initiatives,the landlord under such as accessing additional public or private equity or debt financing for us or for our partner companies and selling our interests in partner companies on terms acceptable to us and in time frames consistent with our expectations.

8

We cannot provide assurance that material weaknesses in our internal control over financial reporting will not be identified in the future.

We cannot assure you that material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in a material weakness, or could result in material misstatements in our Consolidated Financial Statements. These misstatements could result in a restatement of our Consolidated Financial Statements, cause us to fail to meet our reporting obligations and/or cause investors to lose confidence in our reported financial information, leading to a decline in our stock price.original lease.

 

Risks Related to Our Partner Companies

Most of our partner companies have a history of operating losses and/or limited operating history and may never be profitable.

 

Most of our partner companies have a history of operating losses and/or limited operating history, have significant historical losses and may never be profitable. Many have incurred substantial costs to develop and market their products, have incurred net losses and cannot fund their cash needs from operations. We expect that the operating expenses of certain of our partner companies will increase substantially in the foreseeable future as they continue to develop products and services, increase sales and marketing efforts, and expand operations.

Our partner companies face intense competition, which could adversely affect their business, financial condition, results of operations and prospects for growth.

 

There is intense competition in the technology marketplaces, and we expect competition to intensify in the future. Our business, financial condition, and results of operations will be materially adversely affected if our partner companies are not able to compete successfully. Many of the present and potential competitors may have greater financial, technical, marketing and other resources than those of our partner companies. This may place our partner companies at a disadvantage in responding to the offerings of their competitors, technological changes or changes in client requirements. Also, our partner companies may be at a competitive disadvantage because many of their competitors have greater name recognition, more extensive client bases and a broader range of product offerings. In addition, our partner companies may compete against one another.

The success or failure of many of our partner companies is dependent upon the ultimate effectiveness of newly-created technologies, medical devices, financial services, healthcare diagnostics, etc.

 

Our partner companies’ business strategies are often highly dependent upon the successful launch and commercialization of an innovative technology or device, including, without limitation, technologies or devices used in healthcare, financial services or digital media.  Despite all of our efforts to understand the research and development underlying the innovation or creation of such technologies and devices before we deploy capital into a partner company, sometimes the performance of the technology or device does not match our expectations or those of our partnersuch company. In those situations, it is likely that we will incur a partial or total loss of the capital which we deployed in such partner company.

Our partner companies may fail if they do not adapt to changing marketplaces.

 

If our partner companies fail to adapt to changes in technology and customer and supplier demands, they may not become or remain profitable. There is no assurance that the products and services of our partner companies will achieve or maintain market penetration or commercial success, or that the businesses of our partner companies will be successful.

9

 

The technology marketplaces are characterized by:

·

rapidly changing technology;

·

evolving industry standards;

·

frequent introduction of new products and services;

·

shifting distribution channels;

·

evolving government regulation;

·

frequently changing intellectual property landscapes; and

·

changing customer demands.

 

Our future success will depend on our partner companies’ ability to adapt to these evolving marketplaces. They may not be able to adequately or economically adapt their products and services, develop new products and services or establish and maintain effective distribution channels for their products and services. If our partner companies are unable to offer competitive products and services or maintain effective distribution channels, they will sell fewer products and services and forego potential revenue, possibly causing them to lose money. In addition, we and our partner companies may not be able to respond to the marketplace changes in an economically efficient manner, and our partner companies may become or remain unprofitable.

Our partner companies may grow rapidly, including through acquisitions of other businesses, and may be unable to manage their growth.

 

We expect some of our partner companies to grow rapidly. Rapidrapidly, including through acquisitions of other businesses. Such growth often places considerable operational, managerial, integration and financial strain on a business. To successfully manage rapidsuch growth, our partner companies must, among other things:

 

·

improve, upgrade and expand their business infrastructures;

successfully integrate and operate any newly acquired businesses;

·

scale up production operations;

·

develop appropriate financial reporting controls;

·

attract and retain qualified personnel; and

·

maintain appropriate levels of liquidity.

 

If our partner companies are unable to manage their growth successfully, their ability to respond effectively to competition and to achieve or maintain profitability will be adversely affected.

Based on our business model, some or all of our partner companies will need to raise additional capital to fund their operations at any given time. We may not be able to, or decline to, fund some or all of such amounts and such amounts may not be available from third parties on acceptable terms, if at all. Further, if our partner companies do raise additional capital from third parties, either debt or equity, such capital may rank senior to, or dilute, our interests in such companies.

 

We cannot be certain that our partner companies will be able to obtain additional financing on favorable terms when needed, if at all. Because our resources and our ability to raise capital are not unlimited, weWe may not be able to, or decline to, provide partnerour companies with sufficient capital resources to enable them to reach a cash-flow positive position or a sale of the company, even if we wish to do so.company. General economic disruptions and downturns may also negatively affect the ability of some of our partner companies to fund their operations from other stockholders and capital sources. We also may fail to accurately project the capital needs of partner companies. If partnerour companies need capital, but are not able to raise capital from us or other outside sources, then they may need to cease or scale back operations. In such event, our interest in any such partner company will become less valuable. If our partner companies raise additional capital from third parties, either debt or equity, thatsuch capital may be dilutive, making our interests less valuable or if such capital ranks senior to the capital we have deployed, such capital may entitle its holders to receive returns of capital before the dates on which we are entitled to receive any return of our deployed capital. Also, in the event of any insolvency, liquidation, dissolution, reorganization or bankruptcy of a partner company,one or more our companies, holders of such partner company’s instruments that rank senior to our deployed capital will typically be entitled to receive payment in full before we receive any return of our deployed capital. After returning such senior capital, such partner company may not have any remaining assets to use for returning capital to us, causing us to lose some or all of our deployed capital in such partner company.

10

Economic disruptions and downturns may negatively affect our partner companies’ plans and their results of operations.

 

Many of our partner companies are largely dependent upon outside sources of capital to fund their operations. Disruptions in the availability of capital from such sources will negatively affect the ability of such partner companies to pursue their business models and will force such companies to revise their growth and development plans accordingly. Any such changes will, in turn, negatively affect our ability to realize the value of our capital deployments in such partner companies.

 

In addition, downturns in the economy as well as possible governmental responses to such downturns and/or to specific situations in the economy could affect the business prospects of certain of our partner companies, including, but not limited to, in the following ways: weaknesses in the financial services industries; reduced business and/or consumer spending; and/or systemic changes in the ways the healthcare system operates in the United States.

Some of our partner companies may be unable to protect their proprietary rights and may infringe on the proprietary rights of others.

 

Our partner companies assert various forms of intellectual property protection. Intellectual property may constitute an important part of partner companyour companies’ assets and competitive strengths. Federal law, most typically copyright, patent, trademark and trade secret laws, generally protects intellectual property rights. Although we expect that our partner companies will take reasonable efforts to protect the rights to their intellectual property, third parties may develop similar intellectual property independently. Moreover, the complexity of international trade secret, copyright, trademark and patent law, coupled with the limited resources of our partner companies and the demands of quick delivery of products and services to market, create a risk that partner companyour companies’ efforts to prevent misappropriation of their technology will prove inadequate.

 

Some of our partner companies also license intellectual property from third parties and it is possible that they could become subject to infringement actions based upon their use of the intellectual property licensed from those third parties. Our partner companies generally obtain representations as to the origin and ownership of such licensed intellectual property. However, this may not adequately protect them. Any claims against our partner companies’ proprietary rights, with or without merit, could subject the companies to costly litigation and divert their technical and management personnel from other business concerns. If our partner companies incur costly litigation and their personnel are not effectively deployed, the expenses and losses incurred by our partner companies will increase and their profits, if any, will decrease.

 

Third parties have and may assert infringement or other intellectual property claims against our partner companies based on their patents or other intellectual property claims. Even though we believe our partner companies’ products do not infringe any third party’s patents, they may have to pay substantial damages, possibly including treble damages, if it is ultimately determined that they do. They may have to obtain a license to sell their products if it is determined that their products infringe on another person’s intellectual property. Our partner companies might be prohibited from selling their products before they obtain a license, which, if available at all, may require them to pay substantial royalties. Even if infringement claims against our partner companies are without merit, defending these types of lawsuits takes significant time, is expensive and may divert management attention from other business concerns.

11

 

Certain of our partner companies could face legal liabilities from claims made against their operations, products or work.

 

Because the manufacture and sale of certain partner company products entail an inherent risk of product liability, certain partnerof our companies maintain product liability insurance. Although none of our current partner companies have experienced any material losses in this regard, there can be no assurance that they will be able to maintain or acquire adequate product liability insurance in the future and any product liability claim could have a material adverse effect on a partner company’s financial stability, revenues and results of operations. In addition, many of the engagements of our partner companies involve projects that are critical to the operation of their clients’ businesses. If our partner companies fail to meet their contractual obligations, they could be subject to legal liability, which could adversely affect their business, operating results and financial condition. Partner companyOur companies’ contracts typically include provisions designed to limit their exposure to legal claims relating to their services and products. However, these provisions may not protect our partner companies or may not be enforceable. Also, some of our partner companies depend on their relationships with their clients and their reputation for high-quality services and integrity to retain and attract clients. As a result, claims made against our partner companies’ work may damage their reputation, which in turn could impact their ability to compete for new work and negatively impact their revenue and profitability.

Our partner companies’ success depends on their ability to attract and retain qualified personnel.

 

Our partner companies depend upon their ability to attract and retain senior management and key personnel, including trained technical and marketing personnel. Our partner companies also will need to continue to hire additional personnel as they expand. Although our current partner companies have not been the subject of a work stoppage, any future work stoppage could have a material adverse effect on their respective operations. A shortage in the availability of the requisite qualified personnel or work stoppage would limit the ability of our partner companies to grow, to increase sales of their existing products and services, and to launch new products and services.

Government regulations and legal uncertainties may place financial burdens on the businesses of our partner companies.

 

Failure to comply with applicable requirements of the FDA or comparable regulation in foreign countries can result in fines, recall or seizure of products, total or partial suspension of production, withdrawal of existing product approvals or clearances, refusal to approve or clear new applications or notices and criminal prosecution. Manufacturers of pharmaceuticals and medical diagnostic devices and operators of laboratory facilities are subject to strict federal and state regulation regarding validation and the quality of manufacturing and laboratory facilities. Failure to comply with these quality regulation systems requirements could result in civil or criminal penalties or enforcement proceedings, including the recall of a product or a “cease distribution” order. The enactment of any additional laws or regulations that affect healthcare insurance policy and reimbursement (including Medicare reimbursement) could negatively affect some of our partner companies. If Medicare or private payers change the rates at which our partner companies or their customers are reimbursed by insurance providers for their products, such changes could adversely impact our partner companies.

Some of our partner companies may be subject to significant environmental, health, data security and safety regulation.

 

Some of our partner companies may be subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety, including laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials, as well as to the safety and health of manufacturing and laboratory employees. In addition, some of our companies are subject to federal, state and local financial securities and data security regulations, including, without limitation, the Health Insurance Portability and Accountability Act of 1996, as amended, the California Consumer Privacy Act and the European General Data Protection Regulation, which impose varying degrees of additional obligations, costs and risks upon such companies, including the imposition of significant penalties in the event of any non-compliance. Further, the federal Occupational Safety andHealth Administration has established extensive requirements relating to workplace safety. Compliance with such regulationscould increase operating costs at certain of our partner companies, and the failure to comply could negatively affect theoperations and results of some of our partner companies.

12

Catastrophic events may disrupt our partner companies’ businesses.

 

Some of our partner companies are highly automated businesses and rely on their network infrastructure, various software applications and many internal technology systems and data networks for their customer support, development, sales and marketing and accounting and finance functions. Further, some of our partner companies provide services to their customers from data center facilities in multiple locations. Some of these data centers are operated by third parties, and the partner companies have limited control over those facilities. A disruption or failure of these systems or data centers in the event of a natural disaster, telecommunications failure, power outage, cyber-attack, war, terrorist attack or other catastrophic event could cause system interruptions, reputational harm, delays in product development, breaches of data security and loss of critical data. Such an event could also prevent the partner companies from fulfilling customer orders or maintaining certain service level requirements, particularly in respect of their SaaS offerings. While certain of our partner companies have developed certain disaster recovery plans and maintain backup systems to reduce the potentially adverse effect of such events, a catastrophic event that resulted in the destruction or disruption of any of their data centers or their critical business or information technology systems could severely affect their ability to conduct normal business operations and, as a result, their business, operating results and financial condition could be adversely affected.

 

We cannot provide assurance that our partner companies’ disaster recovery plans will address all of the issues they may encounter in the event of a disaster or other unanticipated issue, and their business interruption insurance may not adequately compensate them for losses that may occur from any of the foregoing. In the event that a natural disaster, terrorist attack or other catastrophic event were to destroy any part of their facilities or interrupt their operations for any extended period of time, or if harsh weather or health conditions prevent them from delivering products in a timely manner, their business, financial condition and operating results could be adversely affected.

 

13

Risks Related to an Investment in our Securities

 

Fluctuations in the price of the common stock of our publicly traded holdings may affect the price of our common stock.

From time to time, we may hold equity interests in companies that are publicly traded. Fluctuations in the market prices of the common stock of publicly traded holdings may affect the price of our common stock. Historically, the market prices of our publicly traded holdings have been highly volatile and subject to fluctuations unrelated or disproportionate to operating performance.

 

PART IIIThe continuing costs and burdens associated with being a public company will constitute a much larger percentage of our expenses and we may in the future delist our common stock with the New York Stock Exchange and seek to deregister our common stock with the SEC.

 

ITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

We will remain a public company and will continue to be subject to the listing standards of the New York Stock Exchange and SEC rules and regulations, including the Dodd-Frank Wall Street Reform and Consumer Protection Act and the Sarbanes-Oxley Act of 2002.  The costs and burdens of being a public company will be a significant and continually increasing portion of our expenses if we are able to monetize our company interests.  As part of such monetization efforts, we will likely in the future, once the majority of our company interests have been monetized, delist our common stock from the New York Stock Exchange and seek to deregister our common stock with the SEC.  However, there can be no assurance as to the timing of such transactions, or whether such transactions will be completed at all, and we will continue to face the costs and burdens of being a public company until such time as our common stock is delisted with the New York Stock Exchange and deregistered with the SEC.

 

Names of Directors and other Information:

Economic disruptions and downturns may have negative repercussions for us.

 

Stephen T. Zarrilli, age 56Other public directorships:Virtus Investment
President and Chief Executive OfficerPartners, Inc.
Director since: 2012Former public directorships within past five years:
Safeguard Board Committees:NoneNutrisystem, Inc.

Events in the United States and international capital markets, debt markets and economies may negatively impact our stock price and our ability to pursue certain tactical and strategic initiatives, such as accessing additional public or private equity or debt financing for us or for our companies and selling our interests in companies on terms acceptable to us and in time frames consistent with our expectations.

We cannot provide assurance that material weaknesses in our internal control over financial reporting will not be identified in the future.

We cannot assure you that material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in a material weakness, or could result in material misstatements in our Consolidated Financial Statements. These misstatements could result in a restatement of our Consolidated Financial Statements, cause us to fail to meet our reporting obligations and/or cause investors to lose confidence in our reported financial information, leading to a decline in our stock price.

 

Item 1B.Career Highlights: Unresolved Staff Comments

President and Chief Executive Officer (November 2012 – present); Senior Vice President and Chief Financial Officer (June 2008 – November 2012); and Acting Chief Administrative Officer and Acting Chief Financial Officer (December 2006 – June 2007), Safeguard Scientifics, Inc.
Co-founder and Managing Director, Penn Valley Group, a middle-market management advisory and private equity firm (2004 – June 2008)
Chief Financial Officer, Fiberlink Communications Corporation (2001 – 2004)
Chief Executive Officer, Concellera Software, Inc. (2000 – 2001)
Chief Executive Officer (1999 – 2000) and Chief Financial Officer (1994 – 1998), US Interactive, Inc.
Deloitte & Touche (1983 – 1994)

None.

 

Item 2.Experience and Qualifications Properties:Mr. Zarrilli has more than 30 years of experience in corporate finance and accounting, general operations and executive management; capital markets transactions; debt and equity financings; merger and acquisition transactions; and emerging ventures.

 

Julie A. Dobson, age 61

Our current corporate headquarters and administrative offices in Radnor, Pennsylvania is approximately 100 square feet of office space in one building.  The initial lease term expires in November 2021.  The sublease for our previous corporate headquarters and administrative offices for approximately 4,000 square feet of office space in Radnor, Pennsylvania expired in November 2020 (from a company in which we have an equity interest).

 Additionally, we have additional administrative offices located in Radnor, Pennsylvania comprising approximately 15,600 square feet, that have been sublet to an unaffiliated party through April, 2026, the remainder of the lease term.

Director since: 2003

Safeguard Board Committees:Compensation (Chair), Nominating & Corporate Governance

Other public directorships:None.

Former public directorships within past five years:American Water Works Company Inc., PNM Resources, Inc. and RadioShack Corporation

 

Career HighlightsItem 3.: Legal Proceedings

Chief Operating Officer, Telecorp PCS, Inc., a wireless/mobile phone company that was acquired by AT&T Wireless, Inc. (1998 – 2002)
Various executive positions during her 18-year career with Bell Atlantic Corporation, including President, Bell Atlantic Corporation’s New York/New Jersey Metro Region mobile phone operations, Vice President of Bell Atlantic Enterprises Corporation, and President and Chief Executive Officer of Bell Atlantic Business Systems International

We, as well as our companies in which we hold ownership interests, are from time to time involved in various claims and legal actions arising in the ordinary course of business. While in the current opinion of management, the ultimate disposition of any of these matters which are currently pending will not have a material adverse effect on our consolidated financial position or results of operations, no assurance can be given as to the outcome of these situations, and one or more adverse dispositions could have a material adverse effect on our consolidated financial position and results of operations, or that of our companies. See Note 12 to the Consolidated Financial Statements for a discussion of ongoing claims and legal actions.

 

Experience and QualificationsItem 4.: Mine Safety DisclosuresMs. Dobson has 22 years of corporate and entrepreneurial experience, including experience relevant to corporate finance and accounting matters; strategic planning, corporate development and operations management; capital markets transactions; and debt and equity financings. Ms. Dobson also has relevant experience growing businesses organically and through merger and acquisition transactions and experience serving on public company boards and the principal committees thereof.

14

Russell D. Glass, age 55

Director since: 2018

Safeguard Board Committees:Compensation

Other public directorships:None

Former public directorships within past five years:None

Career Highlights:

Founder and Managing Member of RDG Capital LLC (2005 – present)
Managing Partner of RDG Capital Fund Management, an investment advisory firm (2014 – present)
Senior Adviser at Knights Genesis Group, a private equity firm (2017 – present)
Director of Blue Bite LLC, a digital marketing technology company (2009 – present)
Director of A.G. Spanos Corporation, a national real estate developer and owner of the NFL Los Angeles Chargers (1993 – present)
Managing Member of Princeford Capital Management, an investment advisory firm (2009 – 2014)
Chief Executive Officer of Cadus Pharmaceutical Corporation (n/k/a Cadus Corporation), a biotechnology holding company (2000 – 2003), and director (1998 – 2011)
Co-Chairman and Chief Investment Officer of Ranger Partners, an investment fund management company (2002 – 2003)
President and Chief Investment Officer of Icahn Associates Corporation, a diversified investment firm and principal investment vehicle for Carl Icahn (1998 – 2002)
Partner at Relational Investors LLC, an investment fund management company (1996 – 1998)
Partner at Premier Partners Inc., an investment banking and research firm (1988 – 1996)
Analyst with Kidder, Peabody & Co., an investment banking firm (1984 – 1986)
Holds directorship at the Council for Economic Education and held other previous directorships at Automated Travel Systems, Inc., Axiom Biotechnologies, Global Discount Travel Services/Lowestfare.com, National Energy Group and Next Generation Technology Holdings, Inc.
Received A.B. in Economics from Princeton University
Received M.B.A. from Stanford Graduate School of Business

Experience and Qualifications:Mr. Glass has experience relating to private equity, investment banking, and serving as chief executive officer of a public company. Mr. Glass has experience serving on the boards of public and private companies in a wide range of industries, including biotech, healthcare information technology, pharmacology, enterprise systems software, real estate, energy, and digital marketing.

Stephen Fisher, age 53

Director since: 2015

Safeguard Board Committees:Audit , Compensation

Other public directorships:Vonage Holdings Corp., Inc.

Former public directorships within past five years:None

Career Highlights:

Senior Vice President and Chief Technology Officer, eBay Inc., a leading ecommerce company (September 2014 – present)
Executive Vice President, Technology (December 2008 – September 2014) and several other executive positions (October 2004 – December 2008) during his tenure with salesforce.com, a provider of leading, worldwide customer relationship management applications and products
Various positions with AT&T Labs (1996 – 1999 and 2001 – 2004)
Founder, President and Chief Executive Officer, NotifyMe Networks (1999 – 2000)

Experience and Qualifications:Mr. Fisher’s corporate experience includes experience relevant to strategic planning; business and product development; operations management; and growing businesses organically. In addition, he possesses deep domain expertise in the technology and communications services sectors.

15

Ira M. Lubert, age 67

Director since: 2018

Safeguard Board Committees:Nominating & Corporate Governance

Other public directorships:None

Former public directorships within past five years:Pennsylvania Real Estate Investment Trust

Career Highlights:

Co-Founder of and a Partner of Quaker Partners Management, L.P., which advises a series of life sciences funds (2002 – present)
Co-Founder of and a Partner of LEM Capital, L.P., which advises a series of real estate funds invested primarily in multifamily properties (2002 – present)
Co-Founder of and a Partner of LBC Credit Management, LP, which advises a series of structured finance funds (2005 – present)
Co-Founder of and a Partner of Patriot Financial Management, L.P., which advises a series of community banking funds (2007 – 2017)
Co-Founder of Versa Capital Management, LLC, specializing in distressed and special situations (2004)
Co-Founder of and a Partner of LLR Management, L.P., which focuses on lower middle market growth companies (1999 – present)
Co-Founder and Chairman of Lubert-Adler Management Company, L.P., which advises a series of real estate funds (1997 – present)
Co-Founder and Chairman of Independence Capital Partners, LLC, which provides services to certain investment advisers (1997 – present)
Managing Director and Co-Founder of TL Ventures, the subsequent Safeguard-affiliated family of early stage venture funds with over $1 billion of capital under management (1986 – 1997)

Experience and Qualifications:Mr. Lubert has 30 years of experience relating to private equity and investment management, including life sciences funds. Mr. Lubert began his private equity career with Safeguard. Mr. Lubert was honored as Drexel University’s LeBow College of Business 60th Business Leader of the Year and was honored by Temple University for his excellence in leadership with the Musser Award.

George MacKenzie, age 69

Director since: 2003

Safeguard Board Committees:Audit (Chair), Compensation, Nominating & Corporate Governance

Other public directorships:American Water Works Company Inc. (Chair) and Tractor Supply Company

Former public directorships within past five years:None

Career Highlights:

Interim Chief Executive Officer, American Water Works Company Inc., a provider of water services in North America (January – April 2006)
Interim Chief Executive Officer, C&D Technologies, Inc., a technology company that markets systems for the conversion and storage of electrical power (March – July 2005)
Executive Vice President and Chief Financial Officer, P.H. Glatfelter Company, a manufacturer of specialty papers and engineered products (September 2001 – June 2002)
Vice Chairman (2000 – 2001) and Chief Financial Officer (1995 – 2001) of, and several other executive positions during his 22-year career with, Hercules, Incorporated, a global chemical specialties manufacturer

Experience and Qualifications:Mr. MacKenzie has extensive experience in corporate finance and accounting. He has served as the chief financial officer of a publicly traded company, and he is a certified public accountant. Mr. MacKenzie also has experience in capital markets transactions; debt and equity financings; global strategic planning and operations management; merger and acquisition transactions; and risk management. In addition, he has extensive public company board experience, including service on multiple audit, compensation and nominating and corporate governance committees.

16

Maureen F. Morrison, age 63

Director since: October, 2017

Safeguard Board Committees:Audit

Other public directorships:None

Former public directorships within past five years:None

Career Highlights:

Audit Partner with PriceWaterhouseCoopers LLP for 28 years, serving public and private multi-national clients in the technology and manufacturing industries. Ms. Morrison led the Atlanta, Georgia Technology Audit Practice for six years, and held other positions at the firm, prior to her retirement in 2015.

Experience and Qualifications:During her tenure at PriceWaterhouseCoopers LLP, Ms. Morrison worked closely with clients concentrated in the technology industry dealing with acquisitions, international expansion, financing transactions, subjective technical matters and regulatory compliance. Ms. Morrison is a certified public accountant and has extensive experience in accounting, finance, mergers and acquisitions and capital markets transactions.

John J. Roberts, age 73

Director since: 2003

Safeguard Board Committees:Audit, Compensation, Nominating & Corporate Governance (Chair)

Other public directorships:Armstrong World Industries, Inc., Vonage Holdings Corp., Inc. and Trustee, Pennsylvania Real Estate Investment Trust

Former public directorships within past five years:None

Career Highlights:

Global Managing Partner and a Member of the Leadership Team, PricewaterhouseCoopers LLP at the time of his retirement in June 2002, completing a 35-year career with the professional services firm during which he served in a variety of client service and operating positions

Experience and Qualifications:Mr. Roberts is a certified public accountant and has extensive experience in corporate finance and accounting; capital markets transactions; debt and equity financings; global strategic planning, corporate development and operations management; management and technology consulting; risk management; and merger and acquisition transactions. He also has extensive public and private company board service experience, including service on multiple audit committees.

17

Robert J. Rosenthal, PhD, age 61

Chairman of the Board (effective May 2016)

Director since: 2007

Safeguard Board Committees:None*

Other public directorships:Bruker Corporation

Former public directorships within past five years: None

*As our current Chairman of the Board, Dr. Rosenthal is an ex officio member of each of our standing committees.

Career Highlights:

Chief Executive Officer and director, Taconic Biosciences, Inc., a provider of research models for pharmaceutical and biotechnology researchers (June 2014 – present)
Chairman and Chief Executive Officer, IMI Intelligent Medical Implants, AG, a medical technology company that developed an intelligent retinal implant for degenerative retinal disorders (January 2010 – December 2013)
President and Chief Executive Officer, Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools (October 2005 – December 2009)
President and Chief Executive Officer, TekCel, Ltd., a provider of life sciences research tools (October 2003 – January 2007)
President and Chief Executive Officer, Boston Life Sciences, Inc., a diagnostic and therapeutic development company (July 2002 – October 2003)
President and Chief Executive Officer, Magellan Discovery Technologies, LLC, a life sciences acquisition company (January 2001 – July 2002)
Senior Vice President, Perkin Elmer Corporation and President of its instrument division (March 1999 – November 2000)
Various executive positions, Thermo Optek Corporation (September 1995 – February 1999)

Experience and Qualifications:Dr. Rosenthal has 30 years of experience relating to companies involved in the development of diagnostics, therapeutics, medical devices and life sciences tools and technologies. His specific experience includes strategic planning and positioning; corporate, business and product development; operations management; capital markets transactions; debt and equity financings; fund-raising; merger and acquisition transactions; and corporate finance. Dr. Rosenthal also has significant public and private company board experience.

 

Names of Officers and Biographical InformationNot applicable.

 

NameAge Position Executive Officer Since
Stephen T. Zarrilli56 President, Chief Executive Officer and Director 2008
Jeffrey B. McGroarty48 Senior Vice President and Chief Financial Officer 2012
Brian J. Sisko57 Chief Operating Officer, Executive Vice President and Managing Director 2007

ANNEX TO PART I — EXECUTIVE OFFICERS OF THE REGISTRANT

Name

Age

 

Position

 

Executive Officer Since

Eric C. Salzman

53

 

Chief Executive Officer

 

2020

Mark A. Herndon

51

 

Senior Vice President and Chief Financial Officer

 

2018

 

Mr. ZarrilliSalzman joined Safeguard as Chief Restructuring Officer in April 2020.  Mr. Salzman began serving as the Chief Executive Officer in December 2020.  Mr. Salzman has a 25-year track record partnering with growth companies as an investor, board member and strategic advisor.  He has worked in M&A, restructuring, growth and special situations investing at a number of investment banks and private equity funds, including Credit Suisse and Lehman Brothers.  Mr. Salzman helped oversee the monetization of a $2 billion portfolio of illiquid assets in the Lehman Brothers Bankruptcy Estate and subsequently advised several investment funds on value-maximization strategies for their respective portfolios.  He currently serves as a director on a number of Safeguard portfolio companies as well as an independent director at publicly traded 8x8, Inc.  Mr. Salzman earned a B.A. Honors from the University of Michigan and an MBA from Harvard University

Mr. Herndon joined Safeguard as Senior Vice President and Chief Financial Officer in June 2008 and became President and Chief Executive Officer in November 2012.September 2018. Prior to joining Safeguard, Mr. Zarrilli co-founded,Herndon served in 2004, the Penn Valley Group, a middle-market management advisoryvariety of client service and private equity firm, and served as a Managing Director there until June 2008. Mr. Zarrilli also served as Acting Senior Vice President, Acting Chief Administrative Officer and Acting Chief Financial Officer of Safeguard from December 2006 to June 2007. Mr. Zarrilli also served as the Chief Financial Officer, from 2001 to 2004, of Fiberlink Communications Corporation, a provider of mobile access solutions for large enterprises; as the Chief Executive Officer, from 2000 to 2001, of Concellera Software, Inc., a developer of content management software; as the Chief Executive Officer, from 1999 to 2000, and Chief Financial Officer, from 1994 to 1998, of US Interactive, Inc. (at the time a public company), a provider of Internet strategy consulting, marketing and technology services; and, previously, with Deloitte & Touche from 1983 to 1994. Mr. Zarrilli is a director of Virtus Investment Partners, Inc. and currently serves as Chair of the Audit Committee and, until June 2015, was a director and Chairman of the Audit Committee of NutriSystem, Inc.

18

Mr. McGroarty joined Safeguard as Vice President and Corporate Controller in December 2005, subsequently became Vice President - Finance and Corporate Controller, and served as Senior Vice President - Finance from November 2012 until his promotion to Senior Vice President and Chief Financial Officer in April 2013. Prior to joining Safeguard, Mr. McGroarty served as Interim Controller of Cephalon, Inc. from October 2005 to December 2005; Vice President-Financial Planning & Analysis and previously Assistant Controllernational office roles at Exide Technologies from March 2002 to September 2005; and, previously, with PricewaterhouseCoopers from 1991 to 2001.2018, including his position as Assurance Partner from 2006 until 2018.

PART II

 

Mr. Sisko joined Safeguard as Senior Vice PresidentItem 5. Market for Registrant’s Common Equity, Related Stockholder Matters and General Counsel in August 2007 and served as Executive Vice President and Managing Director from November 2012 until his promotion to Chief Operating Officer, Executive Vice President and Managing Director in January 2014. Prior to joining Safeguard, Mr. Sisko served as Chief Legal Officer, Senior Vice President and General CounselIssuer Purchases of Traffic.com (atEquity Securities

Our common stock is listed on the time, a public company), a former partner company of Safeguard, from February 2006 until June 2007 (following its acquisition by NAVTEQ Corporation in March 2007); Chief Operating Officer from February 2005 to January 2006 of Halo Technology Holdings, Inc., a public holding company for enterprise software businesses (Halo Technology Holdings filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in August 2007); ran B/T Business and Technology, an advisor and strategic management consultant to a variety of public and private companies, from January 2002 to February 2005; and was a Managing Director from April 2000 to January 2002, of Katalyst, LLC, a venture capital and consulting firm. Mr. Sisko also previously served as Senior Vice President-Corporate Development and General Counsel of National Media Corporation, at the time a New York Stock Exchange-listed multi-media marketing company with operations in 70 countries,Exchange (Symbol: SFE). The high and low sale prices reported within each quarter of 2020 and 2019 were as a partnerfollows: 

  

High

  

Low

 

Fiscal year 2020:

        

First quarter

 $11.11  $4.43 

Second quarter

  7.87   4.92 

Third quarter

  7.12   5.15 

Fourth quarter

  7.25   5.33 

Fiscal year 2019:

        

First quarter

 $11.66  $8.36 

Second quarter

  12.91   10.59 

Third quarter

  12.79   10.92 

Fourth quarter

  12.43   10.57 

The high and low sale prices reported in the corporate finance, mergers first quarter of 2021 through February 26, 2021 were $8.59 and acquisitions practice group$6.35 respectively, and the last sale price reported on February 26, 2021, was $7.65.  As of February 26, 2021, there were approximately 10,487 beneficial holders of our common stock.

Special Dividend

On November 7, 2019, the Board of Directors declared a special cash dividend of $1.00 per share, payable on December 30, 2019 to shareholders of record as of the Philadelphia-based law firm, Klehr, Harrison, Harvey, Branzburg LLP.close of business on December 23, 2019.

 

Skills and QualificationsIssuer Purchases of BoardEquity Securities

 

The following table includesprovides information about our purchases of equity securities during the skills and qualifications of each director that led our Boardquarter ended December 31, 2020 registered pursuant to conclude that the director is qualified to serve on our Board.

George
MacKenzie
Russell
Glass
Ira
Lubert
Maureen
Morrison
John
Roberts
Robert
Rosenthal
Stephen
Zarrilli
Julie
Dobson
Stephen
Fisher
Operational / Direct Management Experienceüüüüüüüüü
Capital Markets Experienceüüüüüüüüü
Private Equity / Venture Capital Industry Experienceüüü��üüüüü
Financial Expertise / Literacyüüüüüüüüü
C-level Experienceüüüüüüüü
Other Public / Private Director Experienceüüüüüüüü

Audit Committee. The Audit Committee held four meetings during 2017. The Audit Committee’s responsibilities, which are described in detail in its charter, include, among other duties, the responsibility to:

·Assist the Board in fulfilling its responsibilities regarding general oversight of the integrity of Safeguard’s financial statements, Safeguard’s compliance with legal and regulatory requirements and the performance of Safeguard’s internal audit function;

·Interact with and evaluate the performance, qualifications and independence of Safeguard’s independent registered public accounting firm;

·Review and approve related party transactions; and

·Prepare the report required by SEC regulations to be included in the proxy statement.

19

The Audit Committee has the sole authority to retain, set compensation and retention terms for, terminate and oversee the relationship with Safeguard’s independent registered public accounting firm (which reports directly to the Audit Committee). The Audit Committee also oversees the activities of the internal auditor, reviews the effectiveness of the internal audit function and approves the appointment of the internal auditor. The Audit Committee has the authority to obtain advice, counsel and assistance from internal and external legal, accounting or other advisors as the Audit Committee deems necessary to carry out its duties and to receive appropriate funding from Safeguard for such advice and assistance. Although the Audit Committee has the powers and responsibilities set forth in its charter, its role is oversight, and management has primary responsibility for the financial reporting process of Safeguard.

The Board has determined that each member of the Audit Committee meets the independence requirements established by SEC regulations, the NYSE listing standards and our Corporate Governance Guidelines. The Board has determined that Ms. Morrison, Mr. Roberts and Dr. Rosenthal are “audit committee financial experts” within the meaning of the SEC regulations, and the Board has determined that each member of the Audit Committee has accounting and related financial management expertise within the meaning of the NYSE listing standards. The Board previously determined that Mr. MacKenzie, who is not standing for re-election at this year’s annual meeting, was an “audit committee financial expert” within the meaning of the SEC regulations. Mr. Roberts serves as a member of the audit committee of the board of directors of four publicly traded companies, including our Audit Committee. The Board has determined that such simultaneous service does not impair Mr. Roberts’ ability to effectively serve on our Audit Committee.

20

Code of Business Conduct and other Charters.

Safeguard’s Corporate Governance Guidelines, Code of Business Conduct and Ethics, Audit Committee Charter, Compensation Committee Charter and Nominating & Corporate Governance Committee Charter are available at www.safeguard.com/governance. The Code of Business Conduct and Ethics is applicable to all employees of Safeguard, including each of our executive and financial officers, and the members of our Board. Safeguard will post information regarding amendments to or waivers from our Code of Business Conduct and Ethics (to the extent applicable to Safeguard’s directors or executive officers) in the Corporate Governance section of our website. Our website is not part of this report. All references to our website address are intended to be inactive textual references only.

Section 16(a) Beneficial Ownership Reporting Compliance.

Section 16(a)12 of the Securities Exchange Act of 1934, requires our directors, executive officers and greater than 10% holdersas amended (the "Exchange Act"):

Period

 Total Number of Shares Purchased (a)  Average Price Paid Per Share  

Total Number of Shares Purchased as Part of Publicly Announced Plan (b)

  

Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plan (b)

 

October 1, 2020 - October 31, 2020

    $     $14,636,135 

November 1, 2020 - November 30, 2020

    $     $14,636,135 

December 1, 2020 - December 31, 2020

  1,456  $6.74     $14,636,135 

Total

  1,456  $6.74        

(a) During the fourth quarter of 2020, we repurchased an aggregate of approximately 1 thousand shares of our common stock initially issued as restricted stock awards to file withemployees and subsequently withheld from employees to satisfy the SEC reportsstatutory withholding tax liability upon the vesting of ownershipsuch restricted stock awards.

(b) In July 2015, our Board of Directors authorized us to repurchase shares of our securities and changesoutstanding common stock with an aggregate value of up to $25.0 million.  These repurchases may be made in ownership of our securities. Based solely on our reviewopen market or privately negotiated transactions, including under plans complying with Rule 10b5-1 of the copiesExchange Act, based on market conditions, stock price, and other factors.  The share repurchase program does not obligate us to acquire any specific number of reports we have received and upon written representations from the reporting persons that no Form 5 reports were required to be filed by those persons, Safeguard believes there were no late filings by our directors and executive officers during 2017. There were no known holders of greater than 10% of our common stock during 2017 who failed to file the required reports.shares.

 

ITEM 11.EXECUTIVE COMPENSATION

 

Compensation Discussion and AnalysisItem 6. Selected Consolidated Financial Data

 

Executive SummaryNot applicable for a smaller reporting company.

 

Our Compensation Committee (for purposes of this discussion, the “Committee”) is responsible for establishing our company-wide compensation philosophy and practices, for determining the compensation for our “named executive officers,” and for approving the compensation for our other senior executives, based on the recommendations of our President and Chief Executive Officer. This CompensationItem 7. Management’s Discussion and Analysis describesof Financial Condition and Results of Operations

Cautionary Note Concerning Forward-Looking Statements

This Annual Report on Form 10-K contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about Safeguard Scientifics, Inc. (“Safeguard” or “we”), the industries in which we operate and other matters, as well as management's beliefs and assumptions and other statements regarding matters that are not historical facts.  These statements include, in particular, statements about our executive compensation programplans, strategies and prospects.  For example, when we use words such as “projects,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “should,” “would,” “could,” “will,” “opportunity,” “potential” or “may,” variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the compensationmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Our forward-looking statements are subject to risks and uncertainties.  Factors that could cause actual results to differ materially include, among others, our ability to make good decisions made for 2017about the deployment of capital, the fact that our ownership interests may vary from period to period, our substantial capital requirements and absence of liquidity from our holdings, competition, our inability to obtain maximum value for our named executive officers. At December 31, 2017, there were three individuals serving as named executive officersownership interests, our ability to attract and retain qualified employees, our ability to execute our strategy, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests companies, our need to manage our assets to avoid registration under the Investment Company Act of Safeguard:

Stephen T. ZarrilliPresident and Chief Executive Officer
Jeffrey B. McGroartySenior Vice President and Chief Financial Officer
Brian J. SiskoChief Operating Officer, Executive Vice President and Managing Director

Our senior executive group is currently comprised1940, and risks associated with our ownership interests and their performance, including the fact that most of the companies in which we have an ownership interest have a totallimited history and a history of six executivesoperating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which they operate, compliance with the titlegovernment regulation and legal liabilities, all of Senior Vice Presidentwhich are discussed in Item 1A. “Risk Factors.” Many of these factors are beyond our ability to predict or higher, including our current three named executive officers. This Compensation Discussion and Analysis (“CD&A”) also describes programs that apply to our senior executive groupcontrol. In addition, as a whole.result of these and other factors, our past financial performance should not be relied on as an indication of future performance. All forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by this cautionary statement. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report might not occur.

 

Overview

Over the recent past, Safeguard has provided capital and relevant expertise to fuel the growth of technology-driven businesses. In January 2018, the Company announced that, effective immediately, the Company would cease making capital deployments into any new partner company opportunitiesmany, but not all cases, we are actively involved, influencing development through board representation and that it would focus its efforts on managing and financially supporting its existing partner companies to exit events, and ultimately returning the net proceeds of such efforts to its shareholders. This strategy is sometimes referred tomanagement support, in this CD&A as the “New Strategy.” Further, on April 6, 2018, the Company announced that the Company promoted Mr. Siskoaddition to the position of Presidentinfluence we exert through our equity ownership. We also continue to hold relatively small equity interests in other enterprises where we do not exert significant influence and Chief Executive Officer, effective as of July 1, 2018,do not participate in management activities. In some cases, those interests relate to succeed Mr. Zarrilli. Mr. Zarrilli will act as a special advisor to the Company through September 30, 2018 and then retire. In addition, Mr. McGroarty will departresidual interests from the Company, effective June 30, 2018. David Kille, currently the Company’s Corporate Controller, will assume the role of Chief Financial Officer, effective June 1, 2018.

21

Other than as specifically noted, the discussion set forthprior larger interests or from companies that acquired companies in this CD&A concerning the Company’s compensation policies and practices, relates to periods prior to the establishment of the New Strategy and, therefore, does not necessarily reflect policies and practices that will prevail or apply under the New Strategy. Set forth below under the heading “New Strategy - Changes in Compensation Policies and Practices” is a summary regarding changes in compensation policies and practices recently adopted by the Committee in the context of the New Strategy.

2017 Business Highlights

Highlights of the year are included below because the Committee believes senior executive compensation should correlate with Safeguard’s performance.

Overall, the Committee believes that Safeguard executed well against its 2017 strategic plan.

·We deployed $36.8 million of additional capital to support the growth of partner companies in which we already had an interest at December 31, 2016.

·Most of our partner companies performed on or ahead of plan, with year over year revenue growth in excess of 23%.

·We returned an aggregate of $16.9 million to our balance sheet, consisting of $15.5 million in cash related to the sale of our interest in Nexxt, Inc., formerly Beyond.com, and $1.4 million from escrows related to prior years’ transactions.

·In addition, we received a $10.5 million promissory note bearing 9.5% interest payable on or before March 1, 2020 in connection with the Beyond.com transaction.

·We repurchased an aggregate of $14 million of our outstanding convertible debentures.

·We entered into a $75 million debt facility with HPS Investment Partners, LLC.

Key 2017 Compensation Decisions

·The 2017 base salaries and target management incentive plan awards for Messrs. Zarrilli, McGroarty and Sisko were unchanged from their 2016 levels.

·After reviewing Safeguard’s performance against the objectives set forth in the 2017 management incentive plan, the Committee approved a 90% achievement level in the partner company performance component of the corporate objectives and a 60% achievement level in overall corporate performance, resulting in a 75% payout (against targeted amounts) to our named executive officers. While the Committee believed the year included positive results in corporate operations, and in most of the partner companies, Safeguard did not meet all of our objectives, particularly in the returns provided to shareholders.

·As part of the deliberations regarding long-term incentive awards made to our management team, the Committee reviewed the competitive market data provided by its consultant, the individual performance of each of our named executive officers and an assessment of the long-term compensation element relative to our peers. Based on such review and taking into consideration that no deployments were made in 2017 into new partner companies and, therefore, a pool of new partner companies to measure performance against does not exist, for the grants made in 2017, the Committee (1) chose to reduce the opportunity to earn long-term incentives by approximately 40% for each of Messrs. Zarrilli, McGroarty and Sisko as compared to the grants made in 2016 and (2) awarded such incentives solely in the form of restricted stock grants subject to time-based vesting. This compares to the value of the 2016 grants that were awarded at a ratio of 1/3 in time-based restricted stock and 2/3 in performance based stock units.

22

Effective Corporate Governance Principles

Below is a summary of what we did and what we didn’t do relating to executive compensation during and related to 2017, and prior to our announcement of the New Strategy:had ownership interests.

WHAT WE DID:
üEmphasized variable pay for performance by linking our named executive officers’ target incentive compensation to Safeguard’s financial performance and the attainment of specified metrics
üMaintained short-term and long-term incentive programs with distinct performance-based measures
üEmphasized a long-term orientation under our equity compensation program by requiring a minimum service vesting period for performance-based equity grants if the performance hurdles are achieved in the near term
üApplied double-trigger change of control vesting of equity awards made to our senior executives
üRetained an independent compensation consulting firm that provides no other services to Safeguard
üMaintained a compensation recoupment policy that will permit us to seek reimbursement of cash and incentive compensation and/or equity grants in certain instances of financial statement restatement
üMaintained meaningful stock ownership guidelines for our senior executives and Board members
WHAT WE DIDN’T DO:
ÄProvide golden parachute excise tax or other tax gross-ups upon a change in control
ÄProvide any material perquisites
ÄPermit repricing of underwater options without shareholder approval
ÄGrant stock option awards or stock appreciation rights (“SARs”) below 100% of fair market value
ÄPermit hedging or short-sales transactions in our stock by our senior executives, or permit the use of Safeguard stock as collateral for indebtedness by our executive officers
ÄProvide a pension plan or special retirement program other than our 401(k) plan, which is available to all employees
ÄProvide post-retirement health coverage

The Committee reviews our compensation philosophy each year to ensure that its principles and objectives are aligned with our overall business strategy and aligned with the interests of our shareholders. We seek to apply a consistent philosophy across our executive group, not just among our named executive officers.

23

Compensation Philosophy and Objectives

Our overall goals in compensating our executives in 2017 were as follows:

·Attract, retain and motivate executives whose experience and skills could be leveraged across our partner companies to facilitate the partner companies’ growth, success and ultimate monetization;

·Promote and reward the achievement of short-term and long-term corporate and individual objectives that our Board and management believe will lead to long-term growth in shareholder value; and

·Encourage meaningful equity ownership and the alignment of executive and shareholder interests as an incentive to increase shareholder value.

Our executive compensation program in 2017 was intended to:

·Provide a mix of fixed and variable at-risk cash compensation;

·Balance rewards for short-term performance with our ultimate goal of producing long-term shareholder value;

·Link variable compensation to specific, identifiable metrics that demonstrate value creation for Safeguard; and

·Facilitate executive retention.

 

In January 2018, Safeguard announced that we will not deploy any capital into new opportunities and will focus on supporting our existing companies and maximizing monetization opportunities to enable returning value to shareholders. In that context, we have, are and will consider initiatives including, among others: the New Strategy. See “New Strategy - Changes in Compensation Policies and Practices” below.

Role of the Compensation Committee in Compensation Decisions

The Committee is responsible for the designsale of our executive compensation program and for making decisions regarding our named executive officers’ compensation. The Committee also makes, or has final approval authority regarding, all compensation decisions for our other senior executives. Annually,ownership interests, the Committee reviews executive compensation practices, including the methodology for setting total named executive officers’ compensation, the goals of the program, and the overall compensation philosophy for Safeguard. In setting executive compensation and designing our overall compensation program, the Committee considers the data and advice provided by its independent compensation consultant (as well as information that may be provided by management) to determine the appropriate level, on an absolute and relative basis, of compensation, as well as the mix of compensation components. The Committee has looked to competitive information for guidance rather than rigid adherence to specific percentages. The Committee believes that the overall objectives of its compensation philosophy are better achieved through flexibility. The Committee ultimately makes decisions regarding executive compensation based on its assessment of Safeguard’s performance and the achievement of individual, partner company and corporate goals.

The Committee is also responsible for approving and granting equity awards to our directors, executives, employees and, from time to time, other independent advisors and consultants, with the exceptionsale of certain limited authority that the Committee has delegated to the President and Chief Executive Officer to make small equity grants between regularly scheduled Committee meetings (primarily to new hires). The Committee’s responsibilities are more fully describedor all ownership interests in its charter, which is available at www.safeguard.com/governance.

Role of Executive Officers in Compensation Decisions

Within the parameters approved by the Committee each year, our named executive officers are responsible for evaluating and setting compensation for our other employees. Our President and Chief Executive Officer annually assesses the performance of each other named executive officer and each of his other senior executive direct reports. When applicable, he also makes recommendations to the Committee concerning the achievement by our other senior executives of their individual short-term objectivessecondary market transactions, or a combination thereof, as well as other performance achievements. In determiningopportunities to maximize shareholder value. We initiated the compensationreturn of our executives, the Committee considers our President and Chief Executive Officer’s assessment and recommendations. However, other than for compensation that has been established contractually or under quantitative formulas established by the Committee each year under our management incentive program, the Committee exercises its own discretionvalue to shareholders in determining whether to accept or modify our President and Chief Executive Officer’s recommendations. These individuals are not present when the Committee and our President and Chief Executive Officer review their performance or when the Committee makes its determinations concerning their compensation.

24

Role of Consultant

During 2017, as in recent years, the Committee engaged Semler Brossy Consulting Group, LLC, an independent compensation consulting firm, to assist the Committee by providing compensation expertise regarding peer group analysis and compensation data, helping the Committee select appropriate performance measures and goals and advising the Committee regarding evolving compensation best practices and trends. Specifically, Semler Brossy provided information relating to competitiveness of pay levels, compensation plan design, specific equity grant matters, market trends, risk assessment and management and technical considerations concerning named executive officers, other executives and directors. Semler Brossy also assisted the Committee2019 with the reporting of executive compensation matters relating to 2017 under applicable SEC disclosure rules. Semler Brossy does not provide services to Safeguard other than those provided to the Committee. Semler Brossy reported to and acted at the direction of, and attended selected meetings as requested by, the Chairperson of the Committee.

The Committee, which has the sole authority to hire and terminate its consultant, evaluates the performance of its consultant annually. In 2017, the Committee considered whether Semler Brossy was “independent,” pursuant to SEC and NYSE rules and our corporate governance documents, and determined that Semler Brossy and its consultants meet those independence standards. In addition, based on its evaluation of Semler Brossy’s independence and information provided by Semler Brossy, the Committee also determined in 2017 that Semler Brossy’s services did not present any conflict of interest.

The Committee has utilized the services of Semler Brossy since 2008. Semler Brossy is compensated on an hourly billing basis. Invoices are directed to and reviewed and approved by the Chairperson of the Committee before payment by Safeguard.

With respect to the New Strategy, Semler Brossy provided assistance to the Committee regarding compensation changes for executives and directors in support of the New Strategy, which included providing competitive information on similar initiatives, developing alternatives and working with the Committee’s other advisors to finalize executive employment agreements and long-term incentive programs.

Setting Executive Compensation

The Committee believes that a very significant portion of each executive’s total compensation should be variable or “at-risk.” It is the view of the Committee that the greater the ability of an executive (based on role and responsibilities at Safeguard) to impact Safeguard’s achievement of its short- and long-term objectives, the greater the percentage of such executive’s overall compensation that should be “at-risk.” In 2017, the Committee principally utilized variable/at-risk cash compensation and time-based equity awards to pursue its objectives in this regard. See “New Strategy - Changes in Compensation Policies and Practices” below.

Because no deployments were made in 2017 into new partner companies and, therefore, a pool of new partner companies to measure performance against does not exist, for the grants made in 2017, the Committee (1) chose to reduce the opportunity to earn long-term incentives by approximately 40% for each of Messrs. Zarrilli, McGroarty and Sisko as compared to the grants made in 2016 and (2) awarded such incentives solely$1.00 per share special dividend. Moving forward, we anticipate additional actions in the form of restricted stock grants subjectrepurchases and/or special dividends based on available cash resources, prevailing market conditions and other factors.

Principles of Accounting for Ownership Interests

We account for our ownership interests using one of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of our influence over the entity, primarily determined by our voting interest in the entity.

Equity Method. We account for companies whose results are not consolidated, but over whom we exercise significant influence, using the equity method of accounting. We also account for our interests in some private equity funds under the equity method of accounting, based on our non-controlling general and/or limited partner interests. Under the equity method of accounting, our share of the income or loss of the company is reflected in Equity income (loss), net in the Consolidated Statements of Operations. We report our share of the income or loss of the equity method companies on a one quarter lag. We include the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets.

When the carrying value of our holdings in an equity method company is reduced to time-based vesting. This compareszero, no further losses are recorded in our Consolidated Statements of Operations unless we have outstanding guarantee obligations or have committed additional funding to the equity method company. When the equity method company subsequently reports income, we will not record our share of such income until it equals the amount of our share of losses not previously recognized.

Other Method. We account for our equity interests in companies which are not accounted for under the equity method or fair value method as equity securities without readily determinable fair values. We account for these securities based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar securities of the same issuer. Under this method, our share of the income or losses of such companies is not included in our Consolidated Statements of Operations. We include the carrying value of these investments in Ownership interests and advances on the Consolidated Balance Sheets.

Critical Accounting Policies and Estimates

Accounting policies, methods and estimates are an integral part of the Consolidated Financial Statements prepared by management and are based upon management’s current judgments. These judgments are normally based on knowledge and experience with regard to past and current events and assumptions about future events. Certain accounting policies, methods and estimates are particularly important because of their significance to the financial statements and because of the possibility that future events affecting them may differ from management’s current judgments. While there are a number of accounting policies, methods and estimates affecting our financial statements as described in Note 1 to our Consolidated Financial Statements, the most significant relate to impairment of ownership interests and advances.

Impairment of Ownership Interests and Advances

On a periodic basis, but no less frequently than at the end of each quarter, we evaluate the carrying value of our ownership interests for possible impairment based on achievement of business plan objectives and milestones, the financial condition and prospects of the company, market conditions and other relevant factors. The business plan objectives and milestones we consider include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships. We then determine whether there has been an other than temporary decline in the value of our ownership interest in the company. Any impairment to be recognized is measured as the amount by which the carrying value of an asset exceeds its fair value. The adjusted carrying value of an ownership interest is not increased if circumstances suggest the value of the 2016 grantscompany has subsequently recovered.

The fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies, or based on other valuation methods including discounted cash flows, valuations of comparable public companies and valuations of acquisitions of comparable companies.

Our companies operate in industries which are rapidly evolving and extremely competitive. It is reasonably possible that our accounting estimates with respect to the ultimate recoverability of the carrying value of ownership interests and advances could change in the near term and that the effect of such changes on our Consolidated Financial Statements could be material. While we believe that the current recorded carrying values of our equity and other method companies are not impaired, there can be no assurance that our future results will confirm this assessment or that a significant write-down or write-off will not be required in the future.

Total impairment charges related to our Ownership interests and advances were awarded at a ratioas follows: 

  

Year Ended December 31,

 

Accounting Method

 

2020

  

2019

 
  

(In thousands)

 

Equity

 $11,282  $2,965 

Other

  8,757   47 

Total

 $20,039  $3,012 

Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of 1/3Operations. Impairment charges related to other investments are included in time-based restricted stockOther income (loss), net in the Consolidated Statements of Operations.

Results of Operations

We operate as one operating segment based upon the similar nature of our technology-driven companies, the functional alignment of the organizational structure, and 2/3the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

There is intense competition in performance based stock units.the markets in which our companies operate. Additionally, the markets in which these companies operate are characterized by rapidly changing technology, evolving industry standards, frequent introduction of new products and services, shifting distribution channels, evolving government regulation, frequently changing intellectual property landscapes and changing customer demands. Their future success depends on each company’s ability to execute its business plan and to adapt to its respective rapidly changing market.

 

The following graphs representis a listing of certain of our ownership interests as of December 31, 2020 and December 31, 2019.

  Safeguard Primary Ownership as of December 31,  

Company Name

 

2020

 

2019

 

Accounting Method

Aktana, Inc.

  15.1%  17.8% 

Equity

Clutch Holdings, Inc.

  42.3%  41.2% 

Equity

Flashtalking

  13.4%  10.1% 

Other

InfoBionic, Inc.

  25.2%  25.2% 

Equity

Lumesis, Inc.

  43.4%  43.5% 

Equity

MediaMath, Inc.

  13.3%  13.3% 

Other

meQuilibrium

  32.0%  32.7% 

Equity

Moxe Health Corporation

  27.6%  29.9% 

Equity

Prognos Health Inc.

  28.5%  28.7% 

Equity

QuanticMind, Inc. *

  24.2%  24.2% 

Equity

Syapse, Inc.

  18.9%  20.0% 

Equity

T-REX Group, Inc.

  13.5%  13.7% 

Other

Trice Medical, Inc.

  16.6%  16.6% 

Equity

WebLinc, Inc. *

  39.9%  38.5% 

Equity

Zipnosis, Inc

  37.2%  37.7% 

Equity

* These entities were sold subsequent to December 31, 2020.  See Note 16 - Subsequent Events, of the percentageconsolidated financial statements.

Year ended December 31, 2020 versus year ended December 31, 2019

  

Year Ended December 31,

 
  

2020

  

2019

  

Variance

 
  

(In thousands)

 

General and administrative expense

 $(9,466) $(9,982) $516 

Other income (loss), net

  (7,708)  12,255   (19,963)

Interest income

  261   2,044   (1,783)

Interest expense

     (14,023)  14,023 

Equity income (loss), net

  (20,702)  64,267   (84,969)

Net income (loss)

 $(37,615) $54,561  $(92,176)

General and Administrative Expense. Our general and administrative expenses consist primarily of total 2017employee compensation, insurance, office costs, travel-related costs, depreciation, office rent and professional services such as consulting, legal, and accounting. General and administrative expense also includes stock-based compensation expense which consists primarily of expense related to grants of stock options, restricted stock and deferred stock units to our employees and directors. General and administrative expense decreased $0.5 million for the year ended December 31, 2020 compared to the prior year primarily due to decreases in depreciation of $0.8 million, employee compensation of $0.4 million, stock-based compensation of $0.3 million, lower office rental costs of $0.2 million, lower professional fees of $0.4 million, certain 2019 retirement costs that did not recur of $0.2 million and other various costs, which were partially offset by $1.8 million of higher severance charges and higher insurance costs of $0.3 million.  General and administrative expenses include amounts estimated for the Transaction Bonus Plan (the "LTIP"), which is a component of employee compensation.  As described in Note 12 in the accompany consolidated financial statements, the LTIP provides a cash bonus pool to employees based upon meeting certain thresholds of sales of the Company's ownership interests.  Expense recognized pursuant to the LTIP was $1.3 million and $0.5 million during the years ended December 31, 2020 and 2019, respectively.  No amounts have been paid yet according to the terms of the LTIP, however $1.5 million is presented as a current liability at December 31, 2020.  General and administrative expense also includes stock based compensation expense of $965,000 for the year ended December 31, 2020 as compared to $1,237,000 for the year ended December 31, 2019.  Stock based compensation for the various elements (assumingyear ended December 31, 2020 includes the short-term and long-term awards are paid at target levels) for our Chief Executive Officer (approximately 70%impact of hisa larger proportion of management's compensation, being variable/at-risk) andincluding a portion of previously existing accruals under the average percentage of total compensation for each of these elements for the other two named executive officers (approximately 59% of their collective compensation being variable/at-risk) in 2017, further illustrating our emphasis on pay for performance:

25

 

Safeguard management provides the Committee with comprehensive tally sheets on an annual basis to facilitate the Committee’s review of the total compensation of our named executive officers and other senior executives.

Specifically with regard to our named executive officers, the Committee annually reviews each element of total compensation and compares them to comparable elements at a group of specific companies and industries against which we believe we compete for talent and for shareholder investment, including the venture capital and private equity industries. The Committee also reviews each element of compensation by reference to industry-specific compensation surveys. The analysis provided to the Committee by Semler Brossy at its meeting in July 2016 for purposes of the Committee’s consideration of 2017 cash and total compensation levels measured our compensation against data from the following sources:

Proxy Peer Group DataàBusiness development companies, registered investment companies and holding companiesincentive plan, that are representative of the unique nature of our business model for a publicly owned company. Included in this group were: Capital Southwest Corporation; 180 Degree Capital Corp. (f/k/a Harris & Harris Group, Inc.); Hercules Capital, Inc. (f/k/a Hercules Technology Growth Capital, Inc.); Actua, Corp. (formerly ICG Group, Inc.); KCAP Financial, Inc.; Main Street Capital Corporation; Triangle Capital Corporation; American Capital Ltd.; Medallion Financial Corp.; and Rand Capital Corp.
Venture Capital Survey Dataà

Surveys used included the following:

Dow Jones Private Equity Analyst – Glocap Compensation Survey (data used is limited to venture capital funds with up to $500 million in assets under management)

US Mercer Benchmark Database – Executive (data used is limited to companies with revenues/sales under $500 million)

(Each of the surveys utilized is broad-based and, therefore, is not highly influenced by the data relating to any one company included in the survey.)

26

The Committee annually evaluates the companies and surveys used for comparison purposes to be certain that the comparables reviewed by the Committee remain appropriate given mergers/acquisitions that may have occurred and any changessettled in relevant business scope. In connection with the commencement of its process for its 2017 compensation review, in July 2016 the Committee determined that reviewing compensation from multiple perspectives was still appropriate given Safeguard’s unique business model. At such time, when the Committee prepared to conduct its annual review of total compensation levels for 2017, Semler Brossy did not recommend any changes to the proxy peer group. In July 2017, when the Committee prepared to conduct its annual review of total compensation levels for 2018, Semler Brossy recommended that the Committee remove American Capital Ltd. from the peer group (as American Capital Ltd. had been acquired). The Committee concurred with such recommendation and American Capital Ltd. was excluded in the competitive assessment used to determine the long-term incentive values for the named executive officers in connection with the December 2017 equity grants.

Recognizing that our business strategy, industry focus, and diverse array of partner companies make comparisons to other companies difficult, and based on the inherent challenge in matching companies, job positions and skill sets, the Committee has looked to competitive information for general guidance rather than rigid adherence to specific percentages. The Committee has determined that the overall objectives of our compensation philosophy are better achieved through flexibility in determining pay levels to address differences in duties and responsibilities, individual experience, skill levels and achievements and any retention concerns.

Outcome of the 2017 Say-on-Pay Vote and Shareholder Outreach

At our 2017 annual meeting of shareholders, our shareholders approved the compensation of our named executive officers, with approximately 82% of shareholder votes being cast in favor of our say-on-pay proposal on executive compensation. The Committee believes that this support from our shareholders is evidence that our pay-for-performance policies were aligned with our shareholders’ interests.

The Committee will continue to consider the outcome of our shareholders’ advisory vote on executive compensation and shareholder feedback when making future compensation decisions for our named executive officers.

27

2017 Compensation Program

During 2017, the Committee used the following principal elements of executive compensation to meet its overall goals:

Compensation ElementObjectiveKey FeaturesPerformance /
At Risk?
Base PayRewards an executive’s core competencies relative to skills, experience, responsibilities and anticipated contributions to us and our partner companies.Reviewed annually in comparison to market data to ensure competitive base pay; subject to adjustment annually based on individual performance, experience, leadership and market factors.No.
Annual IncentivesRewards an executive’s contributions towards the achievement of annual corporate objectives and, if applicable, an executive’s achievement of individual performance objectives.The Committee establishes annual performance objectives that align our compensation practices with our shareholders’ interests.Yes; payout occurs only upon achievement of established measurable goals. May not pay out if annual performance goals are not met.
Stock Options and/or Restricted Stock (each subject to time-based vesting)Encourages executive ownership of ourvested stock and promotes continued employment with us through the use of vesting based on extended tenure with Safeguard.Value is realized based on future stock price, with a direct correlation to changes in shareholder value.Yes; value increases or decreases in correlation to share price.
Stock Options and/or Performance Stock Units (each subject to performance-based vesting)*Correlates realized pay with increases in shareholder value over a long-term period.Aligns the long-term incentive award with the factors critical to the creation of shareholder value.Yes; executives may realize little or no value if pre-determined performance metrics are not achieved.
Health and Welfare BenefitsProvides benefits that are part of our broad-based employee benefit programs, including medical, dental, life insurance, disability plans and our 401(k) plan matching contributions.Ensures competitive market practices and promotes continued employment.No.

Severance and Change-in-Control Arrangements
Helps us retain certain of our named executive officers and other executives, providing us with continuity of executive management.Equity awards to our senior executives provide for double-trigger vesting upon a change in control.No.

* Note that this statement refers to grants made at the end of 2016 as we entered the 2017 calendar year. Because no deployments were made in 2017 into new partner companies and, therefore, a pool of new partner companies to measure performance against does not exist, for the grants made in 2017, long-term performance-based incentives were not awarded in 2017.

28

Base Pay. Base pay is established initially on the basis of several factors, including market competitiveness; past practice; individual performance and experience; the level of responsibility assumed; the level of skills and experience that can be leveraged across our partner companies to facilitate their growth and success; and individual employment negotiations with executives. Each of our named executive officers has an agreement with us that sets a minimum base salary.

Base salaries typically are reviewed annually (at the end of one year and the beginning of the upcoming calendar year) by the Committee, as well as Director compensation, which in connection with a promotion or other changes2020 was settled entirely in job responsibilities. As noted above, Safeguard believes it competesvested stock.

Other income (loss), net. Other income (loss), net decreased by $20.0 million for executive talent with venture capitalthe year ended December 31, 2020, compared to the prior year.  During the year ended December 31, 2020, the Company recorded impairments of $8.8 million related to the ownership interests of T-REX, b8ta and private equity firms, among others. In considering whether to adjust base salary levels of anyothers accounted for under the Other method. The impairments were determined based on declines in the fair value of our executivesownership interests resulting from reduced valuation expectations and extended exit timelines resulting from the more challenging mergers and acquisitions environment related to COVID-19 and the related uncertain economic impact.  The Company also recorded a $0.3 million reduction in the carrying value of an other equity security based on an observable price change. Partially offsetting these impairments, was a $1.5 million non-cash gain for 2017, the Committee took into account:

·The proxy peer group and survey data provided by Semler Brossy;

·The Committee’s assessment of Safeguard’s overall performance during 2016 and the ongoing individual performance of each of our named executive officers;

·United States economic conditions, in general; and

·Changes in scope of job responsibility.

The Committee does not typically make adjustmentsincrease in the fair value our ownership interest in Flashtalking based upon an observable price change. Other income (loss), net for the year ended December 31, 2019 included $4.5 million of non-cash gains on the increase in the value of certain equity securities based upon observable price changes, $5.1 million of income related to the base salary levelsdecrease in the fair value of the Credit Facility repayment feature liability and a $1.7 million gain resulting from the elimination of the remaining estimated liability established related to the retirement for our executives based on cost-of-living typesa former Chairman and CEO of factors.

In December 2016, the Committee reviewedCompany. The Credit Facility was repaid in full during 2019 resulting in the base salarieselimination of our named executive officers, the individual performance of each of our named executive officers and the base salary compensation of our named executive officers relative to our proxy peers and, based on such review, the Committee determined that the base salaries of our named executive officers for 2017 would remain the same as the respective base salaries of our named executive officers for 2016.

Annual Incentives.Credit Facility repayment feature liability.

 

Incentive Opportunity.Interest Income. Interest income decreased $1.8 million for the year ended December 31, 2020 compared to the prior year primarily attributable to lower average notes receivable, lower average investment and cash equivalent balances at lower rates in 2020.

Interest Expense. Interest expense decreased $14.0 million for the year ended December 31, 2020 compared to the prior year due to the pay-off of borrowings under the Credit Facility in 2019.

Equity Income (Loss), net. The Committee annually awards bonusesEquity income (loss), net fluctuates with the number of companies accounted for under the equity method, our voting ownership percentage in those companies and the net results of operations of those companies. We recognize our share of losses to the extent we have cost basis in the equity of the company or we have outstanding commitments or guarantees. Certain amounts recorded to reflect our executives under Safeguard’s Management Incentive Program (“MIP”). The MIP is designed to provide a variable short-term incentive to eachshare of the income or losses of our named executive officers and our other executives and employees principallycompanies accounted for under the equity method are based on Safeguard’s annual performance. These awards are determined annually following the endestimates and on unaudited results of each calendar year, based on the Committee’s assessment of: (i) the achievement by Safeguardoperations of its objectives as a whole;those companies and (ii) if applicable, the achievement by certain executives of individual performance objectives, as measured against target personal and corporate objectives established at the beginning of the year. Payments may be made in cash and/or equity, in the Committee’s discretion. The awards have been paid solely in cash in recent years. Neither the actual awards to be made under the MIP nor the minimum long-term value of any equity grants made is guaranteed.

For 2017, the Committee determined that each of our named executive officers and other senior executives would be eligible to receive an award under the MIP based 100% on the achievement by Safeguard of corporate objectives. Other employees also participated in our 2017 MIP. These other participants were eligible for MIP awards based on varied ratios of corporate and individual achievement based upon each individual’s position within Safeguard. The Committee may adjust the relative weightings of corporate and individual objectives for specified employees under our MIP, including our named executive officers,require adjustments in the future in lightwhen audits of Safeguard’s overall compensation goals.these entities are made final. We report our share of the results of our equity method companies on a one quarter lag basis.

 

We believe that short-term compensation (suchEquity income (loss), net decreased $85.0 million for the year ended December 31, 2020 compared to the prior year. The components of equity income (loss), net for the years ended December 31, 2020 and 2019 were as base salary and annual incentive awards under the MIP) should not be based solely on the short-term performance of our stock, whether favorable or unfavorable, but also on our executives’ management of Safeguard towards achieving the annual goals that we believe will contribute to shareholder value.follows:

 

29

2017 Performance Measures. Specifically, the Committee approved the following weighting for the corporate objectives under the 2017 MIP:

WeightingCorporate Objectives
50% - Partner Company Performance

50% of the total possible points attributable to corporate objectives were based on the achievement by our partner companies of specific performance-related goals (with three or more measurable goals identified for each partner company). Specifically, the Committee:

·     Defined performance-related metrics for each of our partner companies as of the creation of the 2017 MIP (29 partner companies) that varied by partner company based on their business plans and strategies and stages of development. (A table highlighting a summary of the types of performance metrics for the partner companies in which Safeguard had deployed capital and held an active interest as of the adoption of the 2017 MIP is set forth below.)

·     Determined that, for 2017, partner companies would be grouped into three groups, based on the amount of capital deployed into each partner company by Safeguard. Partner companies representing our largest deployments, approximately $177.1 million deployed into 9 partner companies, constitute 47.45% of the target total points; the middle group of companies, representing the deployment of approximately $135.4 million into 11 partner companies, constitute 36.28% of the target total points; and the smaller group of companies, representing the deployment of approximately $60.7 million into 9 partner companies, constitute 16.26% of the target total points. The weighting of partner companies’ performance may vary from year to year based on such factors as the Committee determines to be appropriate. The intent of the weighting is to reward the activities that have the most impact on Safeguard’s value creation.

50% - Overall Corporate Performance

50% of the total possible points attributable to corporate objectives were based on the Committee’s evaluation of the overall corporate performance of Safeguard during 2017. The Committee specifically identified the following corporate objectives that would be considered in making its assessment of overall corporate performance:

·     Judiciously managing capital deployed to coincide with cash in-flow expectations;

·     Returning sufficient capital to pursue overall strategic intentions and exploring alternative financing methods; and

·     Share value appreciation in line with Safeguard’s proxy peer group.

The Committee also reserved the ability to consider its subjective analysis of the achievement of other corporate objectives and factors, such as strategic initiatives and accomplishments.

The Committee established the specific performance-based corporate and partner company target metrics based on recommendations of management and taking into consideration the stage of development of each of our partner companies. Within the specific parameters of the 2017 MIP, the Committee reserved a significant level of discretion in reaching final determinations of achievement levels attained, as described above. The determination to reserve such discretion and flexibility arose from the Committee’s belief, based on prior experience, that, given Safeguard’s business activities, as circumstances change throughout a given fiscal year, on a macro and/or a micro level, specific/rigid formulas or guidelines for measuring achievement set in the beginning of a year, if strictly applied, may well incent activity that does not result in, or compensation grants that do not match, actual shareholder value creation. The award criteria finally adopted were designed to provide management with a meaningful guideline for meeting the Committee’s criteria for a target award, but not guarantee achievement or make achievement somewhat inevitable or impossible. This approach is also intended to provide the possibility of exceeding target awards and some economic recognition, albeit reduced, for near achievement of the target.

The following table summarizes the specific types of performance metrics that we used to assess our partner companies included in the 2017 MIP. The achievement of the specific performance objectives set for our partner companies represents the basis upon which the Committee determined corporate achievement attributable to our partner companies under the 2017 MIP.

30

Partner Companies

AdvantEdge Healthcare Solutions

Aktana

Apprenda

Nexxt, Inc. (formerly Beyond.com)

Brickwork

Cask

CloudMine

Clutch Holdings

Full Measure

Good Start Genetics

Hoopla

InfoBionic

Lumesis

MediaMath

Prognos (formerly Medivo)

meQuilibrium

Moxe

NovaSom

Pneuron

Propeller Health

QuanticMind

Sonobi

Spongecell

Syapse

Transactis

T-Rex

Trice

WebLinc

Zipnosis

2017 Objectives / Targets (may include one or more of the following performance metrics)

·Achieve specified level of annual revenue, annualized contract value, bookings, etc. with a significant focus on growth
·Achieve specified level of EBITDA or specified margin
·Complete additional equity or debt financing
·Complete one or more acquisitions
·Augment management team, board of directors or advisory board
·Explore strategic and corporate development options
·Expand sales efforts to additional territories
·Achieve regulatory approval of specified products
·Achieve product launch or expansion of product reach
·Achieve commercial sales of product(s) or service(s), or successful product implementation
·Increase customer base
·Increase user base

Consistent with their respective employment agreements and Safeguard’s overall compensation philosophy, and based upon multiple factors reviewed by the Committee, including an assessment of competitive compensation data in the market in which Safeguard competes for executive talent and to better align the interests of Safeguard management and our shareholders, the Committee set the following target MIP awards for 2017 for our named executive officers:

 

Name

 

2016 MIP Target

Variable Incentive (1)

  

2017 MIP Target

Variable Incentive (1)

  

2018 MIP Target

Variable Incentive (1)

 
Stephen T. Zarrilli $696,000  $696,000  $696,000 
Jeffrey B. McGroarty $228,750  $228,750  $228,750 
Brian J. Sisko $360,000  $360,000  $360,000 

(1)The 2016 and 2018 MIP target variable incentive amounts have been included for comparison purposes.
  

Year Ended December 31,

 
  

2020

  

2019

  

Variance

 
  

(In thousands)

 

Gains on sales of ownership interests

 $183  $90,139  $(89,956)

Unrealized dilution gains

  4,246   3,206   1,040 

Loss on impairments

  (11,282)  (2,965)  (8,317)

Share of losses of our equity method companies, net

  (13,849)  (26,113)  12,264 
  $(20,702) $64,267  $(84,969)

 

There were no mandatory minimum awards payable undermaterial gains or losses on sales of ownership interests for the 2017 MIP, and awards were paid based uponyear ended December 31, 2020, however Sonobi was sold resulting in $6.6 million of cash proceeds.  The amounts reported as gains on sales of ownership interests for the Committee’s determinationyear ended December 31, 2019 are comprised primarily of the level of achievement of the corporate (and, for certain employees, individual performance) objectives. Payouts were measured in the aggregate on a sliding scale basis from 0% to a possible 150%.

31

Determination of 2017 Payouts.

In late 2017 and early 2018, the Committee reviewed Safeguard’s corporate performance against the corporate objectives set forth above and determined the following payout levels (with the final payouts conditioned upon the completion of the audit of our 2017 consolidated financial statements and internal control over financial reporting without any unexpected material adjustments, each of which has now occurred). Overall, the Committee determined that 2017 was a year of positive results for Safeguard, though not all goals were achieved. The key factors upon which the Committee based its determination of the payout level are also summarized below.

Corporate Objectives:

Payout Level

(as a % of target)

Partner Company Performance90%
·     More than two-thirds of partner companies met or exceeded the majority of their applicable performance goals established as part of the 2017 MIP;
·     Aggregate 2017 revenue for our partner companies as a whole grew by approximately 23% year over year; and
·     Management teams were augmented, follow-on capital was successfully raised and partner companies were positioned for the next stage of development. 
Overall Corporate Performance60%
·     Our total capital provided in the form of follow-on deployments in 2017 approximated $36.8 million to 18 of our partner companies;
·     We realized approximately $16.9 million in aggregate cash proceeds (not including amounts deposited and held in escrow subject to release in future periods, or marketable securities sold for cash in subsequent periods) as follows: (i) $15.5 million related to the sale of our interest in Nexxt, Inc. (formerly, Beyond.com), not including a $10.5 million promissory note which was repaid in full in cash in March 2018 and (ii) $1.4 million in released escrow funds related to three prior year partner company exits (Putney, Quantia and AppFirst);
·     We entered into a $75 million secured, revolving credit facility with HPS Investment Partners, LLC;
·     Our stock price performed below the median performance of our proxy peer group; and
·     We set the stage for 2018 success with multiple exit strategies in play.
Total Percentage75%

Based on its assessment of the partial achievement of the 2017 MIP corporate objectives, the Committee authorized the following individual awards to Safeguard’s named executive officers. The Committee determined, based on consultations with the Committee’s independent consultant and analysis of datagains related to incentive payment practices being followed within Safeguard’s peer groupthe sale of Propeller of $35.1 million and throughoutTransactis of $50.7 million, but also include the U.S. financial services industry as a whole,collection of escrow from various prior transactions, including $3.8 million related to pay 2017 MIP payments to our executives solely in cash.

Name Payout Level (1)  Total Variable Incentive Payment 
Stephen T. Zarrilli  75% $522,000 
Jeffrey B. McGroarty  75% $171,563 
Brian J. Sisko  75% $270,000 
Named Executive Officers, as a group (3 persons)  75% $963,563 

(1)In percentage terms versus targeted incentive amount.

32

Long-Term Incentives.

As noted above, we compete for executive talent with venture capital and private equity firms, and the Committee reviews and includes comparative information regarding venture capital and private equity industry compensation practices as part of its overall compensation analysis. In these industries, executives (referred to as “managing partners” or “managing directors”) typically have compensation programs heavily weighted towards long-term incentive, structured as a share of the fund’s profits, payable in cash (referred to as “carry”). We historically have not, and in 2017 did not, provide our executives with the equivalent of a “carry.” Instead, as part of our overall executive compensation program we review our equity compensation plans in light of the type of economic benefit and performance metrics that would be included in a “carry” approach to compensation. We compared the initial equity awards made to our named executive officers against our assessment of the carry, which would typically be provided to executives in positions of comparable responsibility at private equity and/or venture capital firms at that time. Based upon information available to the Committee through its consultant, we continually reassess the competitiveness of our executives’ long-term compensation opportunity against a carry methodology as well as other relevant metrics from other types of businesses within our peer group. The potential value for long-term equity grants is intended to be competitive with those held by comparable executives at companies included in the comparison data that is reviewed annually by the Committee (as adjusted for the senior executive’s experience).

Through 2017, the principal approach utilized by the Committee to meet the need for a long-term incentive component to Safeguard’s executive compensation program has been the granting of significant amounts of equity to our named executive officers. Our equity compensation plans allow for the grant of: (i) stock options, (ii) restricted stock, (iii) restricted stock units (which include deferred stock units (“DSUs”) and performance stock units (“PSUs”)) and (iv) such other equity-based awards as the Committee may determine to be appropriate from time to time. The mix of the types of equity-based awards have varied from time to time.

Beginning in 2013, the Committee decided that equity grants in the form of restricted stock and restricted stock units would be the principal component of Safeguard’s long-term incentive program, although stock options have been granted from time to time. The decision to use primarily restricted stock and restricted stock units, a significant percentage of which have been subject to performance-based vesting based on the capital-return based vesting model (which the Committee initially implemented in 2008 and is discussed in more detail below) was based, in part, on a recommendation from the Committee’s compensation consultant to further align management’s interests with our shareholders’ interests and to create an appropriate balance for our senior executives between incentive and retention. The Committee also determined at that time that such capital-return based vesting model best aligned the long-term incentive award to the factors critical to the creation of shareholder value.

Entering 2017, the Committee once again determined to allocate equity grants (both initial and any annual grants) between (i) equity grants subject to performance-based vesting using the capital-return based vesting model, as discussed in more detail below, and (ii) equity grants subject to simple time-based vesting. It was the Committee’s view that allocating equity grants in this way aligned the long-term interests of Safeguard management and our shareholders and created a balance for our senior executives between incentive and retention. The Committee has always reserved the right to allocate equity grants in a different manner as circumstances dictate.

Our performance-based equity grants that remain outstanding are all subject to “capital-return based vesting.”Cask Data.

 

The capital-return based vesting model vestsunrealized dilution gains for the particularyear ended December 31, 2020 were the result of Aktana, meQuilibrium, Moxe and Syapse, who each raised additional equity grants awardedcapital that diluted the Company's interest in those entities. The unrealized dilution gains for the year ended December 31, 2019 were related to meQuilibrium, Moxe, Syapse, Trice and T-REX.

During the year ended December 31, 2020 the Company recorded impairments of $11.3 million related to the ownership interests of WebLinc, Inc., QuanticMind, Inc. and Sonobi accounted for under the equity method. The impairments were determined based on aggregate cash returns received by Safeguarddeclines in the fair value of our ownership interests resulting from reduced valuation expectations and extended exit timelines resulting from the ultimate monetizations of phantom “pools” of Safeguard’s partner companies that were typically first funded duringmore challenging mergers and acquisitions environment related to COVID-19 and the same calendarrelated uncertain economic impact.  The loss on impairments for the year in which those equity grants were made.ended December 31, 2019 is due to NovaSom, Inc.'s August 2019 bankruptcy filing.

 

The capital-return based vesting model has evolved over time as conditionsdecrease in our share of losses of our equity method companies for the marketplace have changed and as the Committee has gained further experience with predicting intended or targeted outcomes. The basic capital-return based vesting model utilized entering 2017 provided that, subject to minimum time periods having expired with respect to grants that were granted on or after 2014, vesting will begin to occur once a minimum cash return hurdle with respect2020 year compared to the relevant partner company pool is reached and will continue to occur incrementally over time as cash returned on the relevant partner company pool approaches targeted levels. In all instances since the inception of the capital-return based vesting model, adjustments are made to the required cash return hurdle amounts if and when Safeguard deploys additional capital into any of the partner companies included in the relevant pool of partner companies.

33

For the performance-based equity grants that were granted through 2013, vesting of such grantsbegins to occur after cash proceeds received by Safeguard from the ultimate monetization of the pool of partner companies applicable to such grants equals the aggregate capital deployed by Safeguard in such pool of partner companies plus an amount approximating Safeguard’s annual overhead (“allocated overhead”). Proceeding on a linear basis from that point, all such grants will fully vest upon the achievement of a predetermined target amount of proceeds that must be received by Safeguard from the ultimate monetization of the pool of partner companies applicable to such grants. For such performance-based equity grants made through 2012, such predetermined target amounts of proceeds needed for full vesting are equal to 3 times the aggregate capital deployed by Safeguard in the relevant pool of partner companies (plus allocated overhead). For such performance-based equity grants made in 2013, such predetermined target amounts of proceeds needed for full vesting are equal to 2.4 times the aggregate capital deployed by Safeguard in the relevant pool of partner companies (plus allocated overhead). The foregoing change in target amounts for full vesting (i.e., 2.4 times capital deployed for 2013 deployments versus 3 times capital deployed for deployments through 2012)prior year period was due to the Committee’s determination that such a reduction was appropriate given the overall lower returns experienced generally within the venture capital and private equity markets since 2008. For the same reason, the Committee decided to further revise the predetermined target amounts of proceeds needed for initial vesting and full vesting for performance-based equity grants that were granted starting in 2014, and also considered the actual vesting that was occurring over time relating to the partner company pools previously createddecrease in the earliestnumber of ownership interests accounted for under the equity method and a decrease in losses associated with the remaining ownership interests, including the $1.8 million benefit that resulted from the recognition of revenue in the current period at one of our ownership interests upon the adoption of Accounting Standards Update 2014-09, Revenue from Contracts with Customers, which was considered deferred revenue at the beginning of their adoption period under the new standard.

Income Tax Benefit (Expense)

Income tax benefit (expense) was $0.0 million for the years ended December 31, 2020 and 2019. We have recorded a valuation allowance to reduce our net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the capital-return based vesting model as well as market feedback regarding Safeguard’s long-term incentive program.net operating loss that would have been recognized in each year was offset by changes in the valuation allowance.

 

For performance-based equity grants that were granted since 2014, the predetermined target amounts of proceeds that must be received by Safeguard from the ultimate monetizations of the applicable pool of partner companiesbefore any vesting occurs for such equity grants was raised to 1.25 times the aggregate capital deployed by Safeguard in the applicable pool of partner companies (plus allocated overhead).Subject to minimum time periods having been reached as described below, such performance-based equity grants will vest, as follows:Liquidity And Capital Resources

Required Multiple of Capital Deployed in

Applicable Pool (plus allocated overhead)*

Resulting Cliff Vesting and Cash Payment Metrics
1.25x25% vesting
1.50x50% (incremental 25%) vesting
1.75x75% (incremental 25%) vesting
2.00x100% (incremental 25%) vesting
2.25xCash equal to 25% of performance grant values
2.50xCash equal to 50% (incremental 25%) of performance grant values**

* Notwithstanding the above vesting thresholds, so as to ensure against the unlikely possibility that performance-based equity grants do not vest too quickly (for example, if cash proceeds relating to a particular pool are achieved very soon after the equity grant date), the Committee required that such performance-based equity grants not vest (or cash amounts be paid) more quickly than based upon the following schedule following grant:

·March 15th of the second calendar year following the grant date - 25%; and

·Each September 15th and March 15th thereafter - 12 ½% increments.

In addition, recipients must be actively employed/providing service to Safeguard through such dates.

**Cash amounts will continue to accrue/be paid at the rate of 25% of performance grant values for each .25x of additional return of deployed capital in the applicable pool; provided, however, no cash amounts shall accrue/be payable to any participant who is considered a named executive officer (for reporting purposes under the Securities Exchange Act of 1934) relating to any returns of capital beyond 3x deployed capital in the applicable pool, effectively capping the combined equity and cash incentive payout for named executive officers at 200%. No further vesting or cash accruals/payments will be made beyond the term of the grant, which is 10 years following the grant date.

34

As referenced elsewhere in this CD&A, in January 2018, Safeguard announced its New Strategy, representing a significant change in its business strategy going forward. See also “New Strategy - Changes in Compensation Policies and Practices” below. Because no deployments were made in 2017 into new partner companies and, therefore, a pool of new partner companies to measure performance against does not exist, for the grants made in 2017, the Committee (1) chose to reduce the opportunity to earn long-term incentives by approximately 40% for each of Messrs. Zarrilli, McGroarty and Sisko as compared to the grants made in 2016 and (2) awarded such incentives solely in the form of restricted stock grants subject to time-based vesting. This compares to the value of the 2016 grants that were awarded at a ratio of 1/3 in time-based restricted stock and 2/3 in performance based stock units.

Named Executive Officer 

Restricted

Shares (1)

  

Nominal Value of

Restricted Shares (2)

  PSUs  

Target Value of

PSUs

 
Stephen T. Zarrilli  56,495  $660,000   -   - 
Jeffrey B. McGroarty  12,840  $150,000   -   - 
Brian J. Sisko  23,111  $270,000   -   - 

(1)The shares of restricted stock granted vest 25% on March 1, 2019, and in 12 equal quarterly installments commencing on March 15, 2019, and on the fifteenth day of each June, September, December, and March thereafter, assuming the executive’s continued employment by Safeguard as of such dates.
(2)Based on the average closing price of our stock for the 20 consecutive trading days immediately preceding the grant date (December 29, 2017).

 

As of December 31, 2017,2020, the following vesting under capital-return based vesting grantsCompany had been achieved:$15.6 million of cash and cash equivalents.

 

Performance Pool Expiration Date Vested Percentage 
2008 September 30, 2016 and December 23, 2020  37%
2009 October 30, 2019  0%
2010 November 5, 2020  0%
2011 September 30, 2021  3%
2012 October 2, 2022 and December 5, 2022  0%
2013 October 31, 2023  0%
2014 December 31, 2024  0%
2015 December 31, 2025  0%
2016 December 31, 2026  0%

During April 2019, the Company made a $24.0 million principal payment to its Lender and a related make-whole interest payment of $2.9 million. During July 2019, the Company made a $49.5 million payment to its Lender consisting of $44.5 million of principal, $4.1 million of make-whole interest and $0.9 million of accrued interest, which satisfied all obligations under the Credit Facility.

 

More information regardingIn January 2018, Safeguard announced that, from that date forward, we will not deploy any capital into new opportunities and will focus on supporting our existing companies and maximizing monetization opportunities to return value to shareholders. In that context, we have, are and will consider initiatives including, among others: the equity grants made tosale of our named executive officers during 2017 can be found below under “Executive Compensation — Grantsindividual ownership interests, the sale of Plan-Based Awards – 2017”certain ownership interests in secondary market transactions, or a combination thereof, as well as “New Strategy - Changes in Compensation Policies and Practices.”other opportunities to maximize shareholder value.

 

The Committee annually reviewsSubsequent to the equity awards held by our executivesdebt repayment, on November 7, 2019, the Company's Board of Directors declared a special cash dividend of $1.00 per share, payable on December 30, 2019 to shareholders of record as of the close of business on December 23, 2019. We anticipate continuing to return value to shareholders in the form of stock repurchases and/or dividends based on prevailing market conditions and other employeesfactors when and also may consider awards periodically during a year in an effort to retain and motivate employees and to ensure continuing alignment of executive and shareholder interests. Grants may be made at regularly scheduled meetings or at special meetings convened to approve compensation arrangements for newly hired executives or for executives who have been promoted or are otherwise subject to changes in responsibilities. Any stock options granted are granted with an exercise price equal to the average of the high and low trading prices of our common stock on the date of grant. For administrative convenience, the Committee has adopted a policy of generally issuing approved grants on the last business day of the quarter for new hires and on the last business day of the month in which grants are approved by the Committee for all other grants.if additional liquidity becomes available.

 

35

Perquisites (fringe benefits). During 2017, we provided life insurance coverage ranging from $750,000 to $1,000,000 to eachIn 2015, the Company's Board of our named executive officers at an average annual cost to Safeguard of approximately $2,466 per named executive officer. Our named executive officers also are eligible to participate in the fringe benefits that Safeguard may offer,Directors authorized us, from time to time and depending on a non-discriminatory basismarket conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the years ended December 31, 2020 and 2019, we did not repurchase any shares under this authorization.

Our ability to generate liquidity from transactions involving our ownership interests has been adversely affected from time to time by adverse circumstances in the U.S. capital markets and other factors, including the impact of COVID-19.  We may be required to provide additional capital to our companies, which may cause us to face liquidity issues that will constrain our ability to execute our business strategy and limit our ability to provide financial support to all of our employees.existing companies in the amounts that we desire. The transactions we enter into in pursuit of our strategy could increase or decrease our liquidity at any point in time. As we seek to provide additional funding to existing companies where we have an ownership interest or commit capital to other initiatives, we may be required to expend our cash or incur debt, which will decrease our liquidity. Conversely, as we dispose of our interests in our ownership interests, we may receive proceeds from such sales, which could increase our liquidity. From time to time, we are engaged in discussions concerning deployments and dispositions which, if consummated, could impact our liquidity, perhaps significantly. The Company believes that its cash and cash equivalents at December 31, 2020 will be sufficient to fund operations past one year from the issuance of these financial statements.

 

SeveranceAnalysis of Consolidated Cash Flows

Cash flow activity was as follows: 

  

Year Ended December 31,

 
  

2020

  

2019

  

Variance

 
  

(In thousands)

     

Net cash used in operating activities

 $(8,143) $(19,970) $11,827 

Net cash (used in) provided by investing activities

  (1,269)  126,303   (127,572)

Net cash used in financing activities

  (40)  (89,483)  89,443 
  $(9,452) $16,850  $(26,302)

Net Cash Used In Operating Activities

Year ended December 31, 2020 versus year ended December 31, 2019. Net cash used in operating activities decreased by $11.8 million for the year ended December 31, 2020 compared to the prior year. The activity during the year ended December 31, 2020 was primarily the result of various non-cash adjustments to net loss, including the $20.0 million impairment losses and Change-in-Control Arrangements$9.4 million of equity loss, which were partially offset by non-cash gains, net, of $1.2 million for observable price changes.  The Company did not make any cash interest payments for the year ended December 31, 2020 as compared to $11.5 million of cash interest payments for the year ended December 31, 2019. The activity during the year ended December 31, 2019 was primarily the result of various non-cash adjustments to net income, including $67.2 million of equity income, $3.0 million of impairments, a $5.1 million loss from the increase in the fair value of the repayment feature derivative, a $4.5 million gain for an observable price change, depreciation, and amortization of debt discount of $3.5 million.

Net Cash (Used in) provided by Investing Activities

Year ended December 31, 2020 versus year ended December 31, 2019. Net cash (used in) provided by investing activities decreased by $127.6 million for the year ended December 31, 2020 compared to the prior year.  The decrease primarily related to the prior year's $104.3 million of proceeds from the sale of ownership interests, primarily Propeller and Transactis in the previous year, as compared to the $6.6 million of proceeds from the sale of Sonobi in the third quarter of 2020.  In addition, the Company's investing outflows resulting from acquisitions of ownership interests and advances to ownership interests during the year ended December 31, 2020 were $7.5 million less than the prior year. The Company also did not have any marketable security activity during the year ended December 31, 2020 as compared to $37.9 million of marketable securities sales exceeding purchases during the year ended December 31, 2019.

Net Cash Used In Financing Activities

Year ended December 31, 2020 versus year ended December 31, 2019. Net cash used in financing activities increased by $89.4 million for the year ended December 31, 2020 compared to the prior year. There were no significant financing activities for the year ended December 31, 2020. The primary financing activities in 2019 were the $20.7 million special dividend and the repayment of the Credit Facility for $68.6 million. 

Contractual Cash Obligations and Other Commercial Commitments

  

Payments Due by Period

 
  

Total

  

2021

  

2022 and 2023

  

2024 and 2025

  

After 2025

 
  

(In millions)

 

Contractual Cash Obligations:

                    

Operating leases (a)

 $3.2  $0.6  $1.2  $1.2  $0.2 

Severance payments

  0.2   0.2          

Total Contractual Cash Obligations (b)

 $3.4  $0.8  $1.2  $1.2  $0.2 

(a)  In 2015, we entered into an agreement for the lease of our former principal executive offices which expires in April 2026.  Payments pursuant to this lease are approximately $3.2 million through expiration, however, in March 2019 we entered into a sublease for this office space which is also expected to result in future aggregate sublease receipts of $3.0 million through April 2026. 

(b)  The  maximum aggregate exposure under employment and severance agreements for remaining employees was approximately $2.3 million at December 31, 2020, which includes $0.5 million of annual bonus amounts that will be settled in 2021 in the normal course of business.  We are involved from time to time in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of any of these matters which are currently pending will not have a material adverse effect on our consolidated financial position or results of operation.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Not applicable for a smaller reporting company.

Item 8. Financial Statements and Supplementary Data

The following Consolidated Financial Statements, and the related Notes thereto, of Safeguard Scientifics, Inc. and the Reports of Independent Registered Public Accounting Firm are filed as a part of this Form 10-K.

Page

Report of Independent Registered Public Accounting Firm

22

Consolidated Balance Sheets as of December 31, 2020 and 2019

24

Consolidated Statements of Operations for the years ended December 31, 2020 and 2019

25

Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2020 and 2019

26

Consolidated Statements of Changes in Shareholders' Equity for the years ended December 31, 2020 and 2019

27

Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019

28

Notes to Consolidated Financial Statements

29

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors
Safeguard Scientifics, Inc.:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Safeguard Scientifics, Inc. and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), changes in shareholders’ equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Impairment of Ownership interests and advances

As discussed in Note 1 and Note 2 to the consolidated financial statements, the Company’s ownership interests and advances balance as of December 31, 2020 was $50.4 million, of which $30.4 million is in equity method companies and $20.0 million is in other method companies and funds.  Impairment losses recognized in equity income (loss), net, and other income (loss), net, were $11.3 million and $8.8 million, respectively, for the year ended December 31, 2020. On a periodic basis, but no less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for impairment based on achievement of business plan objectives and milestones, the estimated fair value of each company relative to its carrying value, the financial condition and prospects of the company, and other relevant factors. The business plan objectives and milestones the company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships. Based on the above, management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. If it is determined that there has been an other than temporary decline in the value of its ownership interests in the company, impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The measurement of fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies, and the valuation of acquisitions of similar companies.

We identified the evaluation of impairment of ownership interests and advances as a critical audit matter. Specifically, the assessment encompassed the evaluation of management’s determination of the recognition of an other than temporary decline in value of its ownership interest in a company. The assessment also included the evaluation of the measurement of impairment. Both evaluations involved significant auditor judgment and subjectivity in assessing the results of the impairment analysis because the estimated fair value of certain ownership interests and advances approximate their carrying values, indicating a higher risk of impairment due to measurement uncertainty. The impairment analysis also involved evaluating the valuation methods used to estimate the fair value, which included significant assumptions based on future events that are not under the control of management. Those significant assumptions included projected revenues, likelihood of transaction scenarios, the selection of peer companies and their corresponding trading multiples and the weightings of different outcomes in developing the estimated fair value of the ownership interests. Changes to those assumptions could have a significant effect on the fair value.  In addition, the evaluation of impairment required the involvement of professionals with specialized skills and knowledge to assist in evaluating the audit evidence obtained from these procedures.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design of certain internal controls related to the Company’s impairment assessment. This included controls over the recognition of other than temporary declines in value and the impairment analysis, including financial condition, prospects and other factors present at the company as well as the identification and determination of the significant assumptions used in estimating the fair values. We evaluated the valuation methods and tested the significant assumptions used by management including projected revenue, likelihood of transaction scenarios, the selection of peer companies and their corresponding trading multiples, and the weightings of different outcomes in developing the estimated fair value. Evaluating management’s significant assumptions related to the projected revenue involved considering the equity investees’ historical revenues and prospects.  In evaluating the likelihood of transaction scenarios, we considered recent financing activities and proposed transactions. Professionals with specialized skills and knowledge were used to assist in evaluating the methods and assessing the peer companies and their corresponding trading multiples assumptions by considering public companies with similar business models that operate in similar industries and by independently obtaining market data for the corresponding peer companies and comparing key characteristics such as size and growth prospects.

/s/ KPMG LLP

We have served as the Company’s auditor since 1986.

Philadelphia, Pennsylvania
March 5, 2021

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

  

As of December 31,

 
  

2020

  

2019

 

ASSETS

        

Current Assets:

        

Cash and cash equivalents

 $15,601  $25,028 

Restricted cash

  0   25 

Prepaid expenses and other current assets

  462   1,297 

Total current assets

  16,063   26,350 

Property and equipment, net

  1,790   2,101 

Ownership interests and advances

  50,398   77,129 

Other assets

  784   1,997 

Total Assets

 $69,035  $107,577 

LIABILITIES AND EQUITY

        

Current Liabilities:

        

Accounts payable

 $56  $39 

Accrued compensation and benefits

  2,677   1,364 

Accrued expenses and other current liabilities

  410   627 

Lease liability - current

  327   399 

Total current liabilities

  3,470   2,429 

Other long-term liabilities

  637   1,027 

Lease liability - non-current

  2,053   2,380 

Total Liabilities

  6,160   5,836 

Commitments and contingencies (Note 12)

          

Equity:

        

Preferred stock, $0.10 par value; 1,000 shares authorized

  0   0 

Common stock, $0.10 par value; 83,333 shares authorized; 21,573 issued at December 31, 2020 and 2019, respectively

  2,157   2,157 

Additional paid-in capital

  807,582   810,856 

Treasury stock, at cost; 688 and 930 shares at December 31, 2020 and 2019, respectively

  (10,200)  (14,024)

Accumulated deficit

  (736,639)  (697,223)

Accumulated other comprehensive loss

  (25)  (25)

Total Equity

  62,875   101,741 

Total Liabilities and Equity

 $69,035  $107,577 

See Notes to Consolidated Financial Statements.

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

  

Year Ended December 31,

 
  

2020

  

2019

 

General and administrative expense

 $9,466  $9,982 

Operating loss

  (9,466)  (9,982)

Other income (loss), net

  (7,708)  12,255 

Interest income

  261   2,044 

Interest expense

  0   (14,023)

Equity income (loss), net

  (20,702)  64,267 

Net income (loss) before income taxes

  (37,615)  54,561 

Income tax benefit (expense)

  0   0 

Net income (loss)

 $(37,615) $54,561 

Net income (loss) per share:

        

Basic

 $(1.81) $2.64 

Diluted

 $(1.81) $2.64 

Weighted average shares used in computing net income (loss) per share:

        

Basic

  20,751   20,636 

Diluted

  20,751   20,636 

See Notes to Consolidated Financial Statements.

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

  

Year Ended December 31,

 
  

2020

  

2019

 

Net income (loss)

 $(37,615) $54,561 

Other comprehensive (loss) income:

        

Share of other comprehensive (loss) of equity method investments

  0   (31)

Reclassification adjustment for sale of equity method investments

  0   6 

Total comprehensive income (loss)

 $(37,615) $54,536 

See Notes to Consolidated Financial Statements.

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(In thousands)

      

Accumulated

  

Accumulated Other Comprehensive

  

Common Stock

  

Additional Paid-In

  

Treasury Stock

 
  

Total

  

Deficit

  

Loss

  

Shares

  

Amount

  

Capital

  

Shares

  

Amount

 

Balance — December 31, 2018

 $66,979  $(731,105) $0   21,573  $2,157  $810,928   914  $(15,001)

Net income

  54,561   54,561   0      0   0      0 

Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net

  (236)  0   0   0   0   (1,213)  16   977 

Stock-based compensation

  1,141   0   0      0   1,141      0 

Other comprehensive loss

  (25)  0   (25)     0   0      0 

Dividends paid

  (20,679)  (20,679)  0      0   0      0 

Balance — December 31, 2019

 $101,741  $(697,223) $(25)  21,573  $2,157  $810,856   930  $(14,024)

Net loss

  (37,615)  (37,615)  0      0   0      0 

Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net

  (40)  0   0   0   0   (3,864)  (242)  3,824 

Stock-based compensation

  590   0   0      0   590      0 

Change in accounting at ownership interests

  (1,801)  (1,801)  0      0   0      0 

Balance — December 31, 2020

 $62,875  $(736,639) $(25)  21,573  $2,157  $807,582   688  $(10,200)

See Notes to Consolidated Financial Statements.

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

  

Year Ended December 31,

 
  

2020

  

2019

 

Cash Flows from Operating Activities:

        

Net income (loss)

 $(37,615) $54,561 

Adjustments to reconcile to net cash used in operating activities:

        

Depreciation

  0   808 

Amortization of debt discount

  0   3,454 

Amortization of right of use asset

  311   260 

Equity (income) loss, net

  9,420   (67,232)
Impairments of ownership interests and advances  20,039   3,012 

Income from change in fair value of derivative

  0   (5,060)

Gain from observable price changes

  (1,224)  (4,526)

Other, net

  175   (2,315)

Stock-based compensation, including liability classified awards

  965   1,237 

Changes in assets and liabilities:

        

Prepaid expenses and other current assets

  (137)  (823)

Accounts payable, accrued expenses, and other current liabilities

  (77)  (3,346)

Net cash used in operating activities

  (8,143)  (19,970)

Cash Flows from Investing Activities:

        

Acquisitions of ownership interests

  (7,534)  (11,640)

Proceeds from sales and distributions from ownership interests

  7,903   104,302 

Advances and loans to ownership interests

  (1,638)  (5,055)

Repayment of advances and loans from ownership interests

  0   750 

Purchase of marketable securities

  0   (57,243)

Proceeds, from sales and maturities in marketable securities

  0   95,189 

Net cash (used in) provided by investing activities

  (1,269)  126,303 

Cash Flows from Financing Activities:

        

Payment of dividend

  0   (20,679)

Repayments on credit facility

  0   (68,568)

Tax withholdings related to equity-based awards

  (40)  (236)

Net cash used in financing activities

  (40)  (89,483)

Net change in cash, cash equivalents and restricted cash

  (9,452)  16,850 

Cash, cash equivalents and restricted cash equivalents at beginning of period

  25,053   8,203 

Cash, cash equivalents and restricted cash at end of period

 $15,601  $25,053 

See Notes to Consolidated Financial Statements.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. General

Liquidity And Capital Resources

As of December 31, 2020, Safeguard ("the Company") had $15.6 million of cash and cash equivalents.

In January 2018, Safeguard announced that, from that date forward, the Company will not deploy any capital into new opportunities and will focus on supporting our existing companies and maximizing monetization opportunities to return value to shareholders. In that context, the Company has, are and will consider initiatives including, among others: the sale of individual ownership interests, the sale of certain or all ownership interests in secondary market transactions, or a combination thereof, as well as other opportunities to maximize shareholder value.

The Company believes that its cash and cash equivalents at December 31, 2020 will be sufficient to fund operations past one year from the issuance of these consolidated financial statements.

Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Safeguard and all of its subsidiaries in which a controlling financial interest is maintained. All intercompany accounts and transactions are eliminated in consolidation.

Principles of Accounting for Ownership Interests in Companies

The Company accounts for its ownership interests using one of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.

In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets.

Equity Method. The Company accounts for ownership interests whose results are not consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an ownership interest depends on an evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a 20% to 50% interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. Under the equity method of accounting, the Company does not reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a one quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.

When the Company’s carrying value in an equity method company is reduced to zero, the Company records no further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. When such equity method company subsequently reports income, the Company will not record its share of such income until it exceeds the amount of the Company’s share of losses not previously recognized.

Other Method. We account for our equity interests in companies which are not accounted for under the equity method as equity securities without readily determinable fair values. We estimate the fair value of these securities based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Under this method, our share of the income or losses of such companies is not included in our Consolidated Statements of Operations. We include the carrying value of these investments in Ownership interests and advances on the Consolidated Balance Sheets.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Accounting Estimates

The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. These estimates include the evaluation of the recoverability of the Company’s ownership interests and advances, the recoverability of deferred tax assets, stock-based compensation and commitments and contingencies. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.

Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and may require adjustments in the future when audits of these entities’ financial statements are completed.

It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At December 31, 2020, the Company believes the carrying value of the Company’s ownership interests and advances is not impaired, although there can be no assurance that the Company’s future results will confirm this assessment, that a significant write-down or write-off will not be required in the future or that a significant loss will not be recorded in the future upon the sale of a company.

Cash and Cash Equivalents and Marketable Securities

The Company considers all highly liquid instruments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits that are readily convertible into cash. The Company determines the appropriate classification of marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Held-to-maturity securities were carried at amortized cost, which approximated fair value. Marketable securities consisted of held-to-maturity securities, primarily consisting of government agency bonds, commercial paper and certificates of deposits. Marketable securities with a maturity date greater than one year from the balance sheet date would be considered long-term. The Company has not experienced any significant losses on cash equivalents and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

Restricted Cash

Restricted cash equivalents represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets:

  

December 31, 2020

  

December 31, 2019

 
  

(In thousands)

 

Cash and cash equivalents

 $15,601  $25,028 

Restricted cash

  0   25 

Total cash, cash equivalents and restricted cash

 $15,601  $25,053 

Financial Instruments

The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. 

Property and Equipment

Property and equipment represents right-of-use assets resulting from the adoption of Accounting Standards Update ("ASU") No.2016-02,Leases, and other previously existing leasehold improvements. The leasehold improvements were amortized over the shorter of the estimated useful lives or the expected remaining term of the lease. The right-of-use assets are reduced over the remaining term of the applicable lease (principally April 2026) in a manner that results in a straight-line lease expense, when combined with the interest factor on the lease liability.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Lease liability

The initial lease liability represents the present value of the fixed escalating lease payments through April 2026 associated with the Company's prior corporate headquarters operating office lease. The discount rate used to calculate the lease liability was based on the Company's incremental borrowing rate, approximately 12%, at the transition to the guidance of ASU No.2016-02,Leases. Subsequent values of the lease liability reflect the reduction in the lease liability for operating lease payments less an amount representing interest, which is included in the straight-line lease expense. There is no residual value guarantee associated with this operating lease arrangement. The Company has incurred operating lease expenses and operating cash outflows of $0.5 million for each of the years ended December 31, 2020 and 2019, respectively, and $0.6 million for each of the years ended December 31, 2020 and 2019.

In March 2019, the Company entered into a sublease of its prior corporate headquarters office space. The term of the sublease is through April 2026, the same as the Company's underlying lease. Fixed sublease payments to the Company are escalating over the term of the sublease and are reported as a component of general and administrative expenses.

In April 2019, the Company entered into a sublease for replacement office space with a related party, an equity method ownership interest, beginning in June 2019. The 18 month term of this sublease expired in 2020. The aggregate payments under this sublease were not material.

A summary of the Company's operating lease cash flows at December 31, 2020 follows:

  Operating lease payments  

Expected sublease receipts

 
  

(In thousands)

 

2021

 $595  $525 

2022

  601   540 

2023

  607   556 

2024

  613   573 

2025

  619   590 

2026

  208   199 

Thereafter

  0   0 

Total future minimum lease payments

  3,243   2,983 

Less imputed interest

  (863)    

Total operating lease liabilities

 $2,380     

Valuation of Credit Facility repayment feature

The fair value of the Credit Facility repayment feature (a Level 3 measurement) was determined quarterly based on the present value of make-whole interest payments that were expected to be paid based on cash flow estimates that included a probability weighted estimate of exit transactions, estimated follow-on deployments, estimated quarterly operating cash flows and other cash commitments that would have resulted in qualified cash exceeding the $50 million threshold specified in the Credit Facility. This fair value of the Credit Facility repayment feature was eliminated in July 2019 upon the repayment of the Credit Facility.

Impairment of Ownership Interests and Advances

On a periodic basis, but no less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated fair value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.

The estimated fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.

Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations.

The reduced cost basis of a previously impaired company accounted for using the Equity method are not written-up if circumstances suggest the value of the company has subsequently recovered.

Income Taxes

The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are not considered more likely than not to be realized.

Net Income (Loss) Per Share

The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies.

Segment Information

The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

Recently Adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No.2014-09,Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"). ASU 2014-09 and related subsequent amendments outline a single comprehensive model to use to account for revenue arising from contracts with customers and supersede most current revenue recognition guidance. For public companies, the guidance was effective for annual periods beginning after December 15, 2017 and any interim periods that fall within that reporting period. For nonpublic companies, the guidance is effective for annual periods beginning after December 15, 2018 and interim periods within annual periods beginning after December 15, 2019 with early adoption permitted. Additionally, on June 3, 2020 the FASB issued ASU 2020-05, which extended the adoption of ASC 606 for all nonpublic business entities that have not issued their 2019 financial statements as of June 3, 2020, until January 1, 2020.

As the new standard superseded most existing revenue guidance, it impacted revenue and cost recognition for companies in which we hold an ownership interest. Any change in revenue or cost recognition for companies in which we hold an ownership interest could affect the Company's recognition of its share of the results of its equity method companies. On July 20, 2017, the SEC staff observer at the FASB’s Emerging Issues Task Force ("EITF") meeting announced that the SEC staff will not object if a private company equity method investee meeting the definition of a public business entity that otherwise would not meet the definition of a public business entity except for the inclusion of its financial statements or financial information in another entity’s filings with the SEC, uses private company adoption dates for the new revenue standard.  As a result, the Company's private, calendar year companies adopted the new revenue standard for the year ending December 31, 2019, including a cumulative effect where applicable as of the first day of the 2019 reporting period. 

For our ownership interests that have adopted ASU 2014-09, the impact of adoption of the new revenue standard is reflected in the Company’s financial results for the interim and annual reporting periods beginning in 2020 on a one quarter-lag basis.  The impact upon adoption resulted in an increase in accumulated deficit and a decrease in ownership interests of $1.8 million, net, due to the deferral of revenue and certain costs at our underlying ownership interests.  Our results of operations for the year ended December 31, 2020 reflect a benefit of $1.8 million due primarily to the recognition of revenue in 2019 that was previously deferred as a result of the adoption of ASU 2014-09.  Accordingly, the cumulative impact of the adoption of ASU 2014-09 was not significant. 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

2. Ownership Interests and Advances

The following summarizes the carrying value of the Company’s ownership interests and advances.

  

December 31, 2020

  

December 31, 2019

 
  

(In thousands)

 

Equity Method:

        

Companies

 $27,550  $34,271 

Private equity funds

  271   271 
   27,821   34,542 

Other Method:

        

Companies

  19,683   27,031 

Private equity funds

  268   453 
   19,951   27,484 

Advances to companies (equity method)

  2,626   15,103 
  $50,398  $77,129 

In September 2020, Sonobi, Inc. was acquired by another entity for cash. The Company received $6.6 million in cash proceeds in connection with this transaction, excluding holdbacks and escrows. The Company recognized an insignificant gain on the sale, which is included in Equity income (loss), net in the Consolidated Statements of Operations.

 

During 2017, allthe year ended December 31, 2020, the Company recorded impairments of $11.3 million related to the ownership interests of WebLinc, Inc., QuanticMind, Inc. and Sonobi, Inc. accounted for under the equity method, which are reflected in Equity income (loss), net in the Consolidated Statement of Operations.  During the year ended December 31,2020, the Company also recorded impairments of $8.8 million related to the ownership interests of T-REX Group, Inc., b8ta and others accounted for under the Other method, which are reflected in Other income (loss), net in the Consolidated Statement of Operations. The impairments were determined based on declines in the fair value of our executive officers were employedownership interests resulting from reduced valuation expectations and extended exit timelines resulting from the more challenging mergers and acquisitions environment related to COVID-19 and the related uncertain economic impact. The measurement of fair value for these impairments was estimated based on evaluating several valuation inputs available for each of the applicable ownership interests, primarily including the value at which independent third parties have invested, the valuation of comparable public companies, the valuation of acquisitions of similar companies and the present value of our expected outcomes. Assumptions considered within these methods include determining which public companies are comparable, projecting forward revenues for the measured ownership interest, discounts to apply for the lack of marketability or lack of comparability, other factors and the relative weight to apply to each valuation input available. Due to the unobservable nature of some of these inputs, we have determined these fair value estimates to be non-recurring Level 3 fair value measurements.

During the year ended December 31, 2020, the Company recorded a $1.5 million non-cash gain based upon an observable price change related to our ownership interest in Flashtalking Inc. accounted for under the Other method, which is reflected in Other income (loss), net in the Consolidated Statement of Operations. During the year ended December 31,2020, the Company also recorded a $0.3 million non-cash Other loss based on an at-will basis. However, eachobservable price change for another ownership interest accounted for under the Other method.

During 2019, the Company recognized an impairment of our named executive officers also have an agreement with Safeguard that provides for certain severance benefits$3.0 million related to NovaSom, which is reflected in Equity income (loss), net in the eventConsolidated Statements of terminationOperations. The impairment was the result of employmentNovaSom Inc.'s August 2019 bankruptcy filing.

In January 2019, Propeller was acquired by Safeguard without “cause” or byanother entity for cash. The Company received $41.5 million in cash proceeds in connection with the officertransaction, and $0.7 million in 2020 for “good reason” (as definedamounts held in escrow. The Company recognized a gain of $35.1 million, which is included in Equity income (loss), net in the agreements).Consolidated Statements of Operations.

 

PursuantIn January 2019, Brickwork merged into another privately-held company. The Company received a preferred equity interest in the acquiror and accounts for this interest as an equity interest without a readily determinable fair value. The Company did not recognize a gain or loss in 2019 as a result of this transaction.

In May 2019, Transactis was acquired by another entity for cash. To date, the Company received $57.5 million in cash proceeds in connection with the transaction, excluding certain amounts that continue to those agreements, uponbe held in escrow that may be released on various dates on or before May 2020. The Company has recognized gains of $50.7 million, which are included in Equity income (loss), net in the occurrenceConsolidated Statements of Operations.

During 2019, the Company ceased accounting for T-REX Group, Inc. and Hoopla Software, Inc. under the equity method as a termination event, each executive will be entitledresult of losing our ability to those benefits outlinedexercise significant influence.

During 2019, the Company recorded $4.5 million of non-cash gains in his agreement with us, which include a multiple of his then current base salary, payment of his pro rata bonus forOther income (loss), net related to the year of termination, accelerated vestingincrease in the value of certain equity awards, extensionsecurities based upon observable price changes.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Summarized Financial Information

The following table provides summarized financial information for ownership interests accounted for under the equity method for the periods presented and has been compiled from respective company financial statements, reflect certain historical adjustments, and are reported on a one quarter lag. Results of operations are excluded for periods prior to their acquisition and subsequent to their disposition. Historical results are not adjusted when the Company exits or writes-off a company. 

  

As of December 31,

 
  

2020

  

2019

 
  

(In thousands)

 

Balance Sheets:

        

Current assets

 $104,024  $91,968 

Non-current assets

  26,352   26,231 

Total assets

 $130,376  $118,199 

Current liabilities

 $72,972  $80,783 

Non-current liabilities

  105,506   87,081 

Shareholders’ deficit

  (48,102)  (49,665)

Total liabilities and shareholders’ deficit

 $130,376  $118,199 
         

Number of equity method ownership interests

  12   13 

  

Year Ended December 31,

 
  

2020

  

2019

 
  

(In thousands)

 

Results of Operations:

        

Revenue

 $153,875  $145,632 

Gross profit

 $92,039  $78,465 

Net loss

 $(82,216) $(127,007)

As of December 31, 2020, the Company’s carrying value in equity method companies, in the aggregate, exceeded the Company’s share of the post-termination exercisenet assets of such companies by approximately $17.9 million. Of this excess, $15.0 million was allocated to goodwill and $2.9 million was allocated to intangible assets.

3. Acquisitions of Ownership Interests

2020 Transactions

The Company deployed an additional $2.5 million to Aktana, Inc. during the three month period ended September 30, 2020. The Company had previously deployed an aggregate of $11.7 million. Aktana leverages big data and machine learning to enable pharmaceutical brands to dynamically optimize their strategy and
enhance sales execution.


       The Company deployed an additional $4.4 million to Syapse, Inc. during the
six month period ended June 30, 2020, including the $0.6 million of convertible loans deployed in the first quarter of 2020 which was converted to equity in the second quarter. The Company had previously deployed $20.6 million. Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models.

The Company deployed an additional $1.0 million to meQuilibrium during the three month period ended March 31, 2020. The Company had previously deployed an aggregate of $13.0 million. meQuilibrium is a digital coaching platform that delivers clinically validated and highly personalized resilience solutions to employers, health plans, wellness providers, and consumers increasing engagement, productivity and performance, as well as improving outcomes in managing stress, health and well-being.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The Company funded an additional $0.7 million of convertible loans to Trice Medical, Inc. during the six month period ended June 30, 2020. The Company had previously deployed an aggregate of $10.2 million. Trice is focused on orthopedic diagnostics using fully integrated camera-enabled technologies to provide clinical solutions to physicians.

The Company deployed an aggregate of $0.2 million to Clutch Holdings during the three month period ended June 30, 2020. The Company had previously deployed an aggregate of $16.7 million. Clutch provides customer intelligence and personalized engagements that empower consumer-focused businesses to identify, understand and motivate each segment of their customer base.

The Company funded an additional $0.2 million of convertible loans to QuanticMind during the three month period ended March 31, 2020. The Company had previously deployed an aggregate of $13.5 million. QuanticMind delivers an intelligent, scalable and fast platform for maximizing digital marketing performance, including paid search and social, for enterprises.  See Note 2 for impairment recorded in 2020 and Note 16 for the sale of this ownership interest in 2021.

The Company funded an aggregate of $0.1 million of convertible loans to WebLinc, Inc. during the three month period ended March 31, 2020.  The Company had previously deployed an aggregate of $16.1 million.  WebLinc is an e-commerce platform for online retailers.  See Note 2 for impairment recorded in 2020 and Note 16 for the sale of this ownership interest in 2021.

2019 Transactions

The Company deployed an additional $5.0 million to Syapse, Inc. 

The Company deployed an additional $2.0 million to Moxe Health Corporation, including $0.3 million that was funded initially as a convertible loan. The Company had previously deployed $5.5 million in Moxe Health.

The Company deployed an additional $1.5 million to Aktana, Inc. 

The Company deployed an additional $1.5 million to meQuilibrium.

The Company deployed an additional $1.5 million to Zipnosis, Inc. The Company had previously deployed $8.5 million in Zipnosis. Zipnosis provides health systems with a white-labeled, fully integrated virtual care platform.

The Company deployed an aggregate of $0.4 million to Clutch Holdings. 

The Company funded an additional $2.0 million of convertible loans to Sonobi, Inc. The Company had previously deployed $11.4 million in Sonobi. Sonobi is an advertising technology developer that was acquired during 2020.  See Note 2 for impairment and sale recorded in 2020.

The Company funded an aggregate of $1.1 million of convertible loans to WebLinc, Inc. See Note 2 for impairment recorded in 2020 and Note 16 for the sale of this ownership interest in 2021.

The Company funded an aggregate of $1.0 million of convertible loans to NovaSom, Inc. The Company had previously deployed an aggregate of $26.4 million in NovaSom. See Note 2 for impairment recorded during the second quarter of 2019.

The Company funded an additional $0.6 million of convertible loans to QuanticMind.  See Note 2 for impairment recorded in 2020 and Note 16 for the sale of this ownership interest in 2021.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

4. Fair Value Measurements

The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within which somedifferent levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument.

Cash equivalents approximate fair value due to their short term nature.  The Company did not have any Level 2 or Level 3 financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019.

5. Credit Facility and Convertible Debentures

Credit Facility     

The Company's credit facility was with HPS Investment Partners, LLC (“Lender”), and was amended in May 2018 ("Credit Facility"). The Credit Facility had a scheduled maturity of May 11, 2020 and interest at a rate of either: (A) LIBOR plus 8.5% (subject to a LIBOR floor of 1%), payable on the last day of the one, two or three month interest period applicable to the LIBOR rate advance, or (B) 7.5% plus the greater of: 2%; the Federal Funds Rate plus 0.5%; LIBOR plus 1%; or the U.S. Prime Rate, payable monthly in arrears. The Credit Facility was secured by all of the equity awards held byCompany's assets in accordance with the executive may be exercised, coverage under our medical, health and life insurance plans for a designated period of time and outplacement services or office space. See “Executive Compensation—Potential Payments upon Termination or Change in Control” below for a summaryterms of the specific benefits that each named executive officer will receive upon the occurrence of a termination event.Credit Facility.

 

AllThe terms of the agreementsCredit Facility included a requirement that if the aggregate amount of the Company’s qualified cash at any quarter end date exceeded $50.0 million, the Company would be required to prepay outstanding principal amounts under which our named executive officers receive benefitsthe Credit Facility, plus any applicable interest and prepayment fees, in the event of a “change in control” require a “double trigger,” namely a change in control coupled with a loss of employment or a substantial change in job duties. We believe a “double trigger” provides retention incentives as well as continuity of management in the event of an actual or threatened change in control.

Key Employee Compensation Recoupment Policy

In April 2013, the Board approved a Key Employee Compensation Recoupment Policy (the “Recoupment Policy”). Under the Recoupment Policy, we have the right to require any “key employee” to reimburse to Safeguard all or any part of an amount equal to anysuch excess. Based on this requirement, the Company made a principal payment of $24.0 million and a make-whole interest payment of $2.9 million on April 15, 2019 based on the Company's qualified cash incentive award, and/orat March 31, 2019. Additionally, the Company repaid the remaining principal of $44.5 million and make-whole interest of $4.1 million in July 2019.

The Company was subject to forfeit all or any part of any equity grant (whether vested or not), awarded, paid and/or made to such key employee within three years of a “Triggering Event”certain debt covenants under the Recoupment Policy. For purposesCredit Facility including maintaining a specified level of liquidity threshold, maintaining an appraised value of ownership interests, limiting deployments to our remaining ownership interests, limiting certain expenses, and restricting any repurchases of outstanding common stock or issuing dividends until such time as the Credit Facility was repaid in full. The Company was in compliance with all applicable covenants.

The Credit Facility required prepayments of outstanding principal and interest amounts when the Company’s qualified cash at any quarter end date exceeded $50.0 million. This provision in the Credit Facility was an embedded derivative that was accounted for separately from the Credit Facility. A liability of $0.5 million was recorded on the 2018 amendment date for the fair value of potential future prepayments based upon management's probability weighted cash forecast. This amount was also included in debt issuance costs and had been amortized over the remaining term of the Recoupment Policy,Credit Facility. The liability was adjusted to fair value at each balance sheet date based upon management's updated probability weighted cash forecast. During 2019, the term “key employee” means eachCompany recorded a decrease in the liability of our named executive officers, each other Safeguard employee$5.1 million, which is included in Other income (loss), net on the Consolidated Statements of Operations.

The Company recorded interest expense under the Credit Facility of $14.0 million for the year ended December 31, 2019. The effective interest rate on the Credit Facility was 15.1%. The Company made interest payments under the Credit Facility of $11.5 million for the year ended December 31, 2019.

6. Equity

In July 2015, the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the years ended December 31, 2020 and 2019, the Company did not repurchase any shares under the existing authorization. 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

In February 2018, the Company's Board of Directors adopted a tax benefits preservation plan (the "Plan") designed to protect and preserve the Company's ability to utilize its net operating loss carryforwards ("NOLs") which was ratified by shareholders at its 2018 Annual Meeting of Shareholders. The purpose of the Plan was to preserve the Company's ability to use its NOLs, which would be substantially limited if the Company experienced an "ownership change" as defined under Section 382 of the Internal Revenue Code. In general, an ownership change would occur if the Company's shareholders who holds the title of Vice President or above, and our controller and assistant controller. A “Triggering Event” is oneare treated as owning five percent or more of the following, as determined by the Board or the Committee, in its sole discretion: (i) it is determined that (a) a key employee engaged in any fraud, misconduct, gross negligence or ethical misconduct which resulted in a financial restatement by Safeguard, or any material adverse impact on Safeguard, and (b) the key employee received any cash incentive award or equity grant from Safeguard, the payment or issuance of which was based in whole or in part on such actions of the key employee; or (ii) it is determined that Safeguard’s consolidated financial statements or any other metric utilized by the Committee to establish, in whole or in part, a cash incentive award or equity grant to the key employee were inaccurate due, in whole or in part, to the fraud, misconduct, gross negligence or ethical misconduct of the key employee. The Committee will administer and enforce the Recoupment Policy on behalfoutstanding shares of Safeguard and has broad, sole discretionary authority to interpret and to make determinations with respect to the Recoupment Policy. The Committee’s determinations will be final and binding on all key employees and other persons.

The Recoupment Policy was adopted in furtherancefor purposes of the commitment by the Committee and the Board to sound executive compensation practices and effective corporate governance, and not in response to any particular situation or circumstance. Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act requires the SEC to promulgate regulations applicable to public companies that require the recovery of incentive compensation382 ("five-percent shareholders") collectively increase their aggregate ownership in the event of a financial statement restatement and certain other circumstances. The Board intends to review the Recoupment Policy following SEC adoption of final rules to implement Section 954 of Dodd-Frank and the effectiveness of the applicable NYSE listing standards to ensure compliance.

36

Deductibility of Executive Compensation

Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”) generally disallows a tax deduction to public companies for compensation in excess of $1 million paid to any of the companies’ chief executive officer and certain other NEOs. Prior to the effectiveness of the Tax Cuts and Jobs Act, performance-based compensation satisfying certain requirements was not subject toCompany's overall shares outstanding by more than 50 percentage points. Whether this deduction limitation. Effective January 1, 2018, the performance-based compensation exception is not available to public companies, except for certain limited grandfathered arrangements.  We periodically reviewed potential consequences of Section 162(m) and, prior to January 1, 2018, the stock options and PSUs awarded under our equity compensation plan were intended to comply with the provisions of Section 162(m).

Stock Ownership Guidelines

Our Boardchange has established stockoccurred would be measured by comparing each five-percent shareholder's current ownership guidelines that are designed to closely align the long-term interests of our named executive officers and other senior executives with the long-term interests of our shareholders. During 2017 our ownership guidelines were as follows:

ExecutiveOwnership Requirement
Chief Executive Officer4X Base Salary
Executive Vice President / Chief Financial Officer3X Base Salary
Senior Vice President2X Base Salary

The Nominating & Corporate Governance Committee monitors compliance with the ownership requirements as of the endmeasurement date to such shareholders' lowest ownership percentage during the three-year period preceding the measurement date. To protect the Company's NOLs from being limited or permanently lost under Section 382, the Plan was intended to deter any person or group from acquiring beneficial ownership of each calendar year. Shares counted toward these guidelines include:

·Shares beneficially owned by the executive officer;
·Vested portion of restricted stock units (including DSUs and PSUs) and restricted stock awards; and
·Net value of shares underlying vested, in-the-money options (“Net Option Value”).

For purposes of calculating the value to be used in monitoring compliance with the ownership guidelines, we utilize (a) the greater4.99% or more of the current value or the cost basis of purchased shares or vested restrictedCompany's outstanding common stock units/restricted stock awards as to which the executive has declared income and paid taxes; and (b) our trailing six-month average share price in determining Net Option Value.

The Nominating & Corporate Governance Committee has also established the timeframe within which each executive must attain the required holding levels. The stock ownership guidelines in effect in 2017 provide that each executive generally must meet the stock ownership requirement by December 31st of the year of the fifth anniversary of the event triggering the stock ownership requirement (or any increase in the stock ownership requirement). No sales of Safeguard stock by our named executive officers are permitted during the period in which the ownership requirement is not met (except for limited stock sales to meet tax obligations), without the approval of the Board, reducing the likelihood of an unintended ownership change. Under the Plan, the Company would issue one preferred stock purchase right (the "Rights") for each share of Safeguard's common stock held by shareholders of record on March 2, 2018. The issuance of the Rights would not be taxable to Safeguard or our Nominating & Corporate Governance Committee. Asits shareholders and would not affect Safeguard's reported earnings per share. The Rights would have traded with Safeguard's common shares and would have expired no later than February 19, 2021. Accordingly, the Plan has now expired.  

On November 7, 2019, the Board of Directors declared a special cash dividend of $1.00 per share, payable on December 30, 2019 to shareholders of record as of the close of business on December 23, 2019, resulting in total dividends paid of $20.7 million.

7. Stock-Based Compensation

Equity Compensation Plans

The 2014 Equity Compensation Plan has 4.1 million shares authorized for issuance. During 2020 and 2019, the Company issued no stock-based awards outside of existing plans. To the extent allowable, service-based options are incentive stock options. Options granted under the plans are at prices equal to or greater than the fair market value at the date of this report, Mr. Sisko, onegrant. Upon exercise of our named executive officers, has achievedstock options, the requiredCompany issues shares first from treasury stock, ownership level.if available, then from authorized but unissued shares. At December 31, 2020, the Company had reserved 2.8 million shares of common stock for possible future issuance under its 2014 Equity Compensation Plan and other previously expired equity compensation plans.

 

Prohibition on Speculation in Safeguard StockClassification of Stock-Based Compensation Expense

 

Safeguard’s policyStock-based compensation expense was recognized in the Consolidated Statements of Operations as follows: 

  

Year Ended December 31,

 
  

2020

  

2019

 
  

(In thousands)

 

General and administrative expense

 $965  $1,237 
  $965  $1,237 

At December 31, 2020, the Company had outstanding options that vest based on securities trading prohibits our executive officers,2 different types of vesting schedules:

1) performance-based; and

2) service-based.

Performance-based awards entitle participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company upon the sale, merger or other exit transaction of certain identified companies. Vesting may occur, if at all, once per year. The requisite service periods for the performance-based awards are based on the Company’s estimate of when the performance conditions will be met. Compensation expense is recognized for performance-based awards for which the performance condition is considered probable of achievement. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated.  The Company did not issue any performance-based units during the years ended December 31, 2020 and 2019.  During the years ended December 31, 2020 and 2019, there were 0 performance-based options that vested.  During the years ended December 31, 2020 and 2019, respectively, 72 thousand and 174 thousand performance-based options were canceled or forfeited. The Company recorded a reduction of compensation expense related to performance-based options of $0.0 million and $0.1 million for the years ended December 31, 2020 and 2019 respectively. The maximum number of unvested options at December 31, 2020 attainable under these grants was 21 thousand shares.

Service-based awards generally vest over four years after the date of grant and expire eight years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based awards is the period over which the award vests. During the years ended December 31, 2020 and 2019, respectively, the Company issued 0 service-based options to employees and recorded $0.0 million compensation expense from the vesting of previously issued awards. During the years ended December 31, 2020 and 2019, respectively, 62 thousand and 57 thousand service-based options were canceled or forfeited.  

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

There were 0 options granted during 2020 and 2019.

Stock-based compensation expense of $1.0 million was recognized during the year ended December 31, 2020 related to Board fees and management bonuses earned in 2020 that were subsequently settled in stock.  The Company had liabilities of $0.5 million and $0.1 million as of December 31, 2020 and 2019, respectively, that were settled through the issuance of common stock in the subsequent period. Compensation expense of $0.1 million was also recognized during the year ended December 31, 2019 related to the dividend payments made to holders of unvested restricted stock awards pursuant to the terms of those instruments.  

Option activity of the Company is summarized below: 

  

Shares

  Weighted Average Exercise Price  

Weighted Average Remaining Contractual Life

  Aggregate Intrinsic Value 
  

(In thousands)

      

(In years)

  

(In thousands)

 

Outstanding at January 1, 2019

  410   14.66         

Options granted

  0   0         

Options exercised

  0   0         

Options canceled/forfeited

  (231)  14.19         

Outstanding at December 31, 2019

  179   15.27         

Options granted

  0   0         

Options exercised

  0   0         

Options canceled/forfeited

  (134)  14.36         

Outstanding at December 31, 2020

  45   14.20   2.29  $0 

Options exercisable at December 31, 2020

  22   14.48   3.08   0 

Shares available for future grant

  2,515             

At December 31, 2020, total unrecognized compensation cost related to non-vested service-based options was immaterial. At December 31, 2020, total unrecognized compensation cost related to non-vested performance-based options was immaterial.

Performance-based stock units vest based on achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified companies, as described above related to performance-based awards. During 2020, the Company also initiated a 2021 CEO bonus award that will be settled in the vesting of performance-based units based on criteria determined by the Board of Directors.  Performance-based stock units represent the right to receive shares of the Company’s common stock, on a one-for-one basis at target or up to 120% for certain specified thresholds.  The maximum fair value associated with this award is $0.7 million, none of which has been recognized during the year ended December 31, 2020.  During the years ended December 31, 2020 and 2019, respectively, 100 thousand and 0 performance-based stock units were issued. NaN performance-based stock units vested during the years ended December 31, 2020 and 2019. During the years ended December 31, 2020 and 2019, respectively, 129 thousand and 339 thousand performance-based stock units were canceled or forfeited. Under the terms of the 2016 and 2015 performance-based awards, once performance-based stock units are fully vested, participants are entitled to receive cash payments based on their initial performance grant values as target capital returns described above are exceeded. At December 31, 2020, the liability associated with such potential cash payments was $0.0 million.

During the years ended December 31, 2020 and 2019, respectively, the Company issued 193 thousand and 31 thousand restricted shares to employees and directors. Restricted shares generally vest over a period of approximately two to four years, or are vested at issuance for directors 65 or older. During the years ended December 31, 2020and other employees from engaging2019, respectively, 10 thousand and 75 thousand restricted shares were canceled or forfeited.

During the years ended December 31, 2020 and 2019, respectively, the Company issued 20 thousand to an employee, and 0 deferred stock units to non-employee directors for annual service grants or fees earned during the preceding quarter. Deferred stock units issued to directors in activities with regardlieu of directors fees are 100% vested at the grant date; matching deferred stock units equal to 25% of directors’ fees deferred vest one year following the grant date or, if earlier, upon reaching age 65. Deferred stock units are payable in stock on a one-for-one basis. Payments related to the deferred stock units are generally distributable following termination of service, death or permanent disability.

Total compensation expense for deferred stock units, performance-based stock units and restricted stock was $0.5 million and $1.2 million, for the years ended December 31, 2020 and 2019, respectively. Unrecognized compensation expense related to deferred stock units, performance stock units and restricted stock at December 31, 2020 was $0.5 million. The total fair value of deferred stock units, performance stock units and restricted stock vested during the years ended December 31, 2020 and 2019 was $1.1 million and $1.2 million, respectively.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Deferred stock unit, performance-based stock unit and restricted stock activity are summarized below: 

  

Shares

  Weighted Average Grant Date Fair Value 
  

(In thousands)

     

Unvested at January 1, 2019

  777  $14.08 

Granted

  31   12.12 

Vested

  (107)  11.79 

Forfeited

  (414)  14.28 

Unvested at December 31, 2019

  287   14.44 

Granted

  313   5.89 

Vested

  (174)  7.77 

Forfeited

  (139)  15.24 

Unvested at December 31, 2020

  287   8.78 

8. Employee Benefit Plan

The Company maintains a qualified 401(k) retirement plan for eligible employees. The Plan’s matching formula is 100% of the first 5% of participants’ qualified compensation. Compensation expense related to our stock that can be considered as speculative, including but not limitedmatching contributions to short selling (profiting if the market price of our securities decreases); buying or selling publicly traded options (e.g.Plan for the years ended December 31, 2020 and 2019, a put option, which is an option or right to sell stock at a specific price prior to a specified date, or a call option, which is an option or right to buy stock at a specific price prior to a specified date);were $0.2 million and hedging or any other type of derivative arrangement that has a similar economic effect. Our executive officers and directors also are prohibited from pledging, directly or indirectly, our common stock or the stock of any of our partner companies, as collateral for indebtedness.$0.2 million, respectively.

9. Income Taxes

 

New Strategy - ChangesThe federal and state provision (benefit) for income taxes was $0.0 million for the years ended December 31, 2020 and 2019.

The total income tax provision (benefit) differed from the amounts computed by applying the U.S. federal income tax rate of 21.0% for the years ended December 31, 2020 and 2019 to net income (loss) before income taxes as a result of the following:

  

Year Ended December 31,

 
  

2020

  

2019

 

Statutory tax (benefit) expense

  21.0%  21.0%

Increase (decrease) in taxes resulting from:

        

Nondeductible expenses

  (4.1)  0.4 

Valuation allowance

  (16.9)  (21.4)
   0.0%  0.0%

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows: 

  

As of December 31,

 
  

2020

  

2019

 
  

(In thousands)

 

Deferred tax asset:

        

Carrying values of ownership interests and other holdings

 $38,361  $32,760 

Tax loss and credit carryforwards

  76,023   70,914 

Disallowed interest carryforwards

  7,292   7,292 

Accrued expenses

  497   213 

Stock-based compensation

  302   432 

Other

  482   604 
   122,957   112,215 

Valuation allowance

  (122,957)  (112,215)

Net deferred tax asset

 $0  $0 

As of December 31, 2020, the Company and its subsidiaries had federal net operating and capital loss carryforwards for tax purposes of approximately $362 million, of which approximately $37 million have an indefinite life. These carryforwards expire as follows: 

  

Total

 
  

(In thousands)

 

2021

 $3,728 

2022

  48,848 

2023

  52,512 

2024

  50,140 

2025 and thereafter

  170,189 
  $325,417 

In assessing the recoverability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has determined that it is more likely than not that certain future tax benefits may not be realized as a result of current and future income. Accordingly, a valuation allowance has been recorded against substantially all of the Company’s deferred tax assets.

The Company recognizes in Compensation Policiesits Consolidated Financial Statements the impact of a tax position if that position is more likely than not to be sustained upon examination, based on the technical merits of the position. All uncertain tax positions relate to unrecognized tax benefits that would impact the effective tax rate when recognized.

The Company does not expect any material increase or decrease in its income tax expense, in the next twelve months, related to examinations or changes in uncertain tax positions.

There were 0 changes in the Company’s uncertain tax positions for the years ended December 31, 2020 and Practices2019.

The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. Tax years 2015 and forward remain open for examination for federal tax purposes and the Company’s more significant state tax jurisdictions. To the extent utilized in future years’ tax returns, net operating loss carryforwards at December 31, 2020 will remain subject to examination until the respective tax year is closed. The Company recognizes penalties and interest accrued related to income tax liabilities in income tax benefit (expense) in the Consolidated Statements of Operations.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

10. Net Income (Loss) Per Share

The calculations of net income (loss) per share were: 

  

Year Ended December 31,

 
  

2020

  

2019

 
  

(In thousands, except per share data)

 

Basic:

        

Net income (loss)

 $(37,615) $54,561 

Weighted average common shares outstanding

  20,751   20,636 

Net income (loss) per share

 $(1.81) $2.64 

Diluted:

        

Net income (loss)

 $(37,615) $54,561 

Weighted average common shares outstanding

  20,751   20,636 

Net income (loss) per share

 $(1.81) $2.64 

Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).

If an equity method company has dilutive stock options, unvested restricted stock, DSUs, or warrants, diluted net income (loss) per share is computed by first deducting from net income (loss) the income attributable to the potential exercise of the dilutive securities of the company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.

Diluted income (loss) per share for the years ended December 31, 2020 and 2019 do not reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:

At December 31, 2020 and 2019, options to purchase 45 thousand and 179 thousand shares of common stock, respectively, at prices ranging from $10.37 to $17.11 per share, and $10.37 to $18.45 per share per share, respectively, were excluded from the calculation.

At December 31, 2020 and 2019, unvested restricted stock, performance-based stock units and DSUs convertible into 0.3 million and 0.3 million shares of stock, respectively, were excluded from the calculations.

For the year ended December 31, 2019, 0.8 million shares of common stock, respectively, representing the effect of assumed conversion of the 2019 Debentures were excluded from the calculations.

11. Related Party Transactions

 

In January 2018,the normal course of business, the Company’s officers and employees hold board positions with companies in which the Company announced its New Strategy. Underhas a direct or indirect ownership interest.

12. Commitments and Contingencies

The Company and the New Strategy, effective immediately,companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, ceased making capital deployments into any new partner company opportunities and is focusing its effortsthe ultimate disposition of these matters will not have a material adverse effect on managing and financially supporting its existing partner companies to exit events, and ultimately returning the net proceeds of such efforts to its shareholders. Other than as specifically noted, the discussion set forth in this CD&A concerning the Company’s compensation policies and practices, relates to periods priorconsolidated financial position or results of operations, however, no assurance can be given as to the establishmentoutcome of these actions, and one or more adverse rulings could have a material adverse effect on the New Strategy,Company’s consolidated financial position and therefore, does not necessarily reflect policies and practicesresults of operations or that will prevail or apply under the New Strategy.of its companies. The Company records costs associated with legal fees as such services are rendered.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

37

The Company had outstanding guarantees of $3.8 million at December 31, 2020 which related to one of the Company's private equity holdings.

 

In connectionOctober 2001, the Company entered into an agreement with a former Chairman and Chief Executive Officer of the New Strategy,Company, to provide for annual payments of $0.65 million per year and certain health care and other benefits for life. The former executive passed away in 2019. Accordingly, the Company recorded a $1.7 million gain in Other income (loss), net which also eliminated the remaining projected benefits related to this agreement that were previously included in Accrued expenses and other current liabilities and Other long-term liabilities on April 10, 2018, the Committee approved, andConsolidated Balance Sheets.

The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under severance agreements for remaining employees is approximately $2.3 million at December 31, 2020.

In 2018, the Board of Directors (the “Board”) of the Company adopted a long-term incentive plan, which was amended in February 2019 and June 2020, known as the Amended and Restated Safeguard Scientifics Inc. Transaction Bonus Plan (the “LTIP”). The purpose of the LTIP is to promote the interests of the Company and its shareholders by providing an additional incentive to employees to maximize the value of the Company in connection with the execution of the New Strategy.

business strategy that the Company adopted and announced in January 2018. The June 2020 amendment lowered the level of the first threshold and the resulting bonus pool percentage as an incentive to employees to accelerate actions consistent with the business strategy.  Under the LTIP, participants, which include certain current and former employees, have received awards that may receive awardsresult in cash payments in connection with sales of the Company’s partner company assetsownership interests (“Sale Transaction(s)”). At the Board’s sole discretion following a Sale Transaction, the Company may, but has no obligation to, provideThe LTIP provides for a bonus pool corresponding to: (i) specified vesting thresholds or (ii) specified events. In the first case, the bonus pool will range from an amount equal to 0.2% (previously 1.0%) of received proceeds at the first threshold to 1.3% at higher thresholds and no bonus pool will be created if the transaction consideration is less than certain minimum thresholds. In the second case, a minimum pool will be created and paid under specified circumstances. The bonus pool will be allocated and paid to participants in the LTIP based on the product of (i) the participant’s applicable bonus pool percentage and (ii) the bonus pool calculated as of the vesting date, minus any previously paid portion of the bonus pool. Any portion of the bonus pool available as of the applicable vesting date that is reserved will be allocated in connection with each vesting date so that the entire bonus pool available as of such vesting date is allocated and payable to participants. Subject to the terms of the LTIP, payments under the LTIP will be paid in the amount of 0.5% or 1.0%cash within 60 days of the transaction consideration (as defined in the LTIP and set forth below), based on a range of transaction consideration and subject to a minimum amount of transaction consideration. For purposes of the LTIP, “transaction consideration” means, in connection with a Sale Transaction (A) the gross value of all cash, securities and other property actually received by the Company, directly or indirectly, from an acquiror and the amount of all indebtedness of the Company assumed by the acquiror, directly or indirectly, in connection with the Sale Transaction, minus (B) the sum of (i) all payments reasonably estimated by the Board to be due from the Company as a result of the Sale Transaction and (ii) the amount of commissions, fees and expenses payable to the Company’s investment bankers and the amount of fees and expenses payable to the Company’s professional advisors in connection with the Sale Transaction.

applicable vesting date. All current officers and employees of the Company are eligible to participate in the LTIP, provided that they remain employed by the Company through at least July 31, 2018.LTIP. The Board, in its sole discretion, will determine the participants to whom awards are granted under the LTIP. The Company has accrued approximately $1.8 million under the LTIP andas of  December 31, 2020, which $1.5 million is estimated as current accrued compensation.

In June 2011, Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc (“Shire”).  Prior to the amountsexpiration of the awardsescrow period in March 2012, Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH (the “Investigation”). In connection with the bonus pool, if any.Investigation, in July 2015 the Company received a Civil Investigation Demand-Documentary Material (“CID”) from the DOJ regarding ABH and Safeguard’s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.  To the Company’s knowledge, the CID was related to multiple qui tam (“whistleblower”) actions, one of which was filed in 2014 by an ex-employee of ABH that named the Company and one of the Company’s employees along with other entities and individuals as defendants.  At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee. In addition, in connection with the above matters, the Company and other former equity holders in ABH entered into a settlement and release with Shire, which resulted in the release to Shire of all amounts held in escrow related to the sale of ABH.

13. Supplemental Cash Flow Information

During the years ended December 31, 2020 and 2019, the Company converted $6.8 million and $2.3 million, respectively, of advances into ownership interests. Cash paid for interest for the years ended December 31, 2020 and 2019 was $0.0 million and $11.5 million, respectively. Cash paid for taxes in each of the years ended December 31, 2020 and 2019 was $0.0 million.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

14. Segment Reporting

 

The Committee also awarded, to all holdersCompany operates as 1 operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance unit and stock unit awards previously grantedallocating resources.

As of December 31, 2020, the Company held ownership interests accounted for using the equity method in 12 non-consolidated companies. During 2019 we ceased using the equity method of accounting for Hoopla Software, Inc. and T-REX Group, Inc. as a result of other new investors diluting our interest. We have retained our ownership interests in those companies under the Other accounting method.

Certain of the Company’s 2014 Equity Compensation Planownership interests as of December 31, 2020 and 2019 included the following:

  Safeguard Primary Ownership as of December 31,  

Company Name

 

2020

 

2019

 

Accounting Method

Aktana, Inc.

  15.1%  17.8% 

Equity

Clutch Holdings, Inc.

  42.3%  41.2% 

Equity

Flashtalking, Inc.

  13.4%  10.1% 

Other

InfoBionic, Inc.

  25.2%  25.2% 

Equity

Lumesis, Inc.

  43.4%  43.5% 

Equity

MediaMath, Inc.

  13.3%  13.3% 

Other

meQuilibrium

  32.0%  32.7% 

Equity

Moxe Health Corporation

  27.6%  29.9% 

Equity

Prognos Health Inc.

  28.5%  28.7% 

Equity

QuanticMind, Inc. *

  24.2%  24.2% 

Equity

Syapse, Inc.

  18.9%  20.0% 

Equity

T-REX Group, Inc.

  13.5%  13.7% 

Other

Trice Medical, Inc.

  16.6%  16.6% 

Equity

WebLinc, Inc. *

  39.9%  38.5% 

Equity

Zipnosis, Inc

  37.2%  37.7% 

Equity

* These entities were sold subsequent to December 31, 2020.  See Note 16 - Subsequent Events, of the consolidated financials statements.

As of December 31, 2020 and 2019, all of the Company’s assets were located in the United States.

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

15. Selected Quarterly Financial Information (Unaudited)

  

Three Months Ended

 
  

March 31

  

June 30

  

September 30 (b)

  

December 31 (b)

 
  

(In thousands, except per share data)

 

2020:

                

General and administrative expense

 $3,532  $2,028  $2,275  $1,631 

Operating loss

  (3,532)  (2,028)  (2,275)  (1,631)

Other income (loss), net

  (3,567)  (2,658)  (820)  (663)

Interest income

  105   52   52   52 

Equity income (loss), net

  (9,014)  (5,277)  (1,300)  (5,111)

Net loss before income taxes

  (16,008)  (9,911)  (4,343)  (7,353)

Income tax benefit (expense)

            

Net loss

 $(16,008) $(9,911) $(4,343) $(7,353)

Net loss per share (a)

                

Basic

 $(0.77) $(0.48) $(0.21) $(0.35)

Diluted

 $(0.77) $(0.48) $(0.21) $(0.35)

2019:

                

General and administrative expense

 $3,057  $2,603  $2,262  $2,060 

Operating loss

  (3,057)  (2,603)  (2,262)  (2,060)

Other income (loss), net

  (1,885)  3,118   8,777   2,245 

Interest income

  873   763   234   174 

Interest expense

  (2,535)  (5,682)  (5,806)   

Equity income (loss), net

  28,267   40,497   (3,440)  (1,057)

Net income (loss) before income taxes

  21,663   36,093   (2,497)  (698)

Income tax benefit (expense)

            

Net income (loss)

 $21,663  $36,093  $(2,497) $(698)

Net income (loss) per share (a)

                

Basic

 $1.05  $1.75  $(0.12) $(0.03)

Diluted

 $1.05  $1.75  $(0.12) $(0.03)

(a)

Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests.

(b)

The three months ended December 31, 2019 includes equity income of $1.4 million related to an equity method investment that should have been recorded during the three months ended September 30, 2019. There was no impact on the full year results.

16. Subsequent Events

In January 2021, WebLinc, Inc. was acquired by another entity.  To date, the Company received $3.2 million in cash proceeds and may receive additional amounts over the next 24 months based on certain transitional performance activities, which could be partially offset by indemnifiable claims.  During February 2021, QuanticMind, Inc. was acquired by another entity, however there were 0 resultant proceeds.

During February 2021, Syapse raised $68 million of preferred capital which reduced our ownership interest to approximately 11%.

44

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Plan”“Exchange Act”), dividend equivalents relatingthat are designed to such awards. The Committee awarded such dividend equivalents, meaning amounts determinedprovide reasonable assurance that the information required to be disclosed by multiplying (i) the number of shares of Company stock or stock units subject to an awardus in reports filed under the Plan byExchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the per-share extraordinary dividend or distribution paid byPrincipal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the Company on its stock as described in Section 5(c)objectives of the Plan (“Dividend Equivalents”),controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020. Based on that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures as of December 31, 2020 are functioning effectively.

(b) Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to granteesprovide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that pertain to the extentmaintenance of records that, in reasonable detail, accurately and fairly reflect the grantees heldtransactions and dispositions of our assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the following awards under the Plan: (1) stock units that have not yet been vested and distributed, and (2) performance units that have not yet been vested and distributed. The Dividend Equivalentseffectiveness to future periods are subject to the same vesting terms and otherrisk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of the existing awards and will be governed by the terms of the existing award and the Plan.

Compensation Committee Report

We have reviewed and discussed the foregoing Compensation Discussion and Analysis with management. Based on our review and discussion with management, we have recommended to the Board of Directors that the Compensation Discussion and Analysis be included in Safeguard’s Annual Report on Form 10-K for fiscal year 2017 and Safeguard’s proxy statement for its 2018 annual meeting of shareholders.

Members of the Compensation Committee:

Julie A. Dobson, Chairperson

Stephen FisherGeorge F. MacKenzie, Jr.John J. Roberts

38

Executive Compensation

Summary Compensation Table — Fiscal Years Ended December 31, 2017, 2016 and 2015

The table below is a summary of total compensation paid to or earned by our named executive officers for the fiscal years ended December 31, 2017, 2016, and 2015. At December 31, 2017, there were three individuals serving as named executive officers of Safeguard.

Name and

Principal Position

 Year 

Salary

($)

  

Bonus

($)(1)

  

Stock

Awards

($)(2)(3)

  

Option

Awards

($)(2)

  

Non-Equity

Incentive Plan

Compensation

($)(4)

  

Change in

Pension Value

and

Nonqualified

Deferred

Compensation

Earnings ($)

  

All Other

Compensation

($)(5)

  

Total

($)

 
Stephen T. Zarrilli 2017  580,000      640,292      522,000      19,254   1,761,546 
President and Chief 2016  580,000   175,000   1,007,718      605,520      19,101   2,387,339 
Executive Officer 2015  550,000      729,748      528,000      17,924   1,825,672 
                                   
Jeffrey B. McGroarty 2017  305,000      145,523      171,563   18,216   15,330   655,632 
Senior Vice President and 2016  305,000      229,031      199,013   8,655   15,080   756,779 
Chief Financial Officer 2015  305,000      202,701      183,000   950   15,080   706,731 
                                   
Brian J. Sisko 2017  400,000      261,931      270,000   11,901   17,900   961,732 
Chief Operating Officer, 2016  400,000      412,243      313,200   5,654   17,650   1,148,747 
Executive Vice President and Managing Director 2015  375,000      364,868      270,000   621   17,521   1,028,010 

(1)The amount reported represents a discretionary bonus awarded by the Compensation Committee for exceptional performance which was outside of the scope of the corporate objectives established under our 2016 Management Incentive Plan (“MIP”).  Amounts earned by our named executive officers under each year’s MIP are reported under “Non-Equity Incentive Plan Compensation.” Payment of this discretionary bonus was made in March of 2017.

(2)Consistent with SEC rules, stock and option awards are required to be valued using the aggregate grant date fair value computed in accordance with stock-based compensation accounting rules (FASB ASC Topic 718). Even though awards may be forfeited, the amounts reported do not reflect this contingency. Amounts reported for these awards do not reflect our accounting expense for these awards during the year and may not represent the amounts that our named executive officers will actually realize from the awards. Whether, and to what extent, our named executive officers realize value will depend on (i) the achievement of the capital-return based vesting criteria associated with certain stock options and PSUs awarded; (ii) our stock price; and (iii) an individual’s continued employment. Vesting of awards held by our named executive officers may be accelerated in certain circumstances as detailed below under “Potential Payments upon Termination or Change in Control.”

(3)For 2017, the Compensation Committee awarded time-based vesting restricted stock. No PSUs were awarded in 2017. The fair value of the restricted stock is based on $11.3336 per share for awards granted on December 29, 2017, which was the average of the high and low trading prices of a share of our common stock on the grant date. The PSUs issued in 2015 and 2016 are subject to capital-return based vesting criteria and vest based on the aggregate cash produced as a result of monetizations involving certain of our partner companies relative to the amount of cash deployed in connection with such partner companies over a 10-year period, plus allocated overhead, as described in detail under “Compensation Discussion and Analysis –– Long-Term Incentives.” Each PSU entitles a named executive officer to receive one share of Safeguard common stock on or about the date upon which the PSU vests, and, if applicable, cash accruals/payments if the capital returned to Safeguard equals or exceeds 2.25 times the capital deployed plus allocated overhead. No named executive officer may receive any cash amounts beyond the point at which the cash returned to Safeguard equals 3.0 times the capital deployed plus allocated overhead, effectively capping the combined equity and cash incentive payout for such named executive officers at 200%. The grant date fair values for the PSUs included in this column were computed based upon the probable outcome of the performance conditions as of the grant date.

(4)The amounts reported in this column represent payments made in March 2018 for awards earned under our 2017 Management Incentive Plan, which is described in detail under “Compensation Discussion and Analysis—2017 Compensation Program.”

(5)For 2017, All Other Compensation includes the following amounts:

Name 

401(k) Matching

Contribution

($)

  

Life Insurance

Premiums

($)

  

Group Life Insurance

Imputed Income

($)

 
Stephen T. Zarrilli  13,500   3,432   2,322 
Jeffrey B. McGroarty  13,500   1,371   459 
Brian J. Sisko  13,500   2,594   1,806 

39

Our named executive officers also have occasional personal use of tickets to various sporting events at no incremental cost to us and are eligible to receive matching charitable contributions under our program, which is available to all employees, subject to a maximum of $1,500 in matching contributions for each individual for each calendar year.

Each of our current named executive officers has an employment agreement with us that sets his initial base salary and respective initial minimum annual cash incentive target award as follows: Mr. Zarrilli ($340,000 salary; $195,000 target award); Mr. McGroarty ($275,000 salary; $206,250 target award); and Mr. Sisko ($340,000 salary; $250,000 target award). Base salaries and annual cash incentive target awards for each named executive officer, which are reviewed by the Compensation Committee each year, currently exceed these contractual minimum amounts. None of the employment agreements provide for a term of employment and each of our executive officers is an “employee-at-will.” The primary focus of these agreements is to provide our executive officers with severance benefits in the event of a termination of employment involuntarily, without cause or for good reason, or upon a change inCompany’s internal control as described below under “Potential Payments upon Termination or Change in Control.”

The components of compensation reported in the Summary Compensation Table, including an explanation of the amount of salary and cash incentive compensation in proportion to total compensation, are described in detail under “Compensation Discussion and Analysis.”

Grants of Plan-Based Awards — 2017

The following table shows non-equity and equity incentive plan awards and stock awards granted during 2017 to our named executive officers.

  Grant 

Date of

Committee

 

Estimated Possible Payouts

Under Non-Equity Incentive

Plan Awards (1)

  

Estimated Future Payouts

Under Equity Incentive Plan

Awards (2)(3)

  

All Other

Stock

Awards:

Number of

Shares of

Stock or

  

All Other

Option

Awards:

Number of

Securities

Underlying

  

Exercise

or Base

Price of

Option

  

Closing

Market

Price on

Date of

  

Grant

Date

Fair

Value of

Stock

And

Option

 
Name 

Date

(2017)

 

Action

(2017)

 

Threshold

($)

  

Target

($)

  

Maximum

($)

  

Threshold

(#)

  

Target

(#)

  

Maximum

(#)

  

Units

(#)(2)(3)(4)

  

Options

(#)

  

Awards

($/Sh)

  

Grant

($/Sh)

  

Awards

($)(5)

 
Stephen T. 07/25 07/25     696,000   1,044,000                         
Zarrilli 12/29 12/29                    56,495            640,292 
                                                 
Jeffrey B. 07/25 07/25     228,750   343,125                         
McGroarty
 12/29 12/29                     12,840            145,523 
                                                 
Brian J. Sisko 07/25 07/25     360,000   540,000                         
  12/29 12/29                    23,111            261,931 

(1)These awards were made under our 2017 MIP. There were no mandatory minimum awards payable under our 2017 MIP and the maximum awards payable were 150% of the target amounts. The amounts in the table represent payouts that might have been achieved based on performance at target or maximum performance levels. Actual payments under these awards, which have already been determined and were paid in March 2018, are included for 2017 in the Non-Equity Incentive Plan Compensation column of the Summary Compensation Table.

(2)The vesting of equity awards may be accelerated upon death, permanent disability, retirement on or after 65th birthday, termination of employment for good reason or without cause, or termination of employment in connection with a change in control. Further information regarding the equity awards that are subject to acceleration of vesting in each circumstance can be found below under “Potential Payments upon Termination or Change in Control.”

(3)The aggregate 2017 long-term incentive value of the grants made to each of our named executive officers was as follows: Mr. Zarrilli – $660,000; Mr. McGroarty – $150,000; and Mr. Sisko – $270,000. The number of shares of restricted stock awarded to each of our named executive officers was determined by dividing each such value by the average closing price of a share of our common stock on the NYSE composite tape for the 20 consecutive trading days immediately preceding the grant date, which was $11.6825.

(4)The restricted stock vests as to 25% of the underlying shares on March 1, 2019, and as to the remaining 75% of the underlying shares in 12 equal quarterly installments commencing on March 15, 2019, and on the fifteenth day of each June, September, December, and March thereafter. The restricted stock was granted under our 2014 Equity Compensation Plan.

(5)The amounts in this column represent the grant date fair value of the awards computed in accordance with FASB ASC Topic 718. The assumptions used by us in calculating these amounts are incorporated by reference to Note 7 to our Consolidated Financial Statements in the Original Form 10-K.

40

Outstanding Equity Awards at Fiscal Year-End — 2017

The following table shows the equity awards we have made to our named executive officers that were outstanding at December 31, 2017.

    Option Awards  Stock Awards 
  Grant 

Number of

Securities

Underlying

Unexercised

Options

(#)(1)

  

Number of

Securities

Underlying

Unexercised

Options

(#)(1)(2)

  

Equity Incentive

Plan Awards:

Number of

Securities

Underlying

Unexercised

Unearned

Options

  

Option

Exercise

Price

  

Option

Expiration

  

Number of

Shares or

Units of

Stock That

Have Not

Vested

  

Market

Value of

Shares or

Units of

Stock That

Have Not

Vested

  

Equity Incentive

Plan Awards:

Number of

Unearned

Shares, Units or

Other Rights

That Have Not

Vested

  

Equity Incentive

Plan Awards:

Market or

Payout Value of

Unearned

Shares, Units or

Other Rights

That Have Not

Vested

 
Name Date Exercisable  Unexercisable  (#)(2)  ($)  Date  (#)(2)(3)  ($)(4)  (#)(2)(5)  ($)(4) 
Stephen T. 10/30/09        10,875(6)  9.825   10/30/19             
Zarrilli 10/30/09                       7,250   81,200 
  11/05/10  3,755         15.105   11/05/18             
  11/05/10        11,265(6)  15.105   11/05/20             
  11/05/10                       5,630   63,056 
  09/30/11  4,914         15.070   09/30/19             
  09/30/11  453      14,288(6)  15.070   09/30/21             
  09/30/11                       7,144   80,013 
  10/02/12  4,789         15.435   10/02/20             
  10/02/12        14,368(6)  15.435   10/02/22             
  10/02/12                       7,184   80,461 
  12/05/12  19,813         13.890   12/05/20             
  12/05/12        59,437(6)  13.890   12/05/22             
  12/05/12                       29,719   332,853 
  10/31/13                       24,745   277,144 
  12/31/14                 3,004   33,645   24,037   269,214 
  12/31/15                 10,090   113,008   40,359   452,021 
  12/30/16                 29,914   335,037   59,827   670,062 
  12/29/17                 56,495   632,744       
                                       
Jeffrey B. 10/30/09        2,625(6)  9.825   10/30/19             
McGroarty 10/30/09                       1,750   19,600 
  11/05/10  875         15.105   11/05/18             
  11/05/10        2,625(6)  15.105   11/05/20             
  11/05/10                       1,313   14,706 
  09/30/11  875         15.070   09/30/19             
  09/30/11  81      2,544(6)  15.070   09/30/21             
  09/30/11                       1,273   14,258 
  10/02/12  875         15.435   10/02/20             
  10/02/12        2,625(6)  15.435   10/02/22             
  10/02/12                       1,313   14,706 
  12/05/12  1,800         13.890   12/05/20             
  12/05/12        5,400(6)  13.890   12/05/22             
  12/05/12                       2,700   30,240 
  10/31/13                       6,748   75,578 
  12/31/14                 851   9,531   6,807   76,238 
  12/31/15                 2,802   31,382   11,211   125,563 
  12/30/16                 6,799   76,149   13,597   152,286 
  12/29/17                 12,840   143,808       

41

    Option Awards  Stock Awards 
  Grant 

Number of

Securities

Underlying

Unexercised

Options

(#)(1)

  

Number of

Securities

Underlying

Unexercised

Options

(#)(1)(2)

  

Equity Incentive

Plan Awards:

Number of

Securities

Underlying

Unexercised

Unearned

Options

  

Option

Exercise

Price

  

Option

Expiration

  

Number of

Shares or

Units of

Stock That

Have Not

Vested

  

Market

Value of

Shares or

Units of

Stock That

Have Not

Vested

  

Equity Incentive

Plan Awards:

Number of

Unearned

Shares, Units or

Other Rights

That Have Not

Vested

  

Equity Incentive

Plan Awards:

Market or

Payout Value of

Unearned

Shares, Units or

Other Rights

That Have Not

Vested

 
Name Date Exercisable  Unexercisable  (#)(2)  ($)  Date  (#)(2)(3)  ($)(4)  (#)(2)(5)  ($)(4) 
Brian J. 10/30/09        10,875(6)  9.825   10/30/19             
Sisko 10/30/09                       7,250   81,200 
  11/05/10  3,755         15.105   11/05/18             
  11/05/10        11,265(6)  15.105   11/05/20             
  11/05/10                       5,630   63,056 
  09/30/11  3,879         15.070   09/30/19             
  09/30/11  358      11,280(6)  15.070   09/30/21             
  09/30/11                       5,640   63,168 
  10/02/12  3,672         15.435   10/02/20             
  10/02/12        11,015(6)  15.435   10/02/22             
  10/02/12                       5,508   61,690 
  12/05/12  810         13.890   12/05/20             
  12/05/12        2,430(6)  13.890   12/05/22             
  12/05/12                       1,215   13,608 
  10/31/13                       12,373   138,578 
  12/31/14                 1,368   15,322   10,945   122,584 
  12/31/15                 5,045   56,504   20,179   226,005 
  12/31/16                 12,237   137,054   24,475   274,120 
  12/29/17                 23,111   258,843       

(1)Unless otherwise identified by footnote, options are subject to time-based vesting, with 25% of the underlying shares vesting on the first anniversary date of the grant date and the remaining underlying shares vesting in 36 equal installments each month thereafter.

(2)Vesting of equity awards may be accelerated upon death, permanent disability, retirement on or after 65th birthday, termination of employment for good reason or without cause, or termination of employment in connection with a change in control. Further information regarding the equity awards that are subject to acceleration of vesting in each circumstance can be found below under “Potential Payments upon Termination or Change in Control.”

(3)The shares included in this column vest as follows: (i) awards granted before 2013 vest 25% on the first anniversary date of the grant date, with the remaining 75% of the shares vesting in equal monthly installments over the next 36 months thereafter; (ii) awards granted in 2013 vest 25% on the fifteenth day of the month following the first anniversary of the grant date, with the remaining 75% of the shares vesting in equal monthly installments over the next 36 months thereafter; and (iii) awards granted in 2014, 2015, 2016 and 2017 vest 25% on March 1 in the second calendar year following the grant and in 12 equal quarterly installments commencing on March 15 in the second calendar year following the grant and on the fifteenth day of each June, September, December, and March thereafter.

(4)Under SEC rules, the value is calculated based on the year-end closing stock price of $11.20, as reported on the NYSE composite tape, multiplied by the number of shares or the number of shares of stock underlying the PSUs that have not vested.

(5)The PSUs included in this column are subject to capital-return based vesting and vest based on the aggregate cash produced as a result of monetizations involving certain of our partner companies relative to the amount of cash deployed in connection with such partner companies over a 10-year period, as described in detail under “Compensation Discussion and Analysis –– Long-Term Incentives.” The capital-return based vesting for the PSUs included in this column is tied to the following partner companies: (i) for the 2009, 2011, 2014, 2015 and 2016 grants, those partner companies into which we first deployed capital during the preceding 12 months; (ii) for the 2010 and 2012 grants, those partner companies into which we first deployed capital during the preceding 24 months; and (iii) for the 2013 grants, those partner companies into which we first deployed capital during the period November 2012 through December 2013. Each PSU entitles a named executive officer to receive one share of Safeguard common stock on or about the date upon which the PSU vests, and, for PSUs awarded in 2014, 2015 and 2016, cash accruals/payments if the capital returned to Safeguard exceeds 2.0 times the capital deployed plus allocated overhead. No named executive officer may receive any cash amounts relating to the 2014, 2015 and 2016 PSUs, respectively, beyond the point at which the cash returned to Safeguard equals 3.0 times capital deployed (plus allocated overhead), effectively capping the combined equity and cash incentive payout for such named executive officers at 200%. Notwithstanding the above, so as to ensure against the unlikely possibility that grants could, in theory, vest quickly if cash proceeds relating to a particular pool are achieved very soon after the equity grant date, the Committee required, beginning in 2014, that none of such equity may vest (or cash amounts be paid) more quickly than based upon the following schedule following grant: March 15 in the second calendar year following the grant - 25%; each semi-annual anniversary of the grant thereafter through March 15 in the fifth calendar year following the grant - 12 ½% increments.

42

(6)These options are subject to capital-return based vesting and vest based on the aggregate cash produced as a result of monetizations involving certain of our partner companies relative to the amount of cash deployed in connection with such partner companies, as described in detail under “Compensation Discussion and Analysis –– Long-Term Incentives.” The capital-return based vesting for the options is tied to the following partner companies: (i) for the 2009 and 2011 grants, those partner companies into which we first deployed capital during the preceding 12 months; and (ii) for the 2010 and 2012 grants, those partner companies into which we first deployed capital during the preceding 24 months.

Option Exercises and Stock Vested — 2017

The following table shows stock options that were exercised by our named executive officers during 2017 and restricted stock awards that vested during 2017.

  Option Awards  Stock Awards 
Name 

Number of Shares

Acquired on Exercise

(#)

  

Value Realized on

Exercise

($)(1)

  

Number of Shares

Acquired on Vesting

(#)

  

Value Realized on

Vesting

($)(2)

 
Stephen T. Zarrilli  3,625   9,697   14,985   184,420 
Jeffrey B. McGroarty  875   3,609   4,169   51,300 
Brian J. Sisko  3,625   7,250   7,358   90,591 

(1)The value realized on exercise is determined by multiplying the number of shares acquired on exercise by the difference between the exercise price and the average of the high and low trading prices of Safeguard’s common stock, as reported on the NYSE consolidated tape, on the exercise date, or, for those shares that were sold upon exercise of the options, the difference between the sales price of the shares underlying the options exercised and the applicable exercise price of those options.

(2)The value realized on vesting is determined by multiplying the number of shares vested by the average of the high and low trading prices of Safeguard’s common stock, as reported on the NYSE consolidated tape, on each vesting date.

Nonqualified Deferred Compensation — 2017

In 2003, Safeguard adopted an Executive Deferred Compensation Plan, which is a nonqualified, unfunded plan that provided for a designated group of employees to obtain credits in the form of Safeguard contributions that were allocated to accounts for the benefit of each participant. Participants were not able to defer compensation under the plan. This plan was adopted in order to approximate matching contributions under our 401(k) plan which, based upon the terms and structure of our 401(k) plan, were not available to our most highly compensated personnel.

During 2008, the Compensation Committee approved a change to our 401(k) plan which allowed matching contributions for all of our employees beginning in 2009. Therefore, no contributions have been made to this plan since 2009, and we do not expect to make any future contributions under this plan. Amounts accrued for prior periods will remain credited, and earnings on those prior amounts will continue to be credited, to prior participants in accordance with the terms of the plan.

Lump sum distributions of the vested balance in a named executive officer’s account are made six months following termination.

A committee appointed by Safeguard’s Board selects the funds or indices that are used for purposes of calculating the earnings that are credited to each participant’s account based on a notional investment in the selected funds or indices. Since July 2011, we have calculated earnings based on the performance of the notional investment in the Vanguard 500 Index Admiral Fund (VFIAX), one of the investment choices available to participants in our 401(k) plan. The committee, in its discretion, may replace this fund and add new funds.

The following table shows earnings during 2017 and account balances at December 31, 2017, for our named executive officers.

Name 

Registrant Contributions

in Last Fiscal Year

($)

  

Aggregate Earnings

in Last Fiscal Year

($)(1)

  

Aggregate Withdrawals/
Distributions

($)

  

Aggregate Balance

at Last Fiscal Year End

($)(2)

 
Stephen T. Zarrilli            
Jeffrey B. McGroarty     18,216      97,584 
Brian J. Sisko     11,901      63,752 

(1)Earnings in the last fiscal year are included in the Summary Compensation Table under “Change in Pension Value and Nonqualified Deferred Compensation Earnings.”

(2)The balance in each named executive officer’s account consists of contributions credited by us and notional accrued gains or losses. At December 31, 2017, each of our named executive officers was fully vested.

43

CEO Pay Ratio – 7.3:1

The Committee reviewed a comparison of our President and Chief Executive Officer’s annual total compensation in 2017 to that of all other Safeguard employees for the same period. The calculation of annual total compensation of all employees was determined based on base salary received in 2017 and payment received under the Management Incentive Program for performance in 2017 (which was paid in March 2018):

Our calculation includes all employees as of November 30, 2017.

We determined our median employee by: (i) calculating the annual total compensation described above for each of our employees, (ii) ranking the annual total compensation of all employees except for the CEO from lowest to highest (a list of 26 employees) and (iii) because we have an even number of employees when not including the CEO, determining the average of the annual total compensation of the two employees ranked 13th and 14th on the list (the “Median Employee”).

Following the same methodology used to calculate “Total ($)” for our President and Chief Executive Officer as shown in the “Summary Compensation Table” in this report, the annual total compensation for 2017 for our President and Chief Executive Officer was $1,761,546 and the annual total compensation for 2017 for the Median Employee was $240,276. The resulting ratio of our President and Chief Executive Officer’s pay to the pay of our Median Employee for 2017 is 7.3 to 1.

Potential Payments upon Termination or Change in Control

Agreements with Messrs. Zarrilli, McGroarty, and Sisko

Messrs.  Zarrilli, McGroarty and Sisko each have agreements with us that provide for certain benefits upon termination of employment without cause or for good reason, either involuntarily or in connection with a change in control. Under these agreements, the following definitions apply:

CauseàViolation of any of our written policies; appropriation of a material business opportunity of our company; misappropriation of company assets; conviction of a felony or any other crime with respect to which imprisonment is a possible punishment; or breach of any material term of the executive’s employment agreement or any other agreement with, or duty owed to, us or any of our partner companies.
Good ReasonàA material diminution, without the executive’s consent, in the nature or status of the executive’s position, title,over financial reporting relationship, duties, responsibilities or authority; a material reduction of the executive’s base salary; a material breach by us of the executive’s agreement; the relocation of our principal office by more than 30 to 35 miles (as specified in each individual’s agreement); or an executive’s assignment, without his consent, to be based anywhere other than our principal office.
Change in Controlà

A change in control generally occurs when:

·     A person becomes the beneficial owner of securities having 50% or more of the combined voting power of our securities;

·     Less than a majority of our Board consists of continuing directors (which means a director who either is a member of the Board as of the effective date of the change in control or is nominated or appointed to serve as a director by a majority of the then continuing directors);

·     We are subject to a merger or other business combination transaction as a result of which holders of a majority of our equity securities do not own a majority of the equity securities of the surviving company; or

·     We sell all or substantially all of our assets or are liquidated.

44

Payments Made upon Involuntary Termination of Employment without Cause or for Good Reason

Messrs. Zarrilli, McGroarty and Sisko will receive the following benefits upon involuntary termination of employment without cause or for good reason:

·A lump sum payment equal to 1.5 times the executive’s then current base salary and the executive’s earned prorated bonus for the year of termination;
·All time-vested stock options will fully vest and remain exercisable for 36 months and vested performance-based stock options will remain exercisable for 12 months (unless any of the options would by their terms expire sooner, in which case they may be exercised at any time prior to expiration);
·12 months’ continued coverage under our medical, dental, and life insurance plans; and
·Up to $20,000 for outplacement services or office space.

Payments Made upon a Change in Control or Involuntary Termination of Employment without Cause or for Good Reason in Connection with a Change in Control

Messrs. Zarrilli, McGroarty and Sisko will not be entitled to any other payments or benefits (except those that are provided on a non-discriminatory basis to our employees generally upon termination of employment) unless the change in control is coupled with a loss of employment or a substantial change in job duties as described above.

Upon involuntary termination of employment without cause or for good reason within 18 months following a change in control, our named executive officers will receive the following benefits:

·A lump sum payment equal to 1.5 times the executive’s then current base salary and the executive’s earned prorated bonus for the year of termination;
·All time-vested stock options will fully vest and remain exercisable for 36 months and all performance-based stock options that have not otherwise vested will vest and remain exercisable for 24 months (unless any of the options would by their terms expire sooner, in which case they may be exercised at any time prior to expiration);
·All restricted stock awards and PSUs that have not otherwise vested will vest;
·12 months’ continued coverage under our medical, dental, and life insurance plans; and
·Up to $20,000 for outplacement services or office space.

Other Payments Made upon Termination of Employment

Regardless of the manner in which a named executive officer’s employment terminates, he also generally will receive payments and benefits that are provided on a non-discriminatory basis to our employees upon termination of employment, including the following:

·Amounts earned during his term of employment;
·Upon his death, disability or voluntary termination of employment, his accrued unused vacation pay;
·Amounts contributed by us for the year of termination under our 401(k) plan (if he has completed the required hours of service, if any, and is an employee on the date as of which we make a contribution);
·Distribution of accrued and vested plan balances under our 401(k) plan and nonqualified deferred compensation plan;
·Reimbursement of eligible dental expenses for services incurred prior to termination;
·Upon his death, disability or retirement on or after his 65th birthday, accelerated vesting of stock options subject to time-based vesting that have not otherwise vested and extension of the post-termination exercise period for all stock options from 90 days to 12 months; and
·Upon his death or disability, payment of benefits under our other broad-based employee benefit programs, including short-term and long-term disability plans, life insurance program, accidental death and dismemberment plan and business travel insurance plan, as applicable.

45

The following table shows the potential incremental payments and benefits which our named executive officers would have been entitled to receive upon termination of employment in each situation listed in the table below under their respective agreements and our broad-based employee benefit programs. The amounts shown do not include certain payments and benefits available generally to salaried employees upon termination of employment, such as distributions from our 401(k) and deferred compensation plans. The amounts shown in the table are based on an assumed termination as of December 31, 2017, and represent estimates2020. In making this assessment, management used the framework established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the maximum incremental amountsTreadway Commission (COSO). As a result of this assessment and benefits that would have been paid to each executive upon his termination which we have calculated: (i) by assuming each executive officer would have been entitled to his respective 2016 annualized target incentive award for the full year; and (ii) by using our 2017 premium costs for calculating the value of the health and welfare benefits. The actual amounts to be paid to each executive would depend on the time and circumstances of an executive’s separation from Safeguard. On April 6, 2018, the Company announced that it promoted Mr. Sisko to the position of President and Chief Executive Officer, effective as of July 1, 2018, to succeed Mr. Zarrilli. Mr. Zarrilli will act as a special advisor to the Company through September 30, 2018 and then retire. In addition, Mr. McGroarty, will depart from the Company, effective June 30, 2018. David Kille, currently the Company’s Corporate Controller, will assume the role of Chief Financial Officer, effective June 1, 2018. In connection with the foregoing announcement, the Company entered into certain compensatory arrangements with such officers. See our Current Report on Form 8-K filed on April 10, 2018 for a description of theses compensatory arrangements.

46

  

Salary and

Bonus

($)

  

Life Insurance

Proceeds or

Disability

Income

($)

  

Health

and

Welfare

Benefits

($)

  

Acceleration of

Equity Awards

($)(1)

  

Total

Termination

Benefits

($)

 
Stephen T. Zarrilli                    
·  Normal Retirement (65+)               
·  Permanent disability     2,548,400         2,548,400 
·  Death     1,500,000         1,500,000 
·  Involuntary termination without cause or for good reason  1,566,000      34,933      1,600,933 
·  Change-in-control termination, involuntarily or for good reason  1,566,000      34,933   3,435,411   5,036,344 
                     
Jeffrey B. McGroarty                    
·  Normal Retirement (65+)               
·  Permanent disability     3,082,483         3,082,483 
·  Death     1,055,000         1,055,000 
·  Involuntary termination without cause or for good reason  686,250      35,586      721,836 
·  Change-in-control termination, involuntarily or for good reason  686,250      35,586   787,654   1,509,490 
                     
Brian J. Sisko                    
·  Normal Retirement (65+)               
·  Permanent disability     1,950,600         1,950,600 
·  Death     1,150,000         1,150,000 
·  Involuntary termination without cause or for good reason  960,000      30,495      990,495 
·  Change-in-control termination, involuntarily or for good reason  960,000      30,495   1,526,685   2,517,180 

(1)Under SEC rules, the value related to the acceleration of equity awards in each scenario is calculated as of December 31, 2017, based on (i) the number of shares underlying stock options for which vesting would have been accelerated, multiplied by the difference between our year-end closing stock price, as reported on the NYSE composite tape, and the exercise price of stock options for which vesting would have been accelerated; (ii) for restricted stock awards, the number of shares for which vesting would have been accelerated, multiplied by our year-end closing stock price, as reported on the NYSE composite tape; and (iii) for PSUs, the number of shares underlying PSUs for which vesting would have been accelerated, multiplied by our year-end closing stock price, as reported on the NYSE composite tape.

Board Compensation.During 2017, each of our non-employee directors was compensated for his or her service as a director through cash payments as shown in the table below:

Compensation Item

Amount

($)

Annual Board Retainers (payable relative to a full year of Board service):
Chairman of the Board100,000
Other Directors50,000
Additional Annual Chairperson Retainers (payable relative to a full year of committee service):
Audit Committee15,000
Compensation Committee10,000
Nominating & Corporate Governance Committee10,000
Additional Annual Committee Retainers (payable relative to a full year of committee service):
Audit Committee15,000
Compensation Committee15,000
Nominating & Corporate Governance Committee10,000

Directors’ fees are paid quarterly, in arrears, and retainers are prorated based on actual days of service relative to a full year of Board service. We also reimburse our directors for expenses they incur to attend our Board and committee meetings and for attendance at one director continuing education program during each calendar year or the reasonable cost of one year’s membership in an organization that is focused on director education.

In December 2016, with assistance from Semler Brossy Consulting Group, LLC, an independent compensation consulting firm, the Compensation Committee reviewed the compensation of our non-employee directors and recommended the elimination of meeting fees paid to such directors for their service on the Board’s committees and, in place of such meeting fees, recommended the payment of annual retainers to such directors in the amounts set forth in the above table. Such change from the payment of meeting fees to the payment of annual retainers to directors for their service on the Board’s committees became effective with the new director term that commenced following our 2017 annual meeting.

47

In connection with the Compensation Committee’s review of the compensation of the non-employee directors in December 2016, the Compensation Committee recommended changing such annual equity grant to non-employee directors from a fixed number of deferred stock units (“DSUs”) to a number of DSUs having a value of $85,000, based upon the average closing price of a share of our common stock on the New York Stock Exchange composite tape for the 20 consecutive trading days immediately preceding the grant date.  The Board concurred with this recommendation and on May 31, 2017 each non-employee director received 7,406 DSUs, which had a value of $85,000 based upon the average closing price of a share of our common stock on the New York Stock Exchange composite tape for the 20 consecutive trading days immediately preceding May 31, 2017. The annual service DSU grants are fully vested at issuance for directors who have reached age 65 and otherwise vest on the first anniversary of the grant date or, if earlier, once a director reaches age 65. The DSUs represent the right to receive shares of Safeguard common stock, on a one-for-one basis, following the date upon which the director leaves the Board.

Safeguard also maintains a Group Deferred Stock Unit Program for Directors (“Directors’ DSU Program”) which allows each outside director, at his or her election, to receive DSUs in lieu of the cash retainers paid to each director, as described above, for service on the Board and its committees (“Directors’ Fees”). The deferral election applies to Directors’ Fees to be received for the calendar year following the year in which the election is made and remains in effect for each subsequent year unless the director elects otherwise by the end of the calendar year prior to the year in which the services are rendered. The number of DSUs awarded is determined by dividing the Directors’ Fees by the fair market value of Safeguard’s stock on the date on which the director would have otherwise received the Directors’ Fees. Each director also receives a number of matching DSUs, based on the same fair market value calculation, equal to 25% of the Directors’ Fees deferred. A director is always fully vested in DSUs awarded in lieu of Directors’ Fees deferred; the matching DSUs are fully vested at grant for directors who have reached age 65 and otherwise vest on the first anniversary of the date the matching DSUs were credited to the director’s account or, if earlier, once a director reaches age 65. Each DSU entitles the director to receive one share of Safeguard common stock following the date upon which the director leaves the Board. A director also may elect to receive the stock in annual installments over a period of up to five years after leaving the Board.

Director Compensation – 2017.The following table provides information on compensation earned for services provided during 2017 by each non-employee director who served on our Board at any time during 2017:

Name 

Fees Earned or

Paid in Cash

($)(1)

  

Stock

Awards

($)(2)(3)

  

Option

Awards

($)(3)

  

All Other

Compensation

($)(4)

  

Total

($)(5)

 
Mara G. Aspinall  24,280            24,280 
Julie A. Dobson  81,110   86,424         167,534 
Stephen Fisher  74,132   99,249         173,381 
George MacKenzie  98,176   81,466         179,642 
Maureen F. Morrison  12,188      19,659      31,847 
John J. Roberts  91,676   103,384         195,060 
Robert J. Rosenthal  100,000   81,466      831   182,297 

(1)The amounts included in this column reflect Directors’ Fees earned for services provided during 2017, including amounts deferred under our Directors’ DSU Program. Of the amount of Directors’ Fees earned for services provided during 2017, Ms. Dobson deferred payment of 25% and Mr. Fisher and Mr. Roberts deferred payment of 100%. Each director received DSUs in lieu of Directors’ Fees that they deferred and matching DSUs equal to 25% of the Directors’ Fees that they deferred. Directors who defer fees and receive DSUs are essentially investing in common stock equivalents that are initially valued based on the fair market value of our common stock on the date of issuance. As a result, the value of their DSUs fluctuates with the market value of our common stock.

(2)These amounts do not represent compensation actually received. Rather, these amounts represent the grant date fair values of the matching DSUs and the annual service grant of DSUs computed in accordance with stock-based compensation accounting rules (FASB ASC Topic 718). The fair value of the DSUs is determined by multiplying the number of shares underlying the DSUs by the average of the high and low trading prices of Safeguard’s common stock, as reported on the NYSE composite tape, on the grant date. The matching DSUs issued in January 2017 related to fees deferred that were earned during the fourth quarter of 2016. The following table presents the grant date fair value for each DSU award made to each non-employee director during 2017:

48

  Grant Date Fair Value ($) 
Name 1/15/17  4/15/17  5/31/17  7/15/17  10/15/17 
Julie A. Dobson  1,214   1,215   81,466   1,199   1,330 
Stephen Fisher  4,255   4,253   81,466   4,280   4,995 
George MacKenzie        81,466       
Maureen F. Morrison               
John J. Roberts  5,255   5,245   81,466   5,164   6,254 
Robert J. Rosenthal        81,466       

(3)The directors’ aggregate holdings of DSUs and stock options to purchase shares of our common stock (both vested and unvested), as of December 31, 2017, were as follows:

Name 

DSUs

(#)

  

Stock Options

(#)

 
Julie A. Dobson  59,365   15,000 
Stephen Fisher  27,258   8,333 
George MacKenzie  42,102   15,000 
Maureen F. Morrison     8,333*
John J. Roberts  61,338   10,000 
Robert J. Rosenthal  43,540   15,000 

*In connection with Ms. Morrison’s appointment and consistent with the Company’s past practices, Ms. Morrison received an initial stock option grant to purchase 8,333 shares of the Company’s common stock, which option will vest 25% each year commencing on the first anniversary of the grant date and will have an eight-year term.

(4)The amounts in this column represent costs associated with attendance at a director’s continuing education program or a director’s reasonable annual dues for membership in an organization focused on director education.

(5)Directors also are eligible for reimbursement of expenses incurred in connection with attendance at Board and committee meetings. These amounts are not included in the table above.

Stock Ownership Guidelines. Each non-employee director is expected to own a number of shares of our stock having a value at least equal to a designated multiple of the annual retainer paid to such director for service on our Board. Such ownership is expected to be achieved within the later of five years after an individual’s election to our Board or the fifth anniversary following any increasecriteria in the required multiple of the annual retainer. Since 2012, the equity position threshold in our stockCOSO framework, management has concluded that, is required to be held by non-employee directors is three times the annual cash Board retainer. No sales of stock are permitted during the period in which the ownership requirement has not been met (except for limited stock sales to meet tax obligations), without the approval of the Board. Shares counted toward these guidelines include:

·Outstanding shares beneficially owned by the director;
·Vested shares of restricted stock;
·Vested DSUs that have been credited to the director; and
·The net value of shares underlying vested, in-the-money options (“Net Option Value”).

For purposes of calculating the value to be used in monitoring compliance with the ownership guidelines, we utilize (a) the greater of the current value or the cost basis of purchased shares; (b) the greater of the current value or fees deferred in connection with vested DSUs; and (c) our trailing six-month average share price in determining Net Option Value.

Based on information they have provided to us, all of our outside directors, with the exception of Ms. Morrison, who joined our Board in 2017, and Mr. Glass and Mr. Lubert, who joined our Board in 2018, have achieved the required ownership levels.

49

ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Securities Authorized for Issuance Under Equity Compensation Plans

Our equity compensation plans provide a broad-based program designed to attract and retain talent while creating alignment with the long-term interests of our shareholders. Employees at all levels participate in our equity compensation plans. In addition, members of our Board and members of our Advisory Board receive equity grants for their service on our Board and Advisory Board, respectively. Members of our Board also receive deferred stock unit (“DSU”) awards and are eligible to defer directors’ fees and receive DSUs with a value equal to the directors’ fees deferred and matching DSUs equal to 25% of the directors’ fees deferred.

Our 2001 Associates Equity Compensation Plan (“2001 Plan”) provided for the grant of nonqualified stock options, stock appreciation rights, restricted stock, performance units, and other stock-based awards to employees, consultants or advisors of Safeguard and its subsidiaries, provided that no grants could be made under this plan to executive officers or directors of Safeguard. Under the NYSE rules that were in effect at the time this plan was adopted in 2001, shareholder approval of the plan was not required. Except for the persons eligible to participate in the 2001 Plan and the inability to grant incentive stock options under the 2001 Plan, the terms of the 2001 Plan are substantially the same as the other equity compensation plans approved by our shareholders (which are described herein or have been described in previous filings).

A total of 900,000 shares of our common stock were authorized for issuance under the 2001 Plan. At December 31, 2017, 129,902 shares were subject to outstanding options and performance stock units (“PSUs”), no shares were available for future issuance, and 583,772 shares had been issued under the 2001 Plan. The 2001 Plan expired by its terms on February 21, 2011. Equity grants previously awarded under this plan that remained outstanding at December 31, 2017, continue to be administered in accordance with the terms of the grants. Any portions of outstanding equity grants under the 2001 Plan that expire or become unexercisable for any reason shall be canceled and shall be unavailable for future issuance.

During 2011, 2013 and 2016, the Compensation Committee granted “employee inducement” awards to four then newly hired executives. The awards were granted outside of Safeguard’s existing equity compensation plans in accordance with NYSE rules. The employee inducement awards consisted of: (i) options that were outstanding at January 1, 2017 to purchase up to an aggregate of 92,230 shares of Safeguard common stock and (ii) 23,083 shares of restricted stock and 23,083 performance stock units that were granted as inducement awards during 2016. All of the “employee inducement” awards that were granted as stock options have a per share exercise price equal to the average of the high and low prices of Safeguard common stock on the grant date. 38,750 of such stock options were granted with an eight-year term and 53,480 of such stock options were granted with a 10-year term. The 23,083 performance stock units were granted with a 10-year term.

During 2017, there were no shares underlying inducement stock options that were exercised, 6,508 shares of restricted stock underlying certain inducement awards vested and 22,230 of the shares of underlying certain inducement stock options expired.

Of the shares underlying the “employee inducement” awards that were outstanding at December 31, 2017, 40,583 shares (which include both stock options and shares of restricted stock) were subject to time-based vesting, with an aggregate of: (i) 2,188 shares vesting on the first anniversary of the grant date and 6,562 shares vesting in 36 equal monthly installments thereafter, and (ii) 2,188 shares vesting on the second anniversary of the grant date and 6,562 shares vesting in 36 equal monthly installments thereafter, and (iii) 5,771 shares vesting on the first anniversary of the fifteenth day of the first month following the quarter in which the employee began his or her employment and 17,312 shares vesting in 12 quarterly installments thereafter. Of the remaining shares underlying the “employee inducement” awards that were outstanding at December 31, 2017, 75,583 vest based on the aggregate cash produced as a result of monetizations involving certain of our partner companies relative to the amount of cash deployed in connection with such partner companies. With the exception of the market-based vesting or capital-return based vesting provisions, the terms and provisions of the employee inducement awards are substantially the same as equity grants previously awarded to other executives under Safeguard’s equity compensation plans.

50

The following table provides information as of December 31, 20172020, the Company’s internal control over financial reporting was effective.

(c) Change in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

Incorporated by reference to the portions of our Definitive Proxy Statement entitled “Election of Directors,” “Corporate Governance and Board Matters” and “Section 16(a) Beneficial Ownership Reporting Compliance.” Information about our Executive Officers is included in Annex to Part I above.

Item 11.Executive Compensation

Incorporated by reference to the securities authorized for issuance underportions of our equity compensation plans. Definitive Proxy Statement entitled “Compensation Discussion and Analysis,” “Compensation Committee Report” and “Executive Compensation.”

Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The material features of our equity compensation plans are described in Note 7 to the Consolidated Financial Statements filed as part of our Annual Report on Form 10-K for the year ended December 31, 2017.

Equity Compensation Plan Information
  Number of Securities to Be Issued
Upon Exercise of Outstanding
Options, Warrants and Rights (1)
  Weighted-Average Exercise Price
of Outstanding Options,
Warrants and Rights (2)
  Number of Securities Remaining
Available for Future Issuance
Under Equity Compensation Plans
(Excluding Securities Reflected in
Column (a))
 
Plan Category (a)  (b)  (c) 
Equity compensation plans approved by security holders (3)  1,336,670  $14.8500   1,924,755 
Equity compensation plans not approved by security holders (4)  222,985  $14.4440    
Total  1,559,655  $14.7384   1,924,755 

(1)Includes a total of 900,380 shares underlying PSUs and DSUs awarded for no consideration and 66,821 shares underlying DSUs awarded to directors in lieu of all or a portion of directors’ fees.

(2)The weighted average exercise price calculation excludes 967,201 shares underlying outstanding DSUs and PSUs included in column (a) which are payable in stock, on a one-for-one basis.

(3)Represents awards granted under the 1999 Equity Compensation Plan and the 2014 Plan and shares available for issuance under the 2014 Plan.

(4)Includes awards granted under the 2001 Plan and 93,0833 “employee inducement” awards.

Security Ownership of Certain Beneficial Owners and Management2020.

 

The following table shows the number

46

 

  Outstanding
Shares
Beneficially
  Options
Exercisable
  Shares
Beneficially
Owned Assuming
Exercise of
  Percent of
Outstanding
  Other Stock-Based
Holdings (2)
 
Name Owned  Within 60 Days  Options  Shares (1)  Vested  Unvested 
Ariel Investments, LLC
200 E. Randolph Street
Suite 2900
New York, NY 10055
  1,501,367      1,501,367   7.3%      
Blackrock, Inc.
55 East 52nd Street
New York, NY 10055
  1,575,085      1,575,085   7.7%      
Dimensional Fund Advisors LP
Building One
6300 Bee Cave Road
Austin, TX 78746
  1,113,799      1,113,799   5.4%      
First Manhattan Co.
399 Park Avenue
New York, NY 10022
  1,638,254      1,638,254   8.0%      
Horton Capital Partners, LLC,
Maplewood Partners, LLC
and associated shareholders
1717 Arch Street, Suite 3920
Philadelphia, PA 19103
  

 

 

1,055,968

(3)     1,055,968   5.1%      
T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, MD 21202
  1,680,445      1,680,445   8.2%      
Julie A. Dobson  16,332   15,000   31,332   *   59,655   309 
Stephen Fisher     4,167   4,167   *   28,368   1,142 
George F. MacKenzie, Jr.  11,250   15,000   26,250   *   42,102    
Russell D. Glass           *       
Ira M. Lubert           *       
Maureen F. Morrison           *       
John J. Roberts  1,728   10,000   11,728   *   64,153    
Robert J. Rosenthal  4,156   15,000   19,156   *   43,540    
Stephen T. Zarrilli  192,608   33,724   226,332   1.1%      
Jeffrey B. McGroarty  43,131   4,506   47,637   *       
Brian J. Sisko  126,181   12,474   138,655   *       
Executive officers and directors as a group (11 persons)  395,386   109,871   505,257   2.5%  237,818   1,451 

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

(1)Each director and named executive officer has the sole power to vote and to dispose of the shares (other than shares held jointly with an individual’s spouse). An * indicates ownership of less than 1% of the outstanding shares. Shareholding information for Ariel Investments, LLC, BlackRock, Inc., Dimensional Fund Advisors LP, First Manhattan Co., and T. Rowe Price Associates, Inc. is based on information included in the Schedule 13G or Schedule 13G/A filed with the SEC by each such entity as of April 25, 2018.
(2)The shares in this column represent DSUs that have been credited to each individual, inclusive of any applicable matching DSUs credited to such individual as a result of the deferral of director fees. The DSUs, which may not be voted or transferred, are payable, on a one-for-one basis, in shares of Safeguard common stock following an individual’s termination of service on the Board. See “Corporate Governance and Board Matters – Board Compensation.”
(3)These securities are beneficially held by the following persons as reported on a Schedule 13D/A filed with the SEC on April 24, 2018. Horton Capital Management, LLC (1,045,870), Joseph M. Manko, Jr. (1,045,870), Maplewood Advisors IM, LLC (1,022,665), Maplewood Partners, LLC (1,022,665), Darren C. Wallis (1,022,665), Horton Capital Partners, LLC (741,148), Sierra Capital Investments, LP (707,845), Maplewood Global Partners, LLC (707,845), AVI Capital Partners, LP (10,098), Horton Capital Partners Fund, LP (33,303), Maplewood Advisors GP, LLC (10,098), Russell D. Glass (0), Ira M. Lubert (0), Paul McNulty (0).

ITEM 13.CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

ReviewIncorporated by reference to the portions of the Definitive Proxy Statement entitled “Corporate Governance Principles and Board Matters – ‘Board Independence’ and “Review and Approval of Transactions with Related Persons.

Item 14.The Board has adopted a written policy that charges Principal Accountant Fees and Services

Incorporated by reference to the Audit Committee with the responsibility of reviewing with management at each regularly scheduled meeting and determining whether to approve any transaction (other than a transaction that is available to all employees generally on a non-discriminatory basis) between us and our directors, director nominees and executive officers or their immediate family members. Between regularly scheduled meetingsportion of the Definitive Proxy Statement entitled “Independent Public Accountant – Audit Committee, management may preliminarily approve a related party transaction, subject to ratification of the transaction by the Audit Committee. If the Audit Committee does not ratify the transaction, management will make all reasonable efforts to cancel the transaction.Fees.”

 

 

Board Independence.Safeguard’s common stock is listed on the New York Stock Exchange (“NYSE”). To assist the Board in making independence determinations, the Board has adopted categorical standards that are reflected in our Corporate Governance Guidelines. Generally, under these standards, a director does not qualify as an independent director if any of the following relationships exist:

·Currently or within the previous three years, the director has been employed by us; someone in the director’s immediate family has been one of our executive officers; or the director or someone in the director’s immediate family has been employed as an executive officer of another company where any of our present executive officers at the same time serves or served on that company’s compensation committee;

·The director is a current partner or employee, or someone in the director’s immediate family is a current partner of, a firm that is our internal or external auditor; someone in the director’s immediate family is a current employee of the firm and personally works on our audit; or the director or someone in the director’s immediate family is a former partner or employee of such a firm and personally worked on our audit within the last three years;

·The director or someone in the director’s immediate family received, during any 12-month period within the last three years, more than $120,000 in direct compensation from us (other than director and committee fees and pension or other forms of deferred compensation for prior service that are not contingent in any way on continued service);

·The director is a current employee or holder of more than 10% of the equity of another company, or someone in the director’s immediate family is a current executive officer or holder of more than 10% of the equity of another company, that has made payments to or received payments from us, in any of the last three fiscal years of the other company, that exceeds the greater of $1 million or 2% of such other company’s consolidated gross revenues; or

·The director is a current executive officer of a charitable organization to which we have made charitable contributions in any of the charitable organization’s last three fiscal years that exceed the greater of $1 million or 2% of that charitable organization’s consolidated gross revenues.

The Board has determined that each of the directors, other than Mr. Zarrilli, who serves as the Company’s President and Chief Executive Officer, meets the above independence standards and have no other direct or indirect material relationships with us other than their directorship; therefore, each of such directors is independent within the meaning of the NYSE listing standards and satisfies the categorical standards contained in our Corporate Governance Guidelines.

ITEM 14.PRINCIPAL ACCOUNTANT FEES AND SERVICES

Independent Registered Public Accounting Firm — Audit Fees

The following table presents fees for professional services rendered by KPMG LLP (“KPMG”) for the audit of Safeguard’s consolidated financial statements for fiscal year 2017 and fiscal year 2016 and fees billed for audit-related services, tax services and all other services rendered by KPMG for fiscal year 2017 and fiscal year 2016. This table includes fees billed to Safeguard’s consolidated subsidiaries for services rendered by KPMG.

  2017  2016 
Audit Fees (1) $742,000  $676,250 
Audit-Related Fees      
Tax Fees (2)  91,350   87,000 
All Other Fees      
Total $833,350  $763,250 

(1)Audit fees include the aggregate fees for professional services rendered in connection with the audit of the consolidated financial statements included in our Annual Report on Form 10-K, the review of the condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q, services performed relating to consents and consultations and KPMG’s assurance services provided in connection with the assessment and testing of internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002.
(2)Tax fees include the aggregate fees billed by KPMG for tax consultation and tax compliance services.

The Audit Committee pre-approves each service to be performed by KPMG at its regularly scheduled meetings. For any service that may require pre-approval between regularly scheduled meetings, the Audit Committee has delegated to the Chairperson of the Audit Committee the authority to pre-approve services not prohibited by law to be performed by Safeguard’s independent registered public accounting firm and associated fees up to a maximum of $100,000, and the Chairperson communicates such pre-approvals to the Audit Committee at its next regularly scheduled meeting.

53

PART IV

 

ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Item 15. Exhibits and Financial Statement Schedules

 

(a)Consolidated Financial Statements and Schedules

(a) Consolidated Financial Statements and Schedules

 

Incorporated by reference to Item 8 of the Originalthis Report on Form 10-K.

(b) Exhibits

(b)Exhibits

 

The exhibits required to be filed as part of thisAmendment Report are listed in the exhibit index below.

(c) Financial Statement Schedules

(c)Financial Statement Schedules

 

None.

 

Exhibits

 

The following is a list of exhibits required by Item 601 of Regulation S-K filed as part of thisAmendment. Report. For exhibits that previously have been filed, the Registrant incorporates those exhibits herein by reference. The exhibit indextable below includes the Form Type and Filing Date of the previous filing and the location of the exhibit in the previous filing which is being incorporated by reference herein. Documents which are incorporated by reference to filings by parties other than the Registrant are identified in footnotes to this exhibit index.table.

 

EXHIBIT INDEX

 

  

 

Incorporated Filing Reference

Exhibit

Number

  

Description

Form Type & Filing

Date

  

Original

Exhibit Number

1.a

 

Description

 

 

 

3.1.1

  

Seconded Amended and Restated Articles of Incorporation of Safeguard Scientifics, Inc.

Form 8-K

10/25/07

  

3.1

3.1.2

  

Amendment to Seconded Amended and Restated Articles of Incorporation of Safeguard Scientifics, Inc.

Form 8-K

8/27/09

  

3.1

3.1.3

  

Statement with Respect to Shares

Form 10-Q

4/25/14

 

3.1

3.1.4

 

Statement of Designation of Series B Junior Participating Preferred Stock

Form 8-K

2/20/18

  

3.1

3.2

  

Third Amended and Restated By-laws of Safeguard Scientifics, Inc.

Form 8-K

2/13/18

 

3.1

10.1*

  

Safeguard Scientifics, Inc. 1999 Equity Compensation Plan, as amended and restated on October 21, 2008

Form 10-Q

11/6/08

 

10.4

10.2

  

Safeguard Scientifics, Inc. 2001 Associates Equity Compensation Plan, as amended and restated on October 21, 2008

Form 10-Q

11/6/08

 

10.5

10.3*

  

Safeguard Scientifics, Inc. 2014 Equity Compensation Plan, as amended and restated on March 5, 2014

Form 10-Q

7/25/14

 

10.1

10.4*

  

Safeguard Scientifics, Inc. Executive Deferred Compensation Plan (amended and restated as of January 1, 2009)

Form 10-K

3/19/09

 

10.4

10.5*

  

Management Incentive Plan

Form 8-K

4/25/08

 

10.1

10.6*

 

Amended and Restated Safeguard Scientifics, Inc. Transaction bonus plan

Form 10-Q

8/12/20

 

10.6

10.7

  

Compensation Summary — Non-employee Directors

Form 10-K

3/5/21

 10.7

10.9.1*

 

General Release and Agreement between Safeguard Scientifics, Inc. and Brian J. Sisko dated April 20, 2020

Form 8-K

4/21/20

 

10.1

10.9.2*

 

Letter Agreement between Safeguard Scientifics, Inc. and Eric Salzman dated October 1, 2020

Form 8-K

10/1/20

 

10.1

 

  Incorporated Filing Reference
Exhibit
Number
 Description Form Type & Filing
Date
 Original
Exhibit Number
       
3.1.1 Seconded Amended and Restated Articles of Incorporation of Safeguard Scientifics, Inc. Form 8-K
10/25/07
 3.1
       
3.1.2 Amendment to Seconded Amended and Restated Articles of Incorporation of Safeguard Scientifics, Inc. Form 8-K
8/27/09
 3.1
       
3.1.3 Statement with Respect to Shares Form 10-Q
4/25/14
 3.1
       
3.1.4 Statement of Designation of Series B Junior Participating Preferred Stock Form 8-K
2/20/18
 3.1
       
3.2 Third Amended and Restated By-laws of Safeguard Scientifics, Inc. Form 8-K
2/13/18
 3.1
       
4.1.1 Indenture, dated as of November 19, 2012, between Safeguard Scientifics, Inc. and U.S. Bank National Association, as trustee Form 8-K
11/20/12
 4.1
       
4.1.2 Section 382 Tax Benefits Preservation Plan, dated as of February 19, 2018, by and among Safeguard Scientifics, Inc., Computershare Inc. and Computershare Trust Company, N.A. Form 8-K
2/20/18
 4.1
       
10.1* Safeguard Scientifics, Inc. 1999 Equity Compensation Plan, as amended and restated on October 21, 2008 Form 10-Q
11/6/08
 10.4
       
10.2 Safeguard Scientifics, Inc. 2001 Associates Equity Compensation Plan, as amended and restated on October 21, 2008 Form 10-Q
11/6/08
 10.5

 

54


10.3* Safeguard Scientifics, Inc. 2014 Equity Compensation Plan, as amended and restated on March 5, 2014 Form 10-Q
7/25/14
 10.1
       
10.4* Safeguard Scientifics, Inc. Executive Deferred Compensation Plan (amended and restated as of January 1, 2009) Form 10-K
3/19/09
 10.4
       
10.5* Management Incentive Plan Form 8-K
4/25/08
 10.1
       
10.6* Transaction Bonus Plan Form 8-K
4/10/18
 99.2
       
10.7* Compensation Summary — Non-employee Directors Form 10-Q
4/24/15
 10.2
       
10.8.1* Agreement by and between Safeguard Scientifics, Inc. and Stephen Zarrilli dated as of May 28, 2008 Form 8-K
5/29/08
 10.1
       
10.8.2* Letter Amendment dated December 9, 2008, to Agreement by and between Safeguard Scientifics, Inc. and Stephen Zarrilli dated as of May 28, 2008 Form 10-K
3/19/09
 10.9.2
       
10.8.3* Compensation Agreement by and between Safeguard Scientifics, Inc. and Stephen T. Zarrilli dated December 28, 2012 Form 10-K
3/11/13
 10.9.3
       
10.8.4* Compensation Agreement by and between Safeguard Scientifics, Inc. and Stephen T. Zarrilli dated April 6, 2018 Form 8-K
4/10/18
 99.8
       
10.9.1* Amended and Restated Letter Agreement by and between Safeguard Scientifics, Inc. and Brian J. Sisko dated December 3, 2008 Form 10-K
3/19/09
 10.12
       
10.9.2* Compensation Agreement by and between Safeguard Scientifics, Inc. and Brian J. Sisko dated December 14, 2009 Form 10-K
3/16/10
 10.11.2
       
10.9.3*   Compensation Agreement by and between Safeguard Scientifics, Inc. and Brian J. Sisko dated December 28, 2012 Form 10-K
3/11/13
 10.10.3
       
10.9.3*   Compensation Agreement by and between Safeguard Scientifics, Inc. and Brian J. Sisko dated April 6, 2018 Form 8-K
4/10/18
 99.5
       
10.10.1*   Compensation Agreement by and between Safeguard Scientifics, Inc. and Jeffrey B. McGroarty dated January 6, 2014 Form 8-K
1/7/14
 10.1
       
10.11.1*   Compensation Agreement by and between Safeguard Scientifics, Inc. and  David Kille dated September 1, 2015 Form 8-K
4/10/18
 99.6
       
10.11.2* Compensation Agreement by and between Safeguard Scientifics, Inc. and  David Kille dated April 6, 2018 Form 8-K
4/10/18
 99.7
       
10.12.1*   Key Employee Compensation Recoupment Policy Form 10-Q
7/26/13
 10.2
       
10.13.1   Amended and Restated Loan and Security Agreement dated as of May 27, 2009, by and among Silicon Valley Bank, Safeguard Scientifics, Inc., Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. Form 8-K
5/28/09
 10.1

55


10.13.2 Joinder and First Loan Modification Agreement dated as of December 31, 2010, by and among Silicon Valley Bank, Safeguard Scientifics, Inc., Safeguard Delaware, Inc., Safeguard Scientifics (Delaware), Inc. and Safeguard Delaware II, Inc. Form 8-K
1/4/11
 10.1
       
10.13.3 Second Loan Modification Agreement dated as of April 29, 2011, by and among Silicon Valley Bank, Safeguard Scientifics, Inc., Safeguard Delaware, Inc., Safeguard Scientifics (Delaware), Inc. and Safeguard Delaware II, Inc. Form 10-Q
7/28/11
 10.2
       
10.13.4   Third Loan Modification Agreement dated as of December 21, 2012, by and among Silicon Valley Bank, Safeguard Scientifics, Inc., Safeguard Delaware, Inc., Safeguard Delaware II, Inc. and Safeguard Scientifics (Delaware), Inc. Form 8-K
12/27/12
 10.1
       
10.13.5   Fourth Loan Modification Agreement dated as of December 22, 2014, by and among Silicon Valley Bank, Safeguard Scientifics, Inc., Safeguard Delaware, Inc., Safeguard Delaware II, Inc. and Safeguard Scientifics (Delaware), Inc. Form 8-K
12/23/14
 10.1
       
10.13.6   Fifth Loan Modification Agreement dated as of December 29, 2015, by and among Silicon Valley Bank, Safeguard Scientifics, Inc., Safeguard Delaware, Inc., Safeguard Delaware II, Inc. and Safeguard Scientifics (Delaware), Inc. Form 8-K
12/29/15
 10.1
       
10.14   Purchase and Sale Agreement dated as of December 9, 2005 by and among HarbourVest VII Venture Ltd., Dover Street VI L.P. and several subsidiaries and affiliated limited partnerships of Safeguard Scientifics, Inc. Form 10-K
3/13/06
 10.36
       
10.15   Consent Agreement, dated as of May 17, 2011, by and among Shire Pharmaceuticals, Inc. and certain stockholders of Advanced BioHealing, Inc. Form 8-K
5/18/11
 10.1
       
10.16   Lease Agreement, Effective February 2, 2015, Between Safeguard Scientifics, Inc., a Pennsylvania Corporation, and Radnor Properties-SDC, L.P., a Delaware Limited Partnership Form 10-Q
4/24/15
 10.1
       
10.17   Cooperation Agreement dated April 23, 2018 by and among Safeguard Scientifics, Inc. and Horton Capital Management, LLC, Joseph M. Manko, Jr., Maplewood Partners, LLC, Maplewood Advisors IM, LLC, Darren C. Wallis, Horton Capital Partners, LLC, Sierra Capital Investments, LP, Maplewood Global Partners, LLC, Horton Capital Partners Fund, LP, AVI Capital Partners, LP, and Maplewood Advisors GP, LLC Form 8-K
4/24/18
 10.1
       
14.1   Code of Business Conduct and Ethics Form 10-K
3/7/18 
 14.1
       
21.1   List of Subsidiaries Form 10-K
3/7/18 
 21.1
       
23.1   Consent of Independent Registered Public Accounting Firm — KPMG LLP Form 10-K
3/7/18
 23.1
       
31.1   Certification of Stephen T. Zarrilli pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 Form 10-K
3/7/18
 31.1  
       
31.2   Certification of Jeffrey B. McGroarty pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 Form 10-K
3/7/18
 31.2
       
31.3† Certification of Stephen T. Zarrilli pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 - -
       
31.4† Certification of Jeffrey B. McGroarty pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 - -
       
32.1 ‡   Certification of Stephen T. Zarrilli pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Form 10-K
3/7/18
 32.1
       
32.2 ‡   Certification of Jeffrey B. McGroarty pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Form 10-K
3/7/18
 32.2

56


101  The following materials from Safeguard Scientifics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2017, formatted in XBRL (eXtensible Business Reporting Language) (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Statements of Comprehensive Loss; (iv) Consolidated Statements of Changes in Equity; (v) Consolidated Statements of Cash Flows; and (vi) Notes to Consolidated Financial StatementsForm 10-K
3/7/18
101

10.12*

 

Compensation Agreement by and between Safeguard Scientifics, Inc. and Mark Herndon dated September 17, 2018

Form 8-K

9/18/18

 

99.1

10.13*

 

Key Employee Compensation Recoupment Policy

Form 10-Q

7/26/13

 

10.2

10.14

 

Purchase and Sale Agreement dated as of December 9, 2005 by and among HarbourVest VII Venture Ltd., Dover Street VI L.P. and several subsidiaries and affiliated limited partnerships of Safeguard Scientifics, Inc.

Form 10-K

3/13/06

 

10.36

10.15

 

Consent Agreement, dated as of May 17, 2011, by and among Shire Pharmaceuticals, Inc. and certain stockholders of Advanced BioHealing, Inc.

Form 8-K

5/18/11

 

10.1

10.16

 

Lease Agreement, effective February 2, 2015, between Safeguard Scientifics, Inc., a Pennsylvania corporation, and Radnor Properties-SDC, L.P., a Delaware limited partnership

Form 10-Q

4/24/15

 

10.1

10.17

 

Sublease Agreement, effective March 15, 2019, by and between Safeguard Scientifics, Inc., a Pennsylvania corporation and the subtenant named therein

Form 8-K

3/20/19

 

10.1

14.1

 

Code of Business Conduct and Ethics

Form 10-K

3/5/21 

 

14.1

21.1 †

 

List of Subsidiaries

—  

 

—  

23.1 †

 

Consent of Independent Registered Public Accounting Firm — KPMG LLP

—  

 

—  

31.1 †

 

Certification of Eric C. Salzman pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934

—  

 

—  

31.2 †

 

Certification of Mark A. Herndon pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934

—  

 

—  

32.1 ‡

 

Certification of Eric C. Salzman pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

—  

 

—  

32.2 ‡

 

Certification of Mark A. Herndon pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

—  

 

—  

101

 

Inline The following materials from Safeguard Scientifics, Inc. Annual Report on Form 10-K for the year ended December 31, 2020, formatted in XBRL (eXtensible Business Reporting Language); (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Statements of Comprehensive Income (Loss); (iv) Consolidated Statements of Changes in Shareholders' Equity; (v) Consolidated Statements of Cash Flows; and (vi) Notes to Consolidated Financial Statements.

—  

 

—  

104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).—  

 

Filed herewith

 

Furnished herewith

 

*

Furnished rather than filed
*

These exhibits relate to management contracts or compensatory plans, contracts or arrangements in which directors and/or executive officers of the Registrant may participate.

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

SAFEGUARD SCIENTIFICS, INC.

By:

ERIC C. SALZMAN

Eric C. Salzman

Chief Executive Officer

Dated: March 5, 2021

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature

Title

Date

ERIC C. SALZMAN

  Chief Executive Officer
(Principal Executive Officer)

March 5, 2021

Eric C. Salzman

 Safeguard Scientifics, Inc.

MARK A. HERNDON

By:/s/ Stephen T. Zarrilli
Stephen T. Zarrilli

Senior Vice President and Chief ExecutiveFinancial Officer
(Principal Financial and Accounting Officer)  

March 5, 2021

Mark A. Herndon

RUSSELL D. GLASS

Director

March 5, 2021

Russell D. Glass

JOSEPH M. MANKO, JR.

Director

March 5, 2021

Joseph M. Manko, Jr.

MAUREEN F. MORRISON

Director

March 5, 2021

Maureen F. Morrison

ROBERT J. ROSENTHAL

Chairman of the Board of Directors

March 5, 2021

Robert J. Rosenthal

Dated: April 30, 2018

 

58
50